Document:

Exhibit

Exhibit 10.15
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE ARCHERDX, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCHERDX, INC. IF PUBLICLY DISCLOSED.

MASTER SERVICES AGREEMENT
by and between
ASTRAZENECA AB (PUBL)
and
ARCHERDX, INC
2019

Page | 1
Master Services Agreement

	
			
	Definitions
	4

	1.
	Services
	8

	3
	Standards
	9

	4
	Current Good Manufacturing Practices (“GMP”).
	9

	5
	Good Laboratory Practice
	9

	6
	Compensation
	9

	7
	Taxes
	11

	8
	Product Security
	11

	9
	Confidentiality
	13

	10
	Term and Termination
	13

	11
	Indemnification
	15

	12
	Liability
	18

	13
	Subcontracting
	19

	14
	Expectations of Third Parties
	19

	15
	Right to Audit
	20

	16
	Adverse Event Reporting Requirements
	21

	17
	Anti-Bribery Anti-Corruption (“ABAC”)
	22

	18
	Amendments, Changes and Modifications
	22

	19
	Ownership of Results and Background IPR
	22

	20
	Error or Delay in Performance of the Services
	24

	21
	Reserved
	24

	22
	Mediation
	24

	23
	Arbitration
	24

	24
	Assignment
	25

	25
	Reserved
	25

	26
	No Minimum Commitment.
	25

	27
	Further Assurance
	25

	28
	Data Privacy
	25

	29
	Debarment
	25

	30
	Reserved
	26

	31
	Reserved
	26

	32
	Reserved
	26

	33
	Force Majeure
	26

	34
	US Physician Sunshine Act Requirements
	26

	35
	Human Biological Samples (“HBS”)
	27

	36
	Promotional Policies
	27

	37
	Publications
	27

	38
	Representations, Warranties and Covenants
	28

	39
	Reserved
	29

	40
	Safety and Security Requirements
	29

	41
	Travel and Expenses
	29

	42
	Reserved
	30

	43
	Reserved
	30

	44
	Reserved
	30

	45
	Construction
	30

	46
	Entire Agreement and Amendment
	30

Page | 2
Master Services Agreement

	
			
	47
	Governing Law
	31

	48
	Jurisdiction
	31

	49
	Miscellaneous
	31

	SCHEDULE 1 - STATEMENT OF WORK - TEMPLATE
	34

	SCHEDULE 2 - RATE CARD
	37

	SCHEDULE 3 - DATA PROTECTION AND SECURITY REQUIREMENTS
	38

	SCHEDULE 4 - SUMMARY OF ASTRAZENECA PROMOTIONAL POLICIES
	54

	SCHEDULE 5 – HUMAN BIOLOGICAL SAMPLES
	56

	SCHEDULE 6 – KEY PERFORMANCE INDICATORS (SERVICE LEVELS)
	61

	SCHEDULE 7 – DESIGN AND REPORTING OF ESSENTIAL AND EXPLORATORY RESEARCH OBJECTIVES
	62

Page | 3
Master Services Agreement

MASTER SERVICES AGREEMENT
This Master Services Agreement (the “Agreement”) is made effective as of the last date of signature (the “Effective Date”), by and between:
		
	(1)
	ASTRAZENECA AB (PUBL), A COMPANY INCORPORATED IN SWEDEN UNDER NO. 556011-7482, WITH OFFICES AT SE-431 83 MÖLNDAL, SWEDEN (“AstraZeneca”)

		
	(2)
	ARCHERDX, INC, A COMPANY INCORPORATED IN DELAWARE WHOSE REGISTERED OFFICE IS AT 2477 55TH STREET, SUITE 202 BOULDER, CO 80301, USA. (“Supplier”).

Recitals
		
	(A)
	AstraZeneca desires to obtain from time to time the Services (as defined below) of Supplier in order to obtain the benefit of the experience and ability of Supplier; and

		
	(B)
	Supplier is willing to render such Services upon the terms and conditions set forth in this Agreement.

Agreement
In consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, agree as follows:
DEFINITIONS
Unless otherwise specifically provided in this Agreement, the following terms shall have the following meanings:
		
	1.1.
	“Adverse Event” or “AE” is the development of any untoward medical occurrence in a subject or clinical study subject administered a medicinal product and which does not necessarily have a causal relationship with such treatment. An AE can therefore be any unfavourable and unintended sign (e.g. an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The term AE is used to include both serious and non-serious AEs and can include a deterioration of a pre-existing medical occurrence. An AE may occur at any time, including run-in or washout periods, even if no study treatment has been administered.

		
	1.2.
	“Affiliate” means, with respect to a Person, any Person that controls, is controlled by or is under common control with such first Person. For purposes of this definition only, “control” means: (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance, fifty  percent (50%) or more of the outstanding voting securities or other ownership interest of such Person.

		
	1.3.
	“Anti-Corruption Laws” means the US Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of bribery, fraud, racketeering, money laundering or terrorism.

		
	1.4.
	“Applicable Law” means all applicable laws, rules and regulations and any applicable policies of any Regulatory Authorities that may be in effect from time to time, including laws, rules, regulations, guidances, Guidelines and standards relating to the conduct 

Page | 4
Master Services Agreement

of clinical investigations, data protection, the use of investigational drugs in humans and good clinical and good manufacturing practice, including supranational, national and local legislation, regulations and official guidance, ethical principles acceptable to the world community for the conduct of clinical trials and the mandates of the applicable Review Boards.
		
	1.5.
	“Background IPR” means any Intellectual Property Rights necessary in the performance of the Services existing prior to entering into the Statement of Work or generated independently of the Services under this Agreement, which are owned or controlled by Supplier or AstraZeneca or to which Supplier or AstraZeneca represents it has rights on the Effective Date or from time to time during the Term of this Agreement.

		
	1.6.
	“Change of Control” means, with respect to a Party: (i) a merger or consolidation of such Party with a third party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger or consolidation, or (ii) a transaction or series of related transactions in which a third party (who is not a stock or equity holder as of the date hereof), together with its affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party.

		
	1.7.
	“Confidential Information” means any and all data, information or material of a Party or its Affiliates that is provided or communicated by or on behalf of such Party or its Affiliates to the other Party or its Affiliates, or otherwise becomes known to such other Party, or is collected or generated by or on behalf of a Party, in connection with this Agreement, the Services or any other activities contemplated hereunder, including, without limitation, information relating to a Party’s and/or its Affiliates’ business.

		
	1.8.
	“Control” means for purposes of Section 1.2: (i) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance, or (ii) to own, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities or other ownership interest of such Person, or (iii) in the case of a partnership, control of the general partner.

		
	1.9.
	“Employee” shall be defined to include any Supplier employee, contractor, subcontractor or agent, or employee of the same performing Services.

		
	1.10.
	“Force Majeure” means an event which is beyond a Party’s reasonable control, including an act of God (floods, drought, earthquake or other natural disaster), epidemic or pandemic, civil war, riots, terrorist attack on a Party, or requiring closure of buildings and/or sites and shut down of computer systems.

		
	1.11.
	“Good Clinical Practice” means in respect of the Services, that level of skill, care, prudence, judgment, foresight, integrity and diligence that would be reasonably expected of a global market-leading provider of services similar to the Services, including practices that accord with:

		
	(a)
	the ICH Guideline for Good Clinical Practice (E6);

Page | 5
Master Services Agreement

		
	(b)
	good clinical practice requirements as are specified in Directive 2001/20/EC of the European Parliament and the Council of 4 April 2001 relating to medicinal products for human use and in guidance published by the European Commission pursuant to such Directive; and

		
	(c)
	good clinical practice requirements issued by the FDA.

		
	1.12.
	“Good Laboratory Practice” or “GLP” means the current OECD ENV/MC/CHEM(98)17 quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported, as amended from time to time.

		
	1.13.
	“Good Manufacturing Practice” or “GMP” means those current good manufacturing practices, as amended from time to time, related to the manufacture of products as set forth in the FDCA and such standards of good manufacturing practice as are required by the FDA or other Regulatory Authorities (as defined herein), including the United States Code of Federal Regulations (Title 21, Parts 210-211, and 610) and European Community Directive 91/356/EEC (Principles and guidelines of good manufacturing practice for medicinal products) (as amended or replaced from time to time, including by Directive 2003/94/EEC).

		
	1.14.
	“Guidelines” means the standard of practice applicable to the Services and their place of performance required by each of the following, as they may be amended from time to time:

		
	a)
	the Principles on Conduct of Clinical Studies and Communication of Clinical Study Results published by the Pharmaceutical Research and Manufacturers of America (PhRMA);

		
	b)
	all guidelines relating to clinical studies published by a Regulatory Authority or the ICH which are adopted in any of the ICH Regions; and

		
	c)
	the World Medical Association Declaration of Helsinki entitled “Ethical Principles for Medical Research Involving Human Subjects” (1996 version).

		
	1.15.
	“Illegal Trade” means counterfeiting, illegal diversion and theft of medicines.

		
	1.16.
	“Intellectual Property Rights” or “IPR” means confidential know-how, patent rights, trademarks, service marks, trade names, design rights, copyright (including rights in computer software) and any rights or property similar to any of the foregoing in any part of the world, whether registered or not, together with the right to apply for the registration of any such rights, and all rights or forms of protection having equivalent or similar effect, in any part of the world.

		
	1.17.
	“Loss” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties, and reasonable lawyers’ fees and disbursements.

		
	1.18.
	“Parties” means AstraZeneca and Supplier and “Party” shall mean either of AstraZeneca or Supplier.

		
	1.19.
	“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or 

Page | 6
Master Services Agreement

organization, including a government or political subdivision, department or agency of a government.
		
	1.20.
	“Policies and Standards” means all policies, procedures and standards adopted by AstraZeneca or its Affiliates that are relevant to the Services as have been provided to Supplier.

		
	1.21.
	“Regulatory Authority” means the FDA, the EMEA and any other national, supranational or other governmental body having legal authority with respect to the conduct of the Services or the marketing authorization for a study drug or diagnostic identified in a Statement of Work or a product containing the study drug or diagnostic.

		
	1.22.
	“Results” means, with respect to a Party, any ideas, inventions, discoveries, know-how, data, documentation, reports, materials, writings, designs, computer software, processes, principles, methods, techniques and other information, recorded in any form, that are discovered, conceived, reduced to practice or otherwise generated as a result of or in connection with this Agreement, the Services or any other activities contemplated hereunder by or on behalf of such Party or its Affiliate (whether solely or jointly with others) and any patent, trade secret, copyright or other intellectual property rights pertaining to any of the foregoing; provided, that Supplier Results, as defined herein, shall not be deemed to be Results generated on behalf of AstraZeneca.

		
	1.23.
	“Review Board” means an institutional review board, independent ethics committee or other group formally designated by an institution in compliance with 21 C.F.R. Part 56 or analogous provisions of Applicable Law outside the United States to review, to approve the initiation of, and to conduct periodic review of, the Study.

		
	1.24.
	“Sample(s)” means biological materials, including human tissue and its derivatives or components (e.g., cell lines and DNA), as may be further identified in an applicable Statement of Work.

		
	1.25.
	“Services” means the services to be performed by Supplier set forth in each Statement of Work, with such modifications to such Statement of Work as either Party may reasonably request from time to time.

		
	1.26.
	“Service Levels” means the levels of performance of the Services as set out in a Statement of Work and agreed by the Parties which include but is not limited to; delivery of data and results to mutually agreed timelines, which levels will in any event be consistent with Good Industry Practices.

		
	1.27.
	“Statement of Work” or “SOW” means a description of the Services to be undertaken by the Supplier mutually agreed by the Parties in writing, substantially in the form set forth in Schedule 1 (Statement of Work) or as otherwise agreed by the Parties.

		
	1.28.
	“Third Party Licence” mean any Intellectual Property Rights of an individual or organization not a party to this Agreement the use and/or control of which has been granted to Supplier through a license agreement.

		
	1.29.
	“Waste” means, if applicable, waste material from Supplier manufacture, supply or handling of the products identified in a Statement of Work, including any such non-conforming products, and any material carrying an AstraZeneca Trademark.

Page | 7
Master Services Agreement

		
	1.
	SERVICES

		
	1.1
	This Agreement sets forth the terms and conditions under which Supplier agrees to provide, and under which AstraZeneca agrees to retain Supplier to provide, Services. The content and scope of the Services shall be further specified in separate and consecutively numbered Statements of Work, drawn up and signed by both Parties from time to time.Each such Statement of Work shall come into effect when it is signed by both Parties and the provision of the Services set forth therein shall be governed by the terms and conditions of this Agreement. Such engagement shall be on a non-exclusive basis, and AstraZeneca shall at all times have the right to engage other companies for such Services as it in its sole discretion deems necessary or appropriate. For the avoidance of doubt, AstraZeneca has no obligation to place certain amounts of Statements of Work under this Agreement.

		
	1.2
	Any number of Statements of Work may be executed pursuant to this Agreement during the Term. Each Statement of Work will govern the provision of Services set forth therein. Supplier shall not unreasonably refuse to accept a Statement of Work during the Term of this Agreement; provided, that Supplier shall not be obligated to accept a Statement of Work during the Term of this Agreement.

		
	1.3
	Each Statement of Work shall refer to this Agreement and will operate for the term specified therein unless earlier terminated in accordance with Article 10 (Term and Termination).

		
	1.4
	Except as provided in a Statement of Work, Supplier shall furnish, at its own expense, any and all materials, equipment, services or supplies necessary or useful to successfully complete the Services. Supplier shall use commercially reasonable efforts in the performance of the Services and shall perform such Services with the highest professional standards and in compliance with this Agreement and the relevant Statement of Work and all applicable laws and regulations.

		
	1.5
	The Parties agree that completion of the Services within the agreed-upon time period is an essential term of this Agreement.

		
	1.6
	The contact person at AstraZeneca for the Services will be as set forth in the relevant Statement of Work, unless otherwise notified.

		
	1.7
	The Parties shall together perform ongoing measurement of Key Performance Indicators (“KPIs”) and periodic assessment of Service Levels, as further described in the Schedule 6 and/or the applicable SOW. The formulation of specific Service Levels will be proposed for each SOW drafted and agreed between the Project Team Leads. The satisfaction of each such Service Level will be determined by quantitative metrics collected by Parties. Satisfaction of the Service Levels by Supplier will be monitored by the each Party. Persistent uncured breaches of the Service Levels agreed and set forth in Schedule 6 and/or a specific SOW shall be deemed a Material Breach of this Agreement and will give AZ the right to terminate either this Agreement in its entirety or any such specific SOW in accordance with Section 10.

		
	1.8
	In its performance of the Services and other obligations under this Agreement, Supplier shall and shall cause it Affiliates and its and their respective subcontractors, employees 

Page | 8
Master Services Agreement

and representatives to comply with the requirements contained within Schedule 7 regarding the design and reporting of essential and exploratory research objectives.
		
	3
	STANDARDS

		
	3.1
	In its performance of the Services and other obligations under this Agreement, Supplier shall and shall cause it Affiliates and its and their respective subcontractors, employees and representatives to comply with:

		
	3.1.1
	Good Clinical Practice;

		
	3.1.2
	The Guidelines;

		
	3.1.3
	The Policies and Standards; and

		
	3.2
	Applicable Law (in the event of inconsistency among Applicable Law, Supplier shall conduct  the Study in accordance with the law, regulations, guideline or standard that is the most protective of the subjects of such Study and shall consult with such AstraZeneca Affiliate as necessary to assure compliance with Applicable Law).

		
	4
	CURRENT GOOD MANUFACTURING PRACTICES (“GMP”)    .

		
	4.1
	AstraZeneca is specifically required by law to ensure that all AstraZeneca facilities, materials used therein and contractors performing Services impacting the biopharmaceutical operations, including production, laboratory, warehousing, and other areas are in compliance with governmental regulations and mandates. In performing the Services, Supplier agrees to comply with and adhere to those requirements that are necessary for AstraZeneca to meet its obligations to domestic and international governmental agencies. Supplier agrees to use Current Good Manufacturing Practice(s) or GMP in all applicable Services.

		
	5
	GOOD LABORATORY PRACTICE

		
	5.1
	Supplier shall: (a) perform the Services with the highest professional standards, in a good scientific manner, in compliance with the provisions of this Agreement and all Applicable Laws, including as applicable, GLP, and (b) ensure that it has all licenses and consents required to provide the Services and otherwise conduct its business, and shall maintain and comply with all such licenses and consents.

		
	6
	COMPENSATION

		
	6.1
	In consideration for Supplier’s satisfactory performance of the Services, AstraZeneca shall compensate Supplier as set forth in the relevant Statement of Work. Supplier agrees that the compensation set forth in a Statement of Work represents AstraZeneca’s full and complete obligation to compensate Supplier for any and all Services to be performed, rights granted and expenses incurred, by Supplier under such Statement of Work.

		
	6.2
	Purchase Order. If applicable, no payment for Services will be made unless a Purchase Order is issued by AstraZeneca and Supplier invoices must reference a corresponding Purchase Order number. If an Affiliate issues a Purchase Order under this Agreement, then the “Party” for purposes of such Purchase Order will be the Affiliate, and the Affiliate will be deemed substituted in the place of AstraZeneca solely for the purposes of such Purchase Order.

Page | 9
Master Services Agreement

		
	6.3
	Method of Payment. Supplier will deliver invoices to AstraZeneca within fifteen (15) days after the end of each calendar month or as specified in the Statement of Work. Each undisputed invoice shall be payable to Supplier within seventy-five (75) days after receipt by AstraZeneca of such invoice, subject to Supplier’s compliance with Section 3.3 below. Unless otherwise instructed by AstraZeneca in writing, all invoices and supporting documentation should be sent to AstraZeneca in accordance with the details set forth in the relevant Statement of Work. Further, each invoice shall contain: (a) AstraZeneca’s complete order number or reference, (b) the number and date of invoice, (c) the latest date of payment, i.e., seventy-five (75) days following AstraZeneca’s receipt thereof, (d) description of services, (e) name and address of Supplier, (f) Supplier’s VAT registration number (in EC), (g) AstraZeneca’s VAT registration number [**] (in EC), (h) VAT rate (%), (i) taxable amount per VAT rate, (j) VAT amount, (k) legal reference or explanation when VAT is excluded, (l) invoice amount and currency, (m) bank details, preferably IBAN code, otherwise account number and bank code, and (n) SWIFT-address. Invoices will (where applicable) include copies of receipts. Supplier will keep original receipts for a period of five (5) years for audit and reporting purposes.

For US:
[**]
[Intentionally Omitted]
[**]
[**]
[**]
For SWEDEN: [**]
[Intentionally Omitted]
[**]
		
	6.4
	Disputed Invoices. If AstraZeneca contests in good faith, certain elements of any invoice, AstraZeneca will reject the invoice in full and work with Supplier to correct the invoice. AstraZeneca will notify the Supplier in writing not later than ten (10) business days from the date of invoice rejection. AstraZeneca and the Supplier will meet to resolve the disputed amount and Services not later than ten (10) days after Supplier acknowledges the invoice has been disputed. The Supplier may invoice for the Services that are not disputed whilst working to correct the invoice. Should AstraZeneca and the Supplier fail to resolve the disputed amount both agree to escalate to the nominated points of escalation set forth in Schedule 1 (Statement of Work) where both Parties commit to meeting and resolving within ten (10) days of the date of this escalation. Should a resolution not be agreed the Supplier may, without limiting Supplier’s other rights and remedies under this Agreement, (i) consider the failure to pay a material breach of the Agreement; and (ii) upon notice, suspend Services until all disputed amounts are resolved.

		
	6.5
	Electronic Transactions. To facilitate payment, Supplier agrees to participate in an electronic transaction program using either Ariba Interactive Email or the Ariba Supplier Network 

Page | 10
Master Services Agreement

(“ASN”). Participation includes the electronic transmission of Purchase Orders and contracts as well as submitting electronic invoices via the Ariba Interactive Email or Ariba Supplier Network. Supplier acknowledges participation in this program by acceptance of the Ariba Interactive Email (for non-ASN suppliers) or voluntary registration for the Ariba Supplier Network and accountability for the payment of associated ASN fees. Supplier agrees to provide data and to designate a representative to assist in the establishment of the program.
		
	6.6
	Rate Card. In return for the Services performed under this Agreement, AstraZeneca will pay to Supplier fees as set forth in Schedule 2 (Rate Card) or as specified in an Statement of Work. AstraZeneca will not pay fees for Services not performed and Supplier will refund any prepaid fees for work not performed.

		
	7
	TAXES

		
	7.1
	Taxes. The Parties agree that all charges under this Agreement are inclusive of all taxes, levies, duties, contribution, withholding or impost of whatever nature (including related fines, penalties, surcharges of interest) (“Taxes”, each “Tax”) imposed or payable to any government, state or municipality or any local, state, federal or other fiscal, revenue, customs or excise authority, body or official anywhere in the world (“Tax Authority”) except value added or goods and service taxes or other similar taxes computed by reference to turnover that are required by law to be disclosed as a separate item on the relevant invoice (“GST”) that are the responsibility of AstraZeneca under this Agreement.

		
	7.2
	GST Invoice. Where either Party is required under this Agreement to make a supply (“GST Supplying Party”) to the other Party (“GST Receiving Party”) for Tax purposes, and Tax is chargeable on such supply, the GST Supplying Party shall provide the GST Receiving Party with an invoice (“Tax Invoice”) including such particulars as are required by any law imposing Tax and such other information as required to claim any credit allowed under a law imposing Tax in respect of such supply. All Prices are exclusive of GST, which, if payable, shall be borne and paid against provision by the Supplier of a valid Tax Invoice.

		
	7.3
	Excess. To the extent, in any circumstances, AstraZeneca has paid GST to Supplier which it subsequently determines was in excess of the GST actually due, Supplier shall repay to AstraZeneca the excess amount.

		
	7.4
	Tax Deductions. If a deduction or withholding for or on account of Tax (“Tax Deduction”) is required by law to be made by AstraZeneca, the amount of payment due form AstraZeneca to Supplier shall be equal to the payment which would have been due if no Tax Deduction had been required less the Tax Deduction. AstraZeneca shall not be required to make an increased payment to Supplier for a Tax Deduction. AstraZeneca shall co-operate reasonably with Supplier to notify Supplier when AstraZeneca believes a Tax Deduction is required and in connection with any proposed actions of Supplier to reduce or recover the Tax Deduction (e.g., by completing prescribed forms) provided that AstraZeneca shall not dispense or apply a reduced rate of Tax Deduction unless Supplier has provided evidence, in a form reasonably satisfactory to AstraZeneca of authorisation to do so.

		
	8
	PRODUCT SECURITY

		
	8.1
	Destruction of Waste. Supplier shall destroy all Waste generated on mutually acceptable timelines, during the Term and upon termination of this Agreement or a Statement of Work. 

Page | 11
Master Services Agreement

Such Waste shall be secured pending destruction. Supplier shall keep a record of destruction of any Waste and promptly issue certificates of destruction to the extent reasonably requested. The records shall be kept for a period of at least two years and made available to AstraZeneca on request.
		
	8.2
	Standard Operating Procedures. Supplier shall maintain Standard Operating Procedures (“SOPs”) and full records detailing production amounts and the dispersal of produced Products to ensure that product security features of the Products are secured and controlled. The records and Standard Operating Procedures shall be kept for a period of at least two years and made available to AstraZeneca on request.

		
	8.3
	Subcontractors. Supplier shall include in all of its contracts with its suppliers of materials carrying AstraZeneca’s name, insignia, symbol, trademark, trade name, logotype or similar (“AstraZeneca Trademark”), clauses identical or substantially equivalent to this Article 8 (Product Security).

		
	8.4
	Confidential Information. Supplier may disclose AstraZeneca Confidential Information pertaining to pack security features and anti-counterfeiting measures only to those of their suppliers who are pre-approved for such purpose by AstraZeneca in writing (“Approved Supplier”). Such disclosure shall be on a purely need to know basis in so far and to the extent absolutely necessary for the purposes of carrying out Supplier’s obligations under this Agreement and on the condition that the Approved Supplier is bound by similar confidentiality obligations to those binding the Supplier under this Agreement. In the event of breach by an Approved Supplier of its confidentiality obligations, Supplier shall cooperate with AstraZeneca in enforcing any rights in respect thereof.

		
	8.5
	Security Measures. Products shall be delivered by Supplier in a secure manner appropriate to the transportation route and destination. Separate and more stringent security measures such as tamper evident seals may be set out in the Statement of Work. Supplier shall adhere to traceability legislation defined by the US Drug Quality and Security Act (“DQSA”) and the European Parliament Falsified Medicines Directive (Directive 2011/62/EU) (“FMD”) and shall follow AstraZeneca’s specifications, standards and strategy.

		
	8.6
	Security Breaches. Any incident of breach of the security of the Products, machinery, other tools of production or information pertaining to this Agreement or the relevant Statement of Work shall be reported to AstraZeneca within twenty-four (24) hours of discovery of such incident. Supplier shall provide all reasonable assistance to AstraZeneca during any investigation that AstraZeneca may initiate in relation to such incident.

		
	8.8
	Improvement Plan. AstraZeneca shall have the right to audit Supplier to ensure adherence to this Agreement and the Parties will agree on an improvement plan to address any concerns that may emerge during the audit. Inability to agree to such plan within reasonable timelines or non-adherence to an agreed improvement plan will give AstraZeneca the right to terminate this Agreement.

		
	8.8
	Termination. AstraZeneca shall have the right to terminate the Agreement if Supplier or any Employee with the knowledge of Supplier (i) breaches any product security sections, (ii) is convicted of a crime involving Illegal Trade, or (iii) is not so convicted but there is sufficient evidence of their involvement in Illegal Trade including negligence or failure to establish necessary preventive control or where the action could be termed as a deliberate corporate act by Supplier

Page | 12
Master Services Agreement

		
	9
	CONFIDENTIALITY

		
	9.1
	Supplier shall, and shall cause the Supplier’s project manager and all others engaged in the Services to: (a) use AstraZeneca Confidential Information only in connection with the performance of the Services, and (b) keep AstraZeneca Confidential Information in strict confidence and not, during the Term of this Agreement and for a period of seven years following termination or expiration of this Agreement, without AstraZeneca’s prior written consent, disclose, disseminate or otherwise make available AstraZeneca Confidential Information. If Supplier becomes aware of disclosure or misuse, Supplier will immediately notify AstraZeneca and take reasonable steps to prevent further disclosure or misuse.

		
	9.2
	AstraZeneca shall, and shall cause AstraZeneca’s project manager and all others engaged in the Services or activities under this Agreement to: (a) use Supplier’s Confidential Information only in connection with the performance of the Services or the activities contemplated by this Agreement, and (b) keep Supplier’s Confidential Information in strict confidence and not, during the Term of this Agreement and for a period of seven years following termination or expiration of this Agreement, without Supplier’s prior written consent, disclose, disseminate or otherwise make available Supplier Confidential Information. If AstraZeneca becomes aware of disclosure or misuse, AstraZeneca will immediately notify Supplier and take reasonable steps to prevent further disclosure or misuse.

		
	9.3
	The obligations of confidentiality in 9.1 [or 9.2] (Confidentiality 9.1) shall not extend to any Confidential Information that: (a) is or comes into the public domain without breach of this Agreement, (b) was lawfully obtained from a third party without any confidentiality obligations, or (c) the recipient Party can demonstrate by competent evidence was already in its possession without any limitation on use or disclosure prior to the Effective Date.

		
	9.4
	Neither Party shall make any public announcement relating to this Agreement or the transactions covered by it or mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in any publication, press release, promotional material or other form of publicity without the prior written approval of the other Party in each instance.

		
	10
	TERM AND TERMINATION

		
	10.1
	Term. This Agreement shall continue in full force and effect for a period of five (5) years from the Effective Date (the “Term”). If Services are being performed by Supplier under a Statement of Work signed by the Parties during the Term and such five year period has expired, then this Agreement shall continue in effect only with respect to any such Statement of Work until its completion. This Agreement may only be extended by mutual written agreement of the Parties.

		
	10.2
	Termination without Cause. AstraZeneca shall have the right, in its sole discretion and without cause, to terminate this Agreement or any Statement of Work immediately upon twenty (20) days’ prior written notice to Supplier. Upon receipt of such notice of cancellation, Supplier shall inform AstraZeneca of the extent to which performance has been completed through such date and with the applicable SOW. In the event of early termination of this Agreement or any SOW, AstraZeneca’s liability for payment to Supplier under this Agreement shall be limited to payment for satisfactorily completed Services (or prorated for completed portions thereof) delivered to AstraZeneca and other pre-approved or non-

Page | 13
Master Services Agreement

cancelable expenses or obligations incurred by Supplier prior to the termination date or SOW termination date, as applicable.
		
	10.3
	Termination for Cause. Either Party shall have the right to terminate this Agreement or any Statement of Work immediately by written notice to the other Party if the other Party has breached an obligation herein and the breach is not curable. If the breach is curable, the breaching party shall have thirty (30) days from receipt of notice specifying the nature and extent of the breach to cure. This Agreement or the Statement of Work (as applicable) will terminate at the end of this thirty-(30) day period unless the breach is cured or the non-breaching party provides written notice that the cure period is extended beyond thirty (30) days.

		
	10.4
	Bankruptcy. In the event a Party shall: (i) be declared bankrupt, or (ii) become subject to any proceedings relating to its liquidation, reorganization, or insolvency, or for the appointment of a trustee or receiver or similar official, of or for it or any part of its property, or (iii) fail generally or admit in writing its inability to pay its debts as they become due, or (iv) make a general assignment for the benefit of creditors, or (v) be dissolved or otherwise cease business as an ongoing business entity, then the other party may, upon thirty (30) days prior written notice, terminate this Agreement for cause. In the event of the commencement of a case under the United States Bankruptcy Code by or against Supplier, and during the period prior to entry of an order directing or authorizing Supplier or its trustee in bankruptcy to assume, reject or otherwise terminate this Agreement, AstraZeneca may exercise its rights under Bankruptcy Code §365(n), and the exercise of such rights or resort to any remedies provided thereunder shall not be deemed the exclusive rights or remedies available to AstraZeneca, but AstraZeneca shall be entitled to obtain any relief to the fullest extent provided by Applicable Laws.

		
	10.5
	Regulatory Sanction. AstraZeneca may terminate this Agreement immediately by written notice to Supplier if: (i) Supplier or one of Supplier’s Employees is convicted of a crime involving pharmaceutical counterfeiting, diversion or illegal trade, or (ii) there is sufficient evidence of Supplier’s involvement in counterfeiting, diversion or illegal trade, and the involvement was either knowing or the result of a failure to establish necessary preventative controls, or (iii) there is a publicly announced investigation by a Regulatory Authority relating to any suspected or actual violation of Anti-Corruption Laws by the Supplier or any Affiliates, consultants, agents, representatives or sub-contractors (including any Sub-Contractors) of the Supplier or its Affiliates connected with this Agreement

		
	10.6
	Effect of Termination. Termination of a Statement of Work shall not result in the termination of this Agreement or termination of any other Statement of Work. Upon termination of this Agreement for any reason, all Statements of Work then in effect will automatically terminate and Supplier shall cease performing Services (subject to an orderly wind-down of any ongoing activities in accordance with Applicable Law), unless AstraZeneca requests that Supplier complete one or more particular Statements of Work. In such event, the rights and obligations of the Parties under this Agreement will continue in effect with respect to such Statement of Work until their completion unless agreed Section 10.7 (Transition and Exit Plan). Upon termination or expiration of this Agreement for any reason whatsoever, each Party shall return all data, files, records and other materials in its possession or control containing or comprising the other Party’s Information or other Confidential Information to which such first Party does not retain rights under this Agreement (except one copy of which may be retained by the returning Party’s General Counsel solely for archival purposes).

Page | 14
Master Services Agreement

		
	10.7
	Transition and Exit Plan. In the event of termination and to support an orderly transition, AstraZeneca and Supplier will agree upon a Transition and Exit Plan

		
	i.
	Within five (5) days of notification of the termination, AstraZeneca and Supplier will agree upon the last day for Services;

		
	ii.
	AstraZeneca and Supplier will, within fifteen (15) days of notification of the termination and agreement of the last day for Services, meet to agree upon a Transition and Exit Plan;

		
	iii.
	The Transition and Exit Plan will detail all activities, timelines and costs of these activities, including supporting governance in order to allow for a smooth transition and exit; and

		
	iv.
	Both Parties agree to meet frequently to ensure the Transition and Exit Plan activities and timelines are met and that the correct escalation progress is followed in order to speedily resolve any issues.

		
	v.
	Notwithstanding the foregoing, in the event of any termination of this Agreement or a Statement of Work, AstraZeneca shall remain obligated, and shall make payments to Supplier in accordance with the applicable payment terms of this Agreement and the relevant SOW, for (a) all Services provided to AstraZeneca (1) prior to the termination date or SOW termination date, (2) thereafter at AstraZeneca’s request, or (3) as reasonably necessary to conduct a smooth and orderly wind-down of the Services (including as may be required by Applicable Law), and (b) other pre-approved or non-cancelable expenses or obligations incurred by Supplier as of the termination date or SOW termination date, in each case (clause (a) and (b)), independent of the Parties’ mutual agreement on a Transition and Exit Plan.

		
	10.8
	Termination for Change of Control. If the Supplier undergoes a Change of Control (or the Supplier anticipates a Change of Control and subject to AstraZeneca entering into a reasonable confidentiality agreement the Supplier can disclose that potential or actual Change of Control), the Supplier shall promptly (and within five (5) Business Days of that Change of Control) notify AstraZeneca of that actual or potential Change of Control. AstraZeneca is entitled within twenty (20) business days of the later of being notified of the Change of Control in accordance with this Section, or becoming aware of the Change of Control of the Supplier to terminate this Agreement on twenty (20) business days written notice.

		
	10.9
	Survival of Rights and Obligations. The expiration or termination of this Agreement or a Statement of Work shall be without prejudice to any rights or obligations that may have accrued prior to such expiration or termination, and shall not affect any provision which is expressly or by implication intended to come into or continue in force on or after expiration or termination. The respective rights and obligations of the Parties under Articles 0 (Definitions), 19 (Ownership of Results and Background IPR), 9 (Confidentiality) and Sections 10.1 (Termination 10.1) , 10.6 (Effect of Termination 10.6, 10.9 (Survival of Rights and Obligations 10.9), 11.1 (Indemnification 11.1), 47 (Governing Law 47), 48 (Jurisdiction 48), 22 (Mediation 23) and 23 (Arbitration 24), shall survive indefinitely the termination or expiration of this Agreement.

		
	11
	INDEMNIFICATION

		
	11.1
	Indemnification. In addition to any other remedy available to the Parties, each Party shall defend, indemnify and hold harmless the other Party, its Affiliates and its and their respective officers, directors, partners, shareholders, employees and agents from and against any 

Page | 15
Master Services Agreement

and all liabilities, claims, demands, causes of action, damages, losses and expenses, including, without limitation, reasonable attorneys’ fees (collectively, “Losses”) incurred by them to the extent resulting from or arising out of or in connection with any actual or threatened claim by a third party against them to the extent resulting from or arising out of or in connection with: (a) any breach of any obligation in this Agreement by the other Party, (b) the inaccuracy or breach of any representation or warranty made by the other Party in this Agreement, or (c) a breach or alleged breach of intellectual property rights, each of (a) – (c) except to the extent such Losses arise as a result of the negligence, fraud, willful misconduct or wrongful act of the indemnified Party, its Affiliates or its or their respective officers, directors, partners, shareholders, employees or agents.
		
	11.2
	If either Party intends to claim indemnification under this Section (whether for itself or on behalf of another indemnitee), then such Party (the “Indemnified Party”) shall promptly notify the other Party (the “Indemnifying Party”) of any Losses in respect of which the Indemnified Party intends to claim such indemnification reasonably promptly after the Indemnified Party or indemnitee is aware thereof, and the Indemnifying Party shall assume the defense of any related third party action, suit or proceeding with counsel mutually satisfactory to the parties. The indemnity agreement in this Section shall not apply to amounts paid in settlement of any claim, loss, damage or expense if such settlement is effected without the consent of the Indemnifying Party, which consent shall not be withheld, conditioned or delayed unreasonably. The failure of the Indemnified Party to deliver notice to the Indemnifying Party within a reasonable time after the Indemnified Party or the applicable indemnitee becomes aware of any such matter shall not relieve the Indemnifying Party of liability to the Indemnified Party and the indemnitees, except to the extent that the Indemnifying Party is materially prejudiced by any delay in receiving such notice. The Indemnified Party shall, and shall cause its indemnitees to, cooperate fully with the Indemnifying Party and its legal representatives in the investigation of any matter covered by this indemnification.

		
	11.3
	Indemnification by AstraZeneca. AstraZeneca will defend, indemnify and hold harmless Supplier and its officers, directors, employees, agents, shareholders, partners, distributors, sublicencees, successors and assigns, from and against Losses incurred by them to the extent resulting from or arising out of or in connection with any actual or threatened claim by a third party against them to the extent resulting from or arising out of or in connection with: (i) the gross negligence, recklessness or willful misconduct of AstraZeneca, its Affiliates, and their officers, directors, employees, agents, shareholders, partners, distributors, sublicencees, successors and assigns in the performance of AstraZeneca’s obligations under this Agreement, (ii) a breach by AstraZeneca of its obligations under this Agreement, or (iii) the research, testing, development, manufacture, use, marketing, sale, lease, distribution, licensing, commercialization and/or other disposal of an AstraZeneca product (except for any of the foregoing performed by Supplier), except to the extent such Losses arise as a result of the negligence, fraud, willful misconduct or wrongful act of the Supplier, its Affiliates or its or their respective officers, directors, partners, shareholders, employees or agents.

		
	11.4
	Notice of Claim. An Indemnified Party shall give the Indemnifying Party prompt written notice of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this Section (an “Indemnification Claim Notice”). The failure of the Indemnified Party to deliver the Indemnification Claim Notice to the Indemnifying Party within a reasonable time after the Indemnified Party or the applicable 

Page | 16
Master Services Agreement

indemnitee becomes aware of any such matter, if prejudicial to the Indemnifying Party’s ability to defend such action, shall relieve the Indemnifying Party of liability to the Indemnified Party and the indemnitees to the extent that the Indemnifying Party is materially prejudiced by any delay in receiving such Indemnification Claim Notice. Each Indemnification Claim Notice shall contain a description of the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or its or their respective directors, officers, employees and agents shall be made solely by such Party to this Agreement.
		
	11.5
	Indemnification Procedures. The obligations of an Indemnifying Party under this Section shall be governed by and contingent upon the following:

		
	11.5.1
	Assumption of Defense. At its option, the Indemnifying Party may assume the defense of any claim by a third party (“Third Party Claim”) by giving written notice to the Indemnified Party within fourteen (14) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgement that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification.

		
	11.5.2
	Control of Defense. Upon the assumption of the defense of a Third Party Claim by the Indemnifying Party:

		
	(i)
	the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party which shall be reasonably acceptable to the Indemnified Party; and

		
	(ii)
	except as expressly provided in Section 11.5.3 (Right to Participate in Defense 11.6.3), the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including lawyers’ fees and costs of suit) and any Loss incurred by the Indemnifying Party in its defense of the Third Party Claim with respect to such Indemnified Party.

		
	11.5.3
	Right to Participate in Defense. Without limiting Sections 11.5.1 (Assumption of Defense 11.6.1.) or 11.5.2 (Control of Defense 11.6.2), any Indemnified Party shall be entitled to participate in, but not control, the defense of a Third Party Claim and to retain counsel of its choice for such purpose; provided, however, that such retention shall be at the Indemnified Party’s own expense unless: (a) the Indemnifying Party has failed to assume the defense and retain counsel in accordance with this Section 11 (in which case the Indemnified Party shall control the defense), or (b) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the 

Page | 17
Master Services Agreement

representation by the same counsel of both parties under Applicable Law, ethical rules or equitable principles.
		
	11.5.4
	Settlement. With respect to all Losses resulting from or arising out of or in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of a Third Party Claim in accordance with Section 11.5.1(Assumption of Defense 11.6.1): (i) the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses, provided that it obtains the prior written consent of the Indemnified Party which consent shall not be unreasonably withheld, and (ii) no Indemnified Party shall admit any liability with respect to, or settle, compromise or discharge, any such Third Party Claim without the prior written consent of the Indemnifying Party which consent shall not be unreasonably withheld.

		
	11.5.5
	Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party that is a Party to this Agreement shall, and shall cause each of its indemnitees and each of their respective directors, officers, employees and agents to reasonably cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making the Indemnified Party, its Affiliates and its and their respective directors, officers, employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided, and the Indemnifying Party shall reimburse the Indemnified Party for all of its related reasonable out-of-pocket expenses.

		
	11.5.6
	Expenses. Except as expressly provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any claim shall be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

		
	12
	LIABILITY

		
	12.1
	No exclusion or limitation. Nothing in this Agreement limits or excludes the liability of either Party for:

		
	12.1.1
	personal injury or death caused by its negligence;

		
	12.1.2
	fraud or fraudulent misrepresentation;

		
	12.1.3
	wilful misconduct;

		
	12.1.4
	gross negligence;

Page | 18
Master Services Agreement

		
	12.1.5
	breach of the confidentiality and data protection obligations set forth in this Agreement;

		
	12.1.6
	any indemnity obligations set forth in this Agreement;

		
	12.1.7
	any Loss which a Party is obligated to insure; or

		
	12.1.8
	any liability that by laws applicable to the Parties cannot be excluded or limited.

		
	12.2
	EXCLUDED TYPES OF LOSS. EXCEPT FOR LIABILITY TO WHICH SECTION 12.1 APPLIES AND THIRD PARTY CLAIMS SUBJECT TO INDEMNIFICATION UNDER SECTION [11], NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL (INCLUDING WITHOUT LIMITATION LOST PROFITS) OR PUNITIVE DAMAGES IN RELATION TO THIS AGREEMENT, REGARDLESS OF THE FORM AND BASIS OF THE ACTION AT ISSUE.

		
	12.3
	Limitation of liability. Except for liability to which Section 12.1 applies, the total liability of a Party for any one Loss and for the total of all Losses arising from any one act or default under or in connection with this Agreement, shall not exceed a maximum aggregate amount equal to the total payable to the Supplier under this Agreement.

		
	13
	SUBCONTRACTING

		
	13.1
	Subcontractors. Supplier shall be the prime contractor. Supplier may engage subcontractors, at no additional cost to AstraZeneca, provided that: (i) Supplier shall receive AstraZeneca’s prior written approval, (ii) the subcontractor shall be bound by confidentiality provisions at least as stringent as those to which Supplier is subject under this Agreement, (iii) Supplier shall not be relieved of any responsibilities or obligations under this Agreement, (iv) Supplier shall remain AstraZeneca’s sole point of contact and sole contracting party, (v) all subcontractor employees shall be subject to the same provisions of this Agreement as Supplier’s Employees, and (vi) Supplier shall be solely responsible for paying all subcontractors unless otherwise stated in a Statement of Work.

		
	14
	EXPECTATIONS OF THIRD PARTIES

		
	14.1
	Supplier recognizes AstraZeneca’s commitment to work only with suppliers who embrace the standards of ethical behavior consistent with AstraZeneca’s Global Standard: Expectations of Third Parties, which can be found at: https://www.astrazeneca.com/content/dam/az/our-company/Documents/Global-Standard-Expectations-of-Third-Parties.pdf, as amended from time to time with notice to Supplier, and in particular those principles in Section 1 headed “Anti-Bribery and Anti-Corruption” (“Supplier Expectations”)._

		
	14.2
	Supplier represents that it: (i) will perform this Agreement and operate its business in compliance with all Applicable Laws, (ii) has received and read AstraZeneca’s Code of  Ethics, which can be found at: https://www.astrazeneca.com/sustainability.html#our-global-policies-0 (iii) will perform this Agreement and operate its business to ethical standards consistent with those set out in the Supplier Expectations, as amended from time to time with notice to Supplier, and in particular those principles in the Section headed “Anti-Bribery and Anti-Corruption,” (iv) will not take any action that will cause AstraZeneca to be in breach of any Applicable Laws for the prevention of fraud, bribery and corruption, racketeering, money laundering or terrorism, product safety, including the US Foreign Corrupt Practices Act, the UK Bribery Act, the US Drug Quality and Security Act (“DQSA”) and the European 

Page | 19
Master Services Agreement

Parliament Falsified Medicines Directive (Directive 2011/62/EU) (“FMD”), (v) will not offer, pay, request or accept any bribe, inducement, kickback or facilitation payment, and will not make or cause another to make any offer or payment to any individual or entity for the purpose of influencing a governmental decision for the benefit of AstraZeneca, and (vi) will use reasonable efforts to cause its affiliated companies, service providers and subcontractors performing Services with AstraZeneca or its Affiliates to operate their business in compliance with all Applicable Laws and in a manner consistent with the Supplier Expectations, as amended from time to time with notice to Supplier.
		
	14.3
	In the event that Supplier fails to meet or maintain such ethical standards, the Parties shall agree upon what measures should be taken by Supplier to improve Supplier’s performance (the “Improvement Plan”). If the Parties are unable to agree upon an Improvement Plan or Supplier does not implement the Improvement Plan within an agreed reasonable timescale (not to exceed twelve (12) calendar months), AstraZeneca shall be entitled to terminate this Agreement with immediate effect and be relieved of any future obligations under this Agreement.

		
	14.4
	Supplier agrees that any material breach or violation by Supplier of the above representations, warranties and undertakings shall give AstraZeneca the right to terminate this Agreement with immediate effect and be relieved of any future obligations under this Agreement.

		
	15
	RIGHT TO AUDIT

Audits. For the term of this Agreement and six (6) years thereafter, Supplier shall for the purpose of auditing and monitoring its performance of this Agreement grant (or procure the grant) to AstraZeneca, Affiliates of AstraZeneca, any auditors of any of them and any Regulatory Authority the right of access to any premises of Supplier, its Affiliates or any subcontractors used in connection with this Agreement, together with a right to access personnel, systems, processes and records (including financial records) that relate to this Agreement. Audits may be undertaken once a year for each audit type, except that there shall be no such limitation to the number of audits per year to the extent an audit is undertaken as a result of a breach of any of the provisions in this Agreement or a re-audit is required. Audits shall normally be agreed in advance, however, in the event of an undisputed breach of this Agreement audits may be conducted with not less than two (2) business days notice. To the extent that any audit under this Section 15 or any other provision of this Agreement requires access and review by AstraZeneca of any commercially or strategically sensitive information relating to the business of Supplier, its Affiliates or any subcontractors, such activity shall be carried out by non-Affiliate third party professional advisors appointed by AstraZeneca, and such professional advisors shall only report back to AstraZeneca such information as is directly relevant to informing AstraZeneca on compliance with the particular provisions of this Agreement that are the subject of the audit.
		
	15.1
	Regulatory Assistance. If a Regulatory Authority desires to conduct an inspection or audit of Supplier’s facility, or any other facility used in connection with Supplier’s performance of this Agreement (including the facilities of Supplier’s Affiliates or subcontractors), with regard to this Agreement, then Supplier shall promptly notify AstraZeneca, and shall permit and cooperate with such inspection and audit. Following receipt of the inspection or audit observations of such Regulatory Authority (a copy of which Supplier shall provide to AstraZeneca as promptly as practicable), Supplier shall prepare the response to any such 

Page | 20
Master Services Agreement

observations and shall provide a copy of such response to AstraZeneca provided that Supplier may redact any portions thereof that do not relate to a Statement of Work. Supplier shall also provide to AstraZeneca a summary of the findings of any other inspection or audit by a Regulatory Authority of Supplier’s facility, or any facility of Supplier’s Affiliates or subcontractors used in connection with Supplier’s performance of the Agreement, if and to the extent that such findings are relevant to or may otherwise have an impact on the commercialization of any Supplier assay or any AstraZeneca product.
		
	15.2
	Audit Assistance. Supplier shall provide or procure all co-operation and assistance during normal working hours reasonably required by AstraZeneca for the purposes of an audit. AstraZeneca shall procure that any auditor enters into a confidentiality agreement with Supplier equivalent to Article 9 in all material respects. AstraZeneca shall instruct any auditor or other person given access in respect of an audit to cause the minimum amount of disruption to the business of Supplier, its Affiliates and subcontractors and to comply with relevant building and security regulations.

		
	15.3
	Monitoring. AstraZeneca has policies and procedures in place to monitor and review performance by its third party contractors. Supplier shall reasonably cooperate with AstraZeneca in relation to such monitoring and review, and shall supply all information relating to this Agreement reasonably required by AstraZeneca (or to its non-Affiliate third party professional advisors, in the case of commercially or strategically sensitive information relating to the business of Supplier, its Affiliates or any subcontractors).

		
	15.4
	Audit Costs. The Parties shall bear their own costs of an audit or rendering assistance under this Article 15, except where AstraZeneca requires an audit to be undertaken by its non-Affiliate third party professional advisors to verify Supplier’s compliance with Article 14 following an undisputed breach of this Agreement, in which case Supplier shall arrange for the audit to take place and pay the fees of any such non-Affiliate third party professional advisors. Any report generated in connection with any such audit conducted in relation to Article 14 shall be the property of Supplier. However, Supplier agrees that AstraZeneca shall be entitled to review any such audit report and all supporting documents in relation to the audit, subject to redactions required by Applicable Law or contract, and of commercially or strategically sensitive information.

		
	16
	ADVERSE EVENT REPORTING REQUIREMENTS

		
	16.1
	Responsibilities for Safety Information Management. AstraZeneca acknowledges the following: Supplier does not have the ability and is not responsible for source verification of received information, provided, however, Supplier may be requested to perform data quality checks, to the extent of its ability, to assure the information provided to Supplier is complete and accurate and will provide data to AstraZeneca to allow AstraZeneca to perform a reconciliation of Supplier data and source documents, case report forms or other relevant information. Supplier does not assume responsibility for the evaluation of site conduct and compliance with provided instructions related to use of Supplier supplied equipment or data collection; Supplier Services in the contract pertain to the processing of data which is provided to Supplier by AstraZeneca and AstraZeneca’s [clinical trial] sites and that Supplier has no responsibility for formulating the testing program or for ensuring the safety or efficacy of AstraZeneca’s product(s); and Supplier will not provide a medical diagnosis or any other form of patient care or treatment, but rather a data reduction service only, which may be utilized by AstraZeneca for such uses or purposes as AstraZeneca or its sites in their sole 

Page | 21
Master Services Agreement

discretion may determine; and AstraZeneca has informed its sites that the Services shall not in any way be relied upon for purposes of providing medical care or treatment to patients treated with or otherwise involved with products of AstraZeneca, its Affiliates, or their collaborators.
		
	16.2
	Adverse Event Reporting Requirements. In the event that Supplier and its Employees, during the course of performing the Services, become aware of an Adverse Event or other reportable AE safety information (including but not limited to medication error, pregnancies, overdoses and laboratory parameters) reported by investigators or study site employees, Supplier is required to collect and submit within one business day from becoming aware, the appropriate information to AstraZeneca as described in the instructions provided in the applicable clinical study protocol. AstraZeneca is solely responsible for reporting AEs and other safety information to regulatory and government authorities.

		
	17
	ANTI-BRIBERY ANTI-CORRUPTION (“ABAC”)

		
	i.
	As at the Effective Date, Supplier and its Affiliates and to its knowledge, its representatives have not violated any Anti-Corruption Law; and

		
	ii.
	Supplier, its Affiliates and its representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value or do anything on AstraZeneca’s behalf that violates or could violate the Anti-Corruption Laws.

		
	18
	AMENDMENTS, CHANGES AND MODIFICATIONS

		
	(i)
	Amendment; Modification; Waiver. No amendment, modification or waiver of any of the terms of this Agreement or SOW will be deemed valid unless made in writing and duly executed by authorized representatives of both Parties. Each Party will have the right to enforce the Agreement in strict accordance with its terms. The failure of either Party to enforce its rights strictly in accordance with the terms will not be construed as having in any way modified or waived same.

AND
		
	(ii)
	Changes and Modifications. No changes or modifications to this Agreement will be deemed effective unless in writing and executed by the Parties hereto. In the event that Supplier is requested or required to perform Services beyond those which are specifically set forth in a Statement of Work, any such additional Services and an appropriate adjustment to the amounts owed will be negotiated in good faith and must be mutually agreed upon by the Parties in writing prior to the provision of the Services. The Parties may modify the Services by written acceptance of an amended proposal from Supplier, execution of an amendment to a Statement of Work or acceptance by Supplier of a Purchase Order reflecting such additional Services. No modification shall be accepted unless agreed in writing by the Parties.

		
	19
	OWNERSHIP OF RESULTS AND BACKGROUND IPR

Background IPR and License Rights
		
	19.1
	Each Party shall continue to own its own Background IPR.

		
	19.2
	AstraZeneca hereby grants to Supplier a worldwide, royalty-free, non-exclusive license to AstraZeneca’s Background IPR and Results which are the exclusive property of 

Page | 22
Master Services Agreement

AstraZeneca, solely for the purposes of and only to the extent reasonably necessary for providing the Services, and as part of a regulatory approval process with a Regulatory Authority.
		
	19.3
	Supplier hereby grants to AstraZeneca a world-wide, non-exclusive, royalty free license (with the right to sublicense) to that limited part of Supplier’s Background IPR and any improvements, that AstraZeneca or its sub-licensees requires, to perform the Services or otherwise conduct activities contemplated to be performed by AstraZeneca under a  Statement of Work. Supplier hereby grants to AstraZeneca a world-wide, irrevocable, perpetual, non-exclusive, royalty free license (with the right to sublicense) to Supplier Results that AstraZeneca or its sub-licensees requires to develop, use and exploit the Results owned by AstraZeneca. For clarity, such grant to AstraZeneca shall not include a license to Supplier’s Background IPR, and any improvements, to make, have made, use, have used, offer to sell, sell, import, or transfer the Clinical Trial Assay (“CTA”).

		
	19.4
	Supplier shall in the final report if contemplated by the Statement of Work provide  AstraZeneca with information regarding Supplier’s Background IPR and any improvements in sufficient detail to allow AstraZeneca or its sub-licensees to use the right as granted in Section 19.3.

Results
		
	19.5
	Supplier shall fully disclose and deliver to AstraZeneca all Supplier Results. AstraZeneca shall fully disclose and deliver to Supplier all Results that are necessary or useful for Supplier’s provision of Services and the performance of its obligations under this Agreement.

		
	19.6
	Supplier agrees that all Results generated with the use of Samples, are the exclusive property of AstraZeneca (or such Person as AstraZeneca may designate). Results generated by the Supplier under this Agreement, which are generated without the use of Samples, , (“Supplier Results”) AstraZeneca agrees are the exclusive property of Supplier (or such Person as Supplier may designate). Each Party (or its designee), without additional consideration, shall own all right, title and interest in and to their respective Results throughout the world. Copyrightable Results shall be considered “work made for hire” and AstraZeneca (or its designee) shall own all right, title, and interest in and to such Results.

Insurance
		
	19.7
	Insurance. Supplier shall maintain during the Term, and for five years after the end of the Term if written on a claims made basis, insurance coverage of the types and in the amounts typically carried by companies in Supplier’s business. Supplier shall exhibit to AstraZeneca upon written request certificates of insurance evidencing its insurance coverage and limits.

Third Party Licences
		
	19.8
	Supplier shall promptly provide written notice to AstraZeneca upon becoming aware of any potential or actual infringement of any Intellectual Property controlled by a Third Party affecting the use of Supplier’s Background IPR in the activities under a Statement of Work and or the use of the Results by AstraZeneca. In the event a Third Party Licence is necessary to continue to use the Results Supplier shall use commercially reasonable efforts to obtain such Third Party Licence at its own cost.

Page | 23
Master Services Agreement

		
	20
	ERROR OR DELAY IN PERFORMANCE OF THE SERVICES

In the event of an undisputed error or delay by Supplier in the performance of the Services, which renders the Services (in whole or in part) unacceptable to AstraZeneca, then:
		
	(a)
	AstraZeneca shall notify Supplier in writing, detailing the issues and areas of concern.

		
	(b)
	Supplier shall, if so requested by AstraZeneca, provide to AstraZeneca a proposed formal action plan within five (5) working days of AstraZeneca’s notification and the Parties shall then seek to agree such formal action plan no later than 10 days after AstraZeneca’s receipt of Supplier’s proposed action plan.

		
	(c)
	Within 30 days of agreement of the action plan both parties will meet to discuss progress and ensure resolution. If issue(s) continue AstraZeneca shall have the right to terminate the Agreement or the applicable SOW and such termination will be deemed a termination for cause pursuant to Article 10 (Term and Termination)

		
	20.1
	Without prejudice to the above or any other remedies available to AstraZeneca, Supplier shall take the following steps in the event of an undisputed material error or delay,

		
	(i)
	in the event of such error, repeat such Services at Supplier’s own cost and expense, which includes an obligation for Supplier to pay any costs and expenses for replacement of any AstraZeneca materials under Supplier’s control, and

		
	(ii)
	if such error or delay continues without cure then Supplier shall refund to AstraZeneca the portion of compensation already paid by AstraZeneca for the Services which are unacceptable or invalid, and pay to AstraZeneca the difference in cost of a Third Party’s performance of the same Services that were unacceptable or invalid.

		
	21
	RESERVED

		
	22
	MEDIATION

		
	21.1
	If any dispute arises in connection with this Agreement, the parties will attempt to settle it by mediation in good faith in accordance with the Centre for Effective Dispute Resolution (CEDR) Model Mediation Procedure and the mediation will start, unless otherwise agreed between the Parties, within 28 days of one Party issuing a request to mediate to the other. Unless otherwise agreed between the Parties, the mediator will be nominated by CEDR. The mediation will take place in Stockholm and the language of the mediation will be English.The Mediation Agreement referred to in the Model Mediation Procedure will be governed by, and construed and take effect in accordance with, the substantive law of Sweden the dispute is not settled by mediation within 14 days of the start of the mediation or within such further period as the Parties may agree in writing, the dispute will be referred to and finally resolved by arbitration as described below.

		
	23
	ARBITRATION

		
	23.1
	Arbitration. This Agreement shall be governed by the laws of Sweden excluding any conflicts or choice of law, rule or principle that might otherwise refer the construction or interpretation of this Agreement to the substantive law of another jurisdiction. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by arbitration administered by the Arbitration Institute of the Stockholm Chamber of Commerce (the “SCC Institute”). The Rules for Expedited 

Page | 24
Master Services Agreement

Arbitrations of the Arbitration Institute of the Stockholm Chamber of Commerce shall apply, unless the SCC Institute, taking into account the complexity of the case, the amount in dispute and other circumstances, determines, in its discretion, that the Arbitration Rules of the Arbitration Institute of the Stockholm Chamber of Commerce shall apply. In the latter case, the SCC Institute shall also decide whether the arbitral tribunal shall be composed of one or three arbitrators. The arbitration shall take place in Stockholm and be confidential. Notwithstanding the foregoing, nothing in this Agreement shall prevent the Parties from seeking or obtaining injunctive or equitable relief.
		
	24
	ASSIGNMENT

		
	24.1
	Neither Party may assign its rights and/or delegate or subcontract its obligations under this Agreement, except as expressly provided in this Agreement, in whole or in part, without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that each Party shall have the right, without such consent, to assign this Agreement or any or all of its rights, and/or delegate or subcontract any or all of its obligations, hereunder to (a) any of its Affiliates or (b) any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates, provided that a successor in interest of Supplier may not be a competitor of AstraZeneca. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns. Any attempted assignment, delegation or subcontracting in violation of this Article 24 shall be void and of no effect.

		
	25
	RESERVED

		
	26
	NO MINIMUM COMMITMENT.

		
	26.1
	Supplier understands and agrees that AstraZeneca makes no minimum commitment to purchase Services and is under no obligation to execute any Statement of Work under this Agreement.

		
	27
	FURTHER ASSURANCE

		
	27.1
	Each Party shall perform all further acts and things and execute and deliver such further documents as may be necessary or as the other Party may reasonably request to implement or give effect to the plain meaning of this Agreement.

		
	28
	DATA PRIVACY

		
	28.1
	Data Protection and Security Requirements. If the Services involve the transfer, acquisition or Processing of Personal Data by Supplier on behalf of AstraZeneca, Supplier agrees to comply with the requirements as listed in Schedule 3 Data Protection and Security Requirements, with regard to Supplier’s Processing of such Personal Data. Where required, 

additional data protection requirements will be included in the individual Statements of Works.
		
	29
	DEBARMENT

		
	29.1
	Supplier represents and warrants to AstraZeneca that Supplier (i) is not excluded, debarred, suspended or otherwise ineligible to participate in government healthcare programs or in government procurement or non-procurement programs and no debarment is pending or 

Page | 25
Master Services Agreement

has been initiated, (ii) has not been charged with or convicted of a criminal offense that requires exclusion from a government healthcare program, and (iii) is not otherwise disqualified or suspended from performing the Services or subject to any restrictions or sanctions by any governmental or regulatory authority or professional body (an “Ineligible Person”). Supplier further represents and warrants that Supplier is not using, and will not in the future use, any Employee who is an Ineligible Person in the performance of Services. Supplier will immediately notify AstraZeneca in writing if Supplier or any Employee is or becomes an Ineligible Person or if any action, suit, claim, investigation, or other legal or administrative proceeding is pending or, to the best of Supplier’s knowledge, threatened, that would make Supplier or any Employee an Ineligible Person.
		
	30
	RESERVED

		
	31
	RESERVED

		
	32
	RESERVED

		
	33
	FORCE MAJEURE

		
	i.
	No liability shall result from delay in performance or non-performance, in whole or in part, by either of the Parties to this Agreement to the extent that such delay or non-performance is caused by an event of Force Majeure (“Force Majeure Event”).

		
	ii.
	Notification. If a Force Majeure Event occurs or a Party reasonably anticipates that a Force Majeure Event may occur, such Party (the “Force Majeure Party”) shall notify the other Party of the nature, details and expected duration of that event.

		
	iii.
	Force Majeure Events. The Force Majeure Party shall, within five (5) days of the occurrence of a Force Majeure Event, give the other Party written notice specifying the nature and extent of the Force Majeure Event, its anticipated duration and any action being taken to avoid or minimize its effect. Where that notice is given and the Force Majeure Party complies with Section 32, the Force Majeure Party shall not be liable for delay in performance or for non-performance of this Agreement resulting from the Force Majeure Event. This suspension of performance shall be of no greater scope and no longer duration than is reasonably required.

Required Steps. The Force Majeure Party shall take all commercially reasonable steps as are necessary or directed to:
		
	(a)
	remedy its inability to perform; and/or

(b)    find a solution by which its obligations may be performed despite the continuation of the Force Majeure Event. If the Force Majeure Event prevents, hinders or delays Supplier’ performance of its obligations for a continuous period of more than 4 weeks, AstraZeneca may engage a replacement service provider.
		
	34
	US PHYSICIAN SUNSHINE ACT REQUIREMENTS

Any physician licensed to practice in the US and any US teaching hospital is a “Covered Recipient.” A “Payment or Transfer of Value” is any payment or transfer of value as defined in the US Physician Payment Sunshine Act (42 USC 1320(e)(10)), and implementing regulations (42 CFR 403.900 et seq.), and includes compensation, reimbursement for expenses, meals, travel, medical journal reprints, study supplies and medical writing and publications assistance. As applicable, Supplier acknowledges and agrees that any direct or indirect Payments or Transfers of Value to Covered 

Page | 26
Master Services Agreement

Recipients are subject to transparency reporting requirements, including disclosure on AstraZeneca website. Supplier will not contract with or make any Payment or Transfer of Value to a Covered Recipient on behalf of AstraZeneca without AstraZeneca’s prior written approval. All payments to US physicians will be made according to a centrally managed, pre-set rate structure based on a fair market value analysis conducted by AstraZeneca. Supplier acknowledges and agrees that any request for payment of, or reimbursement for, a Payment or Transfer of Value to a Covered Recipient will require that Supplier provide AstraZeneca with detailed expenditure information either through a template and/or system access, or as a file extract out of the Supplier’s own system, provided the Supplier’s file extract includes all the required data fields as outlined by AstraZeneca. AstraZeneca and Supplier will discuss annually, at a minimum, the data collection process to confirm Supplier’s understanding of AstraZeneca’s requirements. Supplier shall provide such expenditure reporting to AstraZeneca by the end of the month following the month in which such Payment or Transfer of Value to a Covered Recipient is made. Documentation concerning Payments or Transfers of Value to a Covered Recipient must be maintained by Supplier for five (5) years.
		
	35
	HUMAN BIOLOGICAL SAMPLES (“HBS”)

To the extent the Services involve the sourcing, use or handling of Human Biological Samples the provisions in Error! Reference source not found. (Schedule 5) shall apply and shall form an integral part of the Agreement.
		
	36
	PROMOTIONAL POLICIES

Promotional Policies. If Supplier provides promotional services that relate to how AstraZeneca promotes its products, it must comply with AstraZeneca’s Promotional Policies summarized in Error! Reference source not found. (Summary of AstraZeneca Promotional Policies). This Schedule summarizes a number of AstraZeneca policies that apply generally to how AstraZeneca promotes its products. These policies apply to Employees of third parties engaged to provide services to AstraZeneca or its Affiliates, and compliance with these policies is mandatory. For further detail on AstraZeneca policies, please contact your AstraZeneca representative.
		
	37
	PUBLICATIONS

		
	37.1
	Publications Policy. If Supplier provides assistance in producing publications and presentations, Supplier agrees to adhere to the requirements set forth in AstraZeneca’s Global Publications Policy, which can be found at: https://www.astrazeneca.com/content/dam/az/our-company/Sustainability/Publications-Policy.pdf, along with any applicable standards provided to Supplier by the AstraZeneca project manager. Such requirements include, but are not limited to:

		
	(a)
	AstraZeneca, not Supplier, will make initial contact with potential authors;

		
	(b)
	Supplier understands that the author must approve the general content and direction of the article before it is written;

		
	(c)
	Supplier will make no attempt to influence the opinions of the authors;

		
	(d)
	Supplier will obtain the author’s approval of the final version of the article before it is submitted to a journal;

		
	(e)
	Supplier will not be the contact for the target journal; and

		
	(f)
	Supplier’s contribution will be openly acknowledged in any resulting publication in line with its level of contribution.

Page | 27
Master Services Agreement

AstraZeneca will contract with authors using AstraZeneca-approved contract templates.
Supplier further agrees that any author of a biomedical manuscript provided under this Agreement must:
		
	(a)
	Fully comply with the International Committee of Medical Journal Editors (“ICMJE”) criteria regarding authorship (available at: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html) and disclosure of any relationship with AstraZeneca and any potential conflicts of interest, including any financial or personal relationships that might be perceived to bias the author’s work;

		
	(b)
	Disclose in any manuscript, journal submission or elsewhere as appropriate or required, any potential conflicts of interest, including any financial or personal relationship with AstraZeneca, the names of any individuals who have provided editorial support for any manuscript or other publication, and all funding sources for the study or publication; and

		
	(c)
	Provide any additional disclosure required by any medical or scientific institution, medical committee or other medical or scientific organization with which the author is affiliated.

		
	38
	REPRESENTATIONS, WARRANTIES AND COVENANTS

		
	38.1
	Representations and Warranties of Supplier

		
	38.1.1
	Supplier represents that it is free to enter into this Agreement and warrants that performance of the Services will not: (i) breach any agreement that obligates Supplier to keep in confidence any trade secrets or confidential information of Supplier or of any third-party entity, or (ii) breach any agreement with a third-party entity that restricts Supplier from providing services to AstraZeneca; or (iii) breaches any Third Party Licence.

		
	38.1.2
	Supplier represents and warrants that payment of fees by AstraZeneca is not a kickback, inducement or reward for the purpose or use of AstraZeneca products and

that Supplier is under no pre-existing duty or obligation, including an obligation imposed by Applicable Laws, payer, or contractual arrangement with a third party, that already requires Supplier to perform the Services.
		
	38.1.3
	Supplier represents and warrants that Supplier and its Employees are, and at all times during the Term of this Agreement will be, qualified by training and experience, with appropriate expertise and necessary licenses, approvals and certifications, to perform safely, adequately and lawfully the obligations of Supplier under this Agreement.

		
	38.1.4
	Supplier warrants that all Supplier Employees performing Services will successfully complete any training required by AstraZeneca as described in a SOW prior to commencing any such Services. AstraZeneca or its designee will be responsible for conducting or providing all instruction and materials necessary for Supplier to conduct any such training.

Page | 28
Master Services Agreement

		
	39
	RESERVED

		
	40
	SAFETY AND SECURITY REQUIREMENTS

		
	40.1
	Safety, Health and Environment (“SHE”) Requirements. Supplier recognizes AstraZeneca’s commitment to working only with suppliers who embrace standards that protect personal health, well-being, safety, and the environment that are consistent with AstraZeneca’s Global Standard: Safety, Health and Environment (“SHE”) which can be found at: https://www.astrazeneca.com/content/dam/az/our-company/Sustainability/SHE-Policy-v50.pdf, as amended from time to time.

		
	40.2
	Site Security and Safety Requirements. Supplier will ensure that all Employees must comply with all Site Security and Safety Requirements (“Site Security and Safety Requirements”) as applicable, unless otherwise agreed. Employees performing Services at any AstraZeneca facility must be submit to a prequalification process which will be the responsibility of AstraZeneca. All costs of meeting the Safety and Security Requirements and any applicable laws and regulations are the responsibility of Supplier. All Employees working at any AstraZeneca facility must complete required training on general procedures regarding AstraZeneca site practices, including procedures on food, drink, smoking, hygiene, and any other procedures deemed relevant to general conduct at an AstraZeneca site.

		
	40.3
	Removal of Employees. The violation of a law, regulation, or Site Security and Safety Requirement or any AstraZeneca policy may result in immediate removal from AstraZeneca property of Employees and termination of Services. Immediate removal from the workplace will also result from: (i) conspiring with or directing others to violate the law, regulation or any of these requirements or an AstraZeneca policy, (ii) failing to cooperate in an AstraZeneca investigation of possible or reported violations, or (iii) failing to promptly report violations of law, regulation, Site Security and Safety Requirement or AstraZeneca policy by Employee to his or her employer.

		
	41
	TRAVEL AND EXPENSES

		
	41.1
	Expenses. AstraZeneca may reimburse Supplier for certain reasonable and authorized expenses that Supplier incurs in the performance of Services. AstraZeneca will have no obligation to reimburse Supplier for expenses that are not invoiced within ninety (90) days of the date that Supplier incurred such expense. Receipts for expenses must be attached to invoices submitted by Supplier. AstraZeneca will not pay a mark-up on any expenses incurred.

		
	41.2
	Travel. If AstraZeneca agrees to reimburse Supplier for travel-related expenses, Supplier must comply with AstraZeneca’s Global Standard: Business Travel (“Business Travel Policy”), which can be found at: https://www.astrazeneca.com/content/dam/az/our-company/Sustainability/Business-Travel-Policy-v5-0.pdf. Travel must be reasonable,justified, properly documented and in compliance with the Business Travel Policy and all other relevant AstraZeneca policies. All travel must be approved by AstraZeneca in writing in advance of travel. Supplier is expected to book the lowest logical rates that shall apply to all travel categories – air travel, lodging, rail, ground transport and rental cars. Any request for reimbursement of travel-related expenses incurred by Supplier must be submitted in invoice form to AstraZeneca. The invoice must detail the nature of the travel, department for which travel was undertaken, the itinerary for the travel period 

Page | 29
Master Services Agreement

and supporting documentation (including receipts for air travel and rail indicating class and cost of ticket, lodging, ground transport, rental cars, meals, etc.).
		
	42
	RESERVED

		
	43
	RESERVED

		
	44
	RESERVED

		
	45
	CONSTRUCTION

		
	45.1
	Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience of reference only. The term “including” or “includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties.

		
	45.2
	The Schedules and Statements of Work (as amended from time to time by agreement of the Parties in writing) form part of this Agreement and have the same force and effect as if expressly set out in the main body of the Agreement. Any reference to the Agreement includes the Schedules and Statements of Work. Any breach of the Schedules and Statements of Work shall be deemed as a breach of this Agreement.

		
	45.3
	If there is any inconsistency between the Schedules and Statements of Work and any of the other provisions of this Agreement, such other provision shall take precedence over the Schedules and Statements of Work unless such Statement of Work specifically references a specific provision of this Agreement and expressly states that such provision is intended to be changed or amended by such Statement of Work. Such change or amendment shall then apply only with respect to such Statement of Work.

		
	45.4
	This Agreement is entered into in the English language. All amendments to this Agreement, all correspondence between the Parties concerning or relating to this Agreement and all notices given and all documentation to be delivered by one Party to another pursuant to this Agreement in whatever form, shall be in the English language. The English language version of this Agreement shall, if there is any conflict or ambiguity, take priority over any translated version.

		
	46
	ENTIRE AGREEMENT AND AMENDMENT

		
	46.1
	This Agreement (including the Statements of Work) constitutes the entire agreement between the Parties and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter.

		
	46.2
	Each Party agrees that it shall have no remedies in respect of any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement. Each Party agrees that it shall have no claim for innocent or negligent misrepresentation based on any statement in this Agreement.

Page | 30
Master Services Agreement

		
	47
	GOVERNING LAW

		
	47.1
	The interpretation and construction of this Agreement shall be governed by the laws of Sweden.

		
	48
	JURISDICTION

		
	48.1
	The Parties hereby consent to the jurisdiction of the courts of the State of Delaware for any action, suit or proceeding arising out of or relating to this Agreement and, except for seeking and obtaining injunctive or equitable relief in a court of competent jurisdiction, agree not to commence any action, suit or proceeding related thereto except in such courts.

		
	49
	MISCELLANEOUS

		
	49.1
	Severability. If any provision or part-provision of this Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deleted. Any modification to or deletion of a provision or part-provision shall not affect the validity and enforceability of the rest of this Agreement.

		
	49.2
	Reserved

		
	49.3
	Notices. Any notice or other communication required or permitted to be given by either Party under this Agreement shall be in writing and shall be deemed given as of (a) the date delivered if delivered by hand, or reputable courier service, (b) the date sent if sent by email (with transmission confirmed), (c) the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service, or (d) the fifth (5th) Business day after mailing if mailed by registered or certified mail, postage prepaid and return receipt requested, addressed to the other Party at the addresses specified below or to such other addresses of which notice shall have been given in accordance with this Section. This Section is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.

Address for Notice
	
			
	Supplier
	To:
	With a copy to:

	 
	ArcherDX, Inc.
2477 55th Street, Suite 202 
Boulder, CO 80301     |     USA
Attention: CEO
	ArcherDX. Inc.
16th Floor
50 Milk Street
Boston, MA 02109
Attention: General Counsel

	AstraZeneca
	To:
	With a copy to:

	 
	AstraZeneca AB
[Intentionally Omitted]
Attention: [**]
	AstraZeneca UK Limited
Corporate Legal
1 Francis Crick Avenue
Cambridge Biomedical Campus Cambridge
CB2 0AA
England
Email: [**] Attention:[**] 

Page | 31
Master Services Agreement

		
	49.4
	Relationship of the Parties. The status of a Party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency relationship between the Parties or, except as otherwise expressly provided in this Agreement, as granting either Party the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements, representations, warranties or commitments on behalf of the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party.

		
	49.5
	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together be deemed to constitute one agreement. The Parties agree that execution of this Agreement by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures. If any proceeding arising under or relating to this Agreement, each Party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed agreement electronically.

Page | 32
Master Services Agreement

		
	49.6
	Execution

This Agreement is executed as of the Effective Date by the authorised representatives of the Parties.
	
					
	SIGNED for and on behalf of
AstraZeneca AB (PUBL.)
	 
	SIGNED for and on behalf of
  ArcherDX, Inc,

	 
	 
	 
	 

	By:
	/s/ Cecilia Persson
	 
	By:
	/s/ Christian LaPointe

	Name:
	Cecilia Persson
	 
	Name:
	Christian LaPointe

	Title:
	Global Category Lead
	 
	Title:
	General Counsel

	 
	24 July 2019
	 
	 
	23 July 2019

Page | 33
Master Services Agreement

SCHEDULE 1 - STATEMENT OF WORK - TEMPLATE
Project: [define]
This Statement of Work (“SOW”), effective as from the date of the last signature (the “SOW Effective Date”), by and between:
[ASTRAZENECA UK LIMITED, a company incorporated in England under No. 3674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England] [or]
[ASTRAZENECA AB, a company incorporated in Sweden under No. 556011-7482 whose registered office is at SE-151 85 Södertälje, Sweden] [or]
[ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership with offices at 1800 Concord Pike, Wilmington, Delaware 19803]
[MEDIMMUNE, LLC, a Delaware limited liability company and a member of the AstraZeneca Group with offices at One MedImmune Way, Gaithersburg, MD 20878]
[OTHER AZ LEGAL ENTITY with offices at [insert address], on its behalf and on behalf of its Affiliates as defined herein (“AstraZeneca”); and
ARCHERDX, INC, A COMPANY INCORPORATED IN DELAWARE WHOSE REGISTERED OFFICE IS AT 2477 55TH STREET, SUITE 202 BOULDER, CO 80301, USA. (“Supplier”).
AstraZeneca and Supplier may be referred to herein individually as a “Party” and collectively as the “Parties”.
		
	1.
	Background

AstraZeneca and Supplier entered into a Master Services Agreement dated [insert effective date of PSA and any amendments] the “Agreement”) pursuant to which Supplier from time to time provides certain services to AstraZeneca; and
		
	2.
	Agreement

In consideration of the promises and of the mutual covenants and agreements set forth, the Parties agree as follows:
Services.   Supplier will perform services as detailed in Attachment 1, Description of Services, of this SOW (the “Services”), attached and incorporated by reference in compliance with the terms of the Agreement. Quality of services and materials produced are essential. AstraZeneca will regularly review performance with key staff and Supplier will meet with AstraZeneca as frequently as AstraZeneca deems necessary to review performance.
2    Modifications. This SOW or any of its Exhibits may only be modified by a written document, signed by both Parties.
3    Counterparts. This SOW may be executed in two counterparts, each of which will be deemed an original and all of which will together be deemed to constitute one agreement. The Parties agree that the execution of this SOW by industry standard electronic signature software and/or by exchanging PDF signatures will have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this SOW, each Party hereby waives any right to raise any defense or waiver based upon execution of this SOW by means of such electronic signatures or maintenance of the executed agreement electronically.

Page | 34
Master Services Agreement

Execution
THIS SOW IS EXECUTED by the authorised representatives of the Parties as of the SOW Effective Date.
	
			
	SIGNED for and on behalf of
	 
	SIGNED for and on behalf of

	 
	 
	 

	[AstraZeneca UK Limited]
[AstraZeneca AB (publ)]
[AstraZeneca Pharmaceuticals LP] [MedImmune, LLC]
[Other AstraZeneca Legal Entity]
	 
	ArcherDX Inc,

	 
	 
	 

	 
	 
	 

	Signature
	 
	Signature

	Name:
	 
	Name:

	Title:
	 
	Title:

Page | 35
Master Services Agreement

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE ARCHERDX, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCHERDX, INC. IF PUBLICLY DISCLOSED.

Attachment 1
Description of Services
_________________________
	
		
	Services Element
	Description of requirements and services

	Points of Contact
	AstraZeneca point of contact name:
Supplier point of contact name:

	Background to the  work
	 

	Study code and compound
	 

	Description of the work
	 

	Deliverables (reporting of Results)
	 

	Standard Operating Procedures (SOPs)
	 

	Budget
	 

	Timeline
	 

	Payment schedule
	 

	Key personnel
	 

	Use of subcontractors
	 

	AZ & Supplier responsibilities
	 

	Key dependencies
	 

	Key assumptions
	 

	Quality standards
	 

	Service
	 

	performance
	 

	Management Governance & Reporting
	 

	Change
	 

	Data transfer
	 

	Supplier systems / and or access to AZ systems
	 

	Completion & exit or transition
	 

	Data Privacy requirements
	 

Page 36 of 62

SCHEDULE 2 - RATE CARD
AstraZeneca will compensate Supplier for performance of the Services in accordance with agreed rates applicable to a particular SOW.  The rates charged under an SOW may be less than the rates set forth below, but may not exceed such rates without the prior written approval of AstraZeneca.
Rates may not be changed without the prior written approval of each Party.
Charges / Pricelist
Rates are quoted in U.S. Dollars.

Page 37 of 62

SCHEDULE 3 - DATA PROTECTION AND SECURITY REQUIREMENTS
		
	1.
	Definitions

For purposes of this Agreement, the following terms have the following meanings:
“Data Protection Laws” means all Applicable Laws in relation to (a) data protection; (b) privacy; (c) interception and monitoring of communications; (d) restrictions on or requirements relating to the Processing of Personal Data of any kind including laws addressing identity theft or security breach,.
“Data Protection Supervisory Authority” means a supervisory authority or other government body responsible for the administration, implementation and enforcement of Data Protection Laws as it relates to the Processing under this Agreement.
“Personal Data” means any information relating to an identified or identifiable natural person who can be identified directly or indirectly and in particular includes but is not limited to the following information about a living individual: first and last name, age, date of birth, gender, address, contact information, government-issued identifiers (such as passport and social security numbers), an identification number, location data, an online identifier, or any specific physical, health related, physiological, genetic, mental, economic, cultural or social information about that natural person.
“Process” or “Processing” means any act performed on In-Scope Personal Data, whether or not by automated means, including, but not limited to, collection, recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, blocking, erasure or destruction.
“In-Scope Personal Data” means any Personal Data provided to Supplier by AstraZeneca in connection with this Agreement or that is acquired, collected, generated or otherwise Processed by Supplier on behalf of AstraZeneca in connection with this Agreement. In-Scope Personal Data includes the following categories of data subjects and Personal Data:
Categories of data subjects:
Patients
Categories of Personal Data:
Medical records, blood samples, genetic data
“Security Incident” means any actual or reasonably suspected accidental, unlawful or unauthorised loss, destruction, alteration, access, use, disclosure of, damage or corruption to In-Scope Personal Data.
“Subcontractor” means any person or entity contracting with Supplier (or any of Supplier’s Affiliates) to perform the Supplier’s obligations under this Agreement or who otherwise Processes In-Scope Personal Data on behalf of the Supplier.
		
	2.
	General Supplier Obligations

		
	2.1
	Supplier represents, warrants and undertakes to perform its obligations in connection with this Agreement, including the Processing of In-Scope Personal Data, in accordance with Data Protection Laws.

		
	2.2
	Supplier shall not be entitled to use or otherwise Process In-Scope Personal Data for any reason other than to provide to AstraZeneca the Services defined in this Agreement and only 

Page 38 of 62

for the duration of time stipulated in this Agreement, as well as to comply with AstraZeneca’s documented instructions.
		
	2.3
	Supplier shall not disclose or transfer In-Scope Personal Data to any third party except as permitted by Clause 3 (Subcontracting) or as compelled by Applicable Laws.

		
	2.4
	Supplier shall not transfer In-Scope Personal Data into any Cloud Computing service without AstraZeneca ́s prior written authorisation.

		
	2.4
	Supplier shall implement appropriate technical and organisational measures reflective of current best industry practice and technological development to protect In-Scope Personal Data against accidental or unlawful destruction or accidental loss (including deletion), alteration (including corruption), unauthorised disclosure, use or access and against all other unlawful forms of Processing. In particular, access controls should be in place and any In-Scope Personal Data downloaded onto a portable device or transferred through electronic means shall be encrypted and there should be a process for regularly testing and assessing the effectiveness of technical and organisational measures for ensuring the security of the Processing.

		
	2.5
	Supplier shall ensure that In-Scope Personal Data are accessible only to Supplier staff on a need-to-know basis and that such staff have been suitably trained according to the nature of the customer data they will be handling and that they are subject to binding confidentiality obligations with respect to their Processing of In-Scope Personal Data.

		
	3.
	Subcontracting

Supplier may use reputable Subcontractors to fulfil its obligations under this Agreement subject to the terms of this Clause 3. Prior to engaging any Subcontractor, or making any additions or replacements to any Subcontractor approved by AstraZeneca, Supplier shall inform AstraZeneca in writing of the same and promptly provide AstraZeneca with any detail in respect Supplier’s use of Subcontractors as may be reasonably requested by AstraZeneca.. In the event AstraZeneca, acting reasonably, does not approve of the use, addition or replacement of a Subcontractor, AstraZeneca may terminate this Agreement without penalty. Any Subcontractor will be permitted to Process In-Scope Personal Data only as necessary to deliver the obligations of Supplier under this Agreement, and Supplier shall procure that the Subcontractor does not Process In-Scope Personal Data for any other purpose. Prior to giving any Subcontractor access to or responsibilities in relation to In-Scope Personal Data, Supplier shall ensure that such Subcontractor has entered into a legally binding agreement with Supplier requiring that the Subcontractor abide by terms for the protection of In-Scope Personal Data not less protective than those in this Agreement and Supplier shall provide AstraZeneca with a copy or summary of such terms upon request. Supplier shall be fully liable for the acts and omissions of any Subcontractor to the same extent as if the acts or omissions were performed by Supplier.
		
	4.
	Security Incidents

		
	4.1
	Supplier shall notify AstraZeneca within 24 hours of becoming aware of any Security Incident and such notification will include, where possible, the categories and approximate number of data subjects concerned and approximate number of AstraZeneca records concerned, the impact and likely consequences on AstraZeneca and the affected data subjects of the Security Incident, and the corrective action to be taken by Supplier.

		
	4.2
	Supplier shall promptly implement, at Supplier’s expense (to the extent that the Security Incident was due to a breach of Supplier obligations under this Agreement), all corrective measures to necessary remedy the causes of the Security Incident and shall consult in good faith with AstraZeneca as regarding what remediation efforts may be necessary and reasonable and reasonably co-operate with any remediation efforts undertaken by AstraZeneca.

Page 39 of 62

		
	4.3
	Supplier shall ensure that such remediation efforts provide for, without limitation, prevention of the recurrence of the same type of Security Incident and inform AstraZeneca of all corrective measures implemented and remediation efforts undertaken.

		
	5.
	Cooperation and Assistance

		
	5.1
	Supplier shall co-operate with AstraZeneca in order to assist AstraZeneca with its obligations under applicable Data Protection Laws, including without limitation breach notification, privacy impact assessments or consultation obligations with a Data Protection Supervisory Authority.

		
	5.2
	Supplier shall also notify AstraZeneca within five (5) business days if it receives any communication from an individual, government authority or other party relating to In-Scope Personal Data. Supplier shall not respond to any such request unless obligated to do so under Applicable Laws or requested to do so by AstraZeneca. Supplier shall provide reasonable and timely assistance to help AstraZeneca respond to any such requests related to In-Scope Personal Data where AstraZeneca has a legal obligation to respond within a given timeframe.

		
	6.
	Term and Termination

		
	6.1
	Any breach by Supplier of the Data Protection and Security Requirements under this Agreement shall be deemed a material breach of this Agreement.

		
	6.2
	On any termination or expiry of this Agreement, completion of the [Services], or when instructed by AstraZeneca in writing, Supplier shall cease all operations on In-Scope Personal Data and shall, at AstraZeneca’s direction, return and/or irretrievably delete all In-Scope Personal Data Processed by Supplier under this Agreement and in a format agreed by the Parties and instruct its Subcontractors to do the same. Should Supplier be prevented by its national law or local regulator from destroying or returning all or part of such In-Scope Personal Data, Supplier shall keep the In-Scope Personal Data confidential and not Processed the In-Scope Personal Data for any other purpose.    Subject to the foregoing, Supplier shall complete the return and/or erasure of In-Scope Personal Data within 60 days of termination or expiry of this Agreement between the Parties.

		
	6.3
	The obligations under the Data Protection and Security Requirements shall expressly survive termination or expiry of this Agreement.

		
	7.
	Record Keeping and Audits

		
	7.1
	Supplier shall maintain all records required by Data Protection Law, including in respect of its Processing of In-Scope Personal Data, and make them available to AstraZeneca upon request.

		
	7.2
	AstraZeneca or its representatives have the right to conduct, with reasonable prior notice and under appropriate confidentiality restrictions and at its own expense, an audit of Supplier’s systems, policies and procedures that involve the Processing of In-Scope Personal Data. Where applicable, this may be done in agreement with a competent Data Protection Supervisory Authority. Such review may be conducted up to once annually, excluding audits at the request of a Data Protection Supervisory Authority that may be requested at any point in time by the Data Protection Supervisory Authorities or following a Security Incident. Following an audit under this Clause, AstraZeneca shall notify Supplier of the manner in which Supplier does not comply with any of the data protection obligations herein. Upon such notice, Supplier shall make any necessary changes to ensure compliance with such obligations.

		
	7.3
	In addition to, and not in lieu of, AstraZeneca’s right to conduct a review as described in the paragraph above, Supplier shall make available to AstraZeneca, upon AstraZeneca’s request all information necessary to demonstrate compliance with Data Protection Law, including but not limited to a copy of any independent auditor’s report which relates directly to Supplier’s performance under this Agreement (to be made not more than once annually).

Page 40 of 62

		
	8.
	Third Party Beneficiaries

AstraZeneca Affiliates may enforce the obligations of this Agreement against Supplier on condition that AstraZeneca will bring any legal action which that AstraZeneca Affiliate would otherwise have if it were a party to this Agreement directly against Supplier on behalf of the AstraZeneca Affiliate, save where the law to which the AstraZeneca Affiliate is subject requires that the AstraZeneca Affiliate itself brings or is party to such legal action.
For the avoidance of doubt, the term “Affiliate” shall mean any business entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control by a party to this Agreement.
		
	9.
	Indemnification and liability

Supplier shall be liable for and shall indemnify, defend, and hold harmless AstraZeneca its Affiliates officers, employees and agents from and against any and all costs, liabilities and claims of whatsoever nature incurred by AstraZeneca or its Affiliates and arising out of or in connection with any breach, negligent act, error or omission by Supplier, Supplier staff or Subcontractors arising out of or in connection with the Data Protection and Security Requirements under this Agreement.
		
	10.
	International Transfers

Supplier shall inform AstraZeneca in advance of the countries and territories in which Supplier and its Subcontractors will Process In-Scope Personal Data and shall comply with any reasonable additional instructions of AstraZeneca in relation to the same. On the date of signature of this Agreement, the Processing of In-Scope Personal Data by Supplier and its Subcontractors will be carried out from the following countries: United States of America, United Kingdom.
When the services involve In-Scope Personal Data originating from any country within the European Economic Area (EEA), which may be shared or transferred to Supplier, a Supplier Affiliate or Subcontractor located outside of the EEA, supplier shall not transfer the data unless: i) the transfer is to a country that has received a positive adequacy decision from the European Commission or ii) the transfer is made as per one of the legally accepted mechanisms covered in the Article 26 of the European Data Protection Directive 95/46/EC or Chapter V of the European General Data Protection Regulation (2016/679), as applicable (such as Standard Contract Clauses or Binding Corporate Rules).
The parties agree that, in relation to any transfers to Supplier of Personal Data relating to Data Subjects in the European Economic Area or Switzerland that takes place under this Agreement, the provisions set out in the Model Terms 2010/87/EU below shall apply and must be accompanied by and signed with this Agreement to be valid. Terms used in this Section that are not specifically defined will have the meaning in the European Data Protection Directive 95/46/EC or its superseding text.
Model Terms 2010/87/EU
Standard Contractual Clauses (Processors)
For the purposes of Article 26(2) of Directive 95/46/EC for the transfer of personal data to processors established in third countries which do not ensure an adequate level of data protection
Name of the data exporting organisation: AstraZeneca UK Limited
Address: ASTRAZENECA UK LIMITED, A COMPANY INCORPORATED IN ENGLAND UNDER NO. 3674842 WHOSE REGISTERED OFFICE IS AT 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE CB2 0AA, ENGLAND

Page 41 of 62

For itself and on behalf of its Affiliates identified in Appendix 3 of these Standard Contractual Clauses, who each are entitled to enforce the Clauses as independent Data Exporters (together the ‘data exporter’)
and
Name of the data importing organisation: ArcherDX, Inc.
Address: ARCHERDX, INC, A COMPANY INCORPORATED IN TEXAS WHOSE REGISTERED OFFICE IS AT 2477 55TH STREET, SUITE 202 BOULDER, CO 80301, USA
TEL.: + 1 877-771-1093
(the “Data Importer)
each a “Party”; together “the Parties,”
HAVE AGREED on the following Contractual Clauses (the Clauses) in order to adduce adequate safeguards with respect to the protection of privacy and fundamental rights and freedoms of individuals for the transfer by the data exporter to the data importer of the personal data specified in Appendix 1.
Clause 1
Definitions
For the purposes of the Clauses:
		
	(a)
	‘personal data’, ‘special categories of data’, ‘process/processing’, ‘controller’, ‘processor’, ‘data subject’ and ‘supervisory authority’ shall have the same meaning as in Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data1;

		
	(b)
	‘the data exporter’ means the controller who transfers the personal data;

		
	(c)
	‘the data importer’ means the processor who agrees to receive from the data exporter personal data intended for processing on his behalf after the transfer in accordance with his instructions and the terms of the Clauses and who is not subject to a third country’s system ensuring adequate protection within the meaning of Article 25(1) of Directive 95/46/EC;

		
	(d)
	‘the subprocessor’ means any processor engaged by the data importer or by any other subprocessor of the data importer who agrees to receive from the data importer or from any other subprocessor of the data importer personal data exclusively intended for processing activities to be carried out on behalf of the data exporter after the transfer in accordance with his instructions, the terms of the Clauses and the terms of the written subcontract;

______________________
1    Parties may reproduce definitions and meanings contained in Directive 95/46/EC within this Clause if they considered it better for the contract to stand alone.

Page 42 of 62

		
	(e)
	‘the applicable data protection law’ means the legislation protecting the fundamental rights and freedoms of individuals and, in particular, their right to privacy with respect to the processing of personal data applicable to a data controller in the Member State in which the data exporter is established;

		
	(f)
	‘technical and organisational security measures’ means those measures aimed at protecting personal data against accidental or unlawful destruction or accidental loss, alteration, unauthorised disclosure or access, in particular where the processing involves the transmission of data over a network, and against all other unlawful forms of processing.

Clause 2
Details of the transfer
The details of the transfer and in particular the special categories of personal data where applicable are specified in Appendix 1 which forms an integral part of the Clauses.
Clause 3
Third-party beneficiary clause
		
	1.
	The data subject can enforce against the data exporter this Clause, Clause 4(b) to (i), Clause 5(a) to (e), and (g) to (j), Clause 6(1) and (2), Clause 7, Clause 8(2), and Clauses 9 to 12 as third-party beneficiary.

		
	2.
	The data subject can enforce against the data importer this Clause, Clause 5(a) to (e) and (g), Clause 6, Clause 7, Clause 8(2), and Clauses 9 to 12, in cases where the data exporter has factually disappeared or has ceased to exist in law unless any successor entity has assumed the entire legal obligations of the data exporter by contract or by operation of law, as a result of which it takes on the rights and obligations of the data exporter, in which case the data subject can enforce them against such entity.

		
	3.
	The data subject can enforce against the subprocessor this Clause, Clause 5(a) to (e) and (g), Clause 6, Clause 7, Clause 8(2), and Clauses 9 to 12, in cases where both the data exporter and the data importer have factually disappeared or ceased to exist in law or have become insolvent, unless any successor entity has assumed the entire legal obligations of the data exporter by contract or by operation of law as a result of which it takes on the rights and obligations of the data exporter, in which case the data subject can enforce them against such entity. Such third-party liability of the subprocessor shall be limited to its own processing operations under the Clauses.

		
	4.
	The parties do not object to a data subject being represented by an association or other body if the data subject so expressly wishes and if permitted by national law.

Clause 4
Obligations of the data exporter
The data exporter agrees and warrants:
		
	(a)
	that the processing, including the transfer itself, of the personal data has been and will continue to be carried out in accordance with the relevant provisions of the applicable data protection law (and, where applicable, has been notified to the relevant authorities of the 

Page 43 of 62

Member State where the data exporter is established) and does not violate the relevant provisions of that State;
		
	(b)
	that it has instructed and throughout the duration of the personal data processing services will instruct the data importer to process the personal data transferred only on the data exporter’s behalf and in accordance with the applicable data protection law and the Clauses;

		
	(c)
	that the data importer will provide sufficient guarantees in respect of the technical and organisational security measures specified in Appendix 2 to this contract;

		
	(d)
	that after assessment of the requirements of the applicable data protection law, the security measures are appropriate to protect personal data against accidental or unlawful destruction or accidental loss, alteration, unauthorised disclosure or access, in particular where the processing involves the transmission of data over a network, and against all other unlawful forms of processing, and that these measures ensure a level of security appropriate to the risks presented by the processing and the nature of the data to be protected having regard to the state of the art and the cost of their implementation;

		
	(e)
	that it will ensure compliance with the security measures;

		
	(f)
	that, if the transfer involves special categories of data, the data subject has been informed or will be informed before, or as soon as possible after, the transfer that its data could be transmitted to a third country not providing adequate protection within the meaning of Directive 95/46/EC;

		
	(g)
	to forward any notification received from the data importer or any subprocessor pursuant to Clause 5(b) and Clause 8(3) to the data protection supervisory authority if the data exporter decides to continue the transfer or to lift the suspension;

		
	(h)
	to make available to the data subjects upon request a copy of the Clauses, with the exception of Appendix 2, and a summary description of the security measures, as well as a copy of any contract for subprocessing services which has to be made in accordance with the Clauses, unless the Clauses or the contract contain commercial information, in which case it may remove such commercial information;

		
	(i)
	that, in the event of subprocessing, the processing activity is carried out in accordance with Clause 11 by a subprocessor providing at least the same level of protection for the personal data and the rights of data subject as the data importer under the Clauses; and

		
	(j)
	that it will ensure compliance with Clause 4(a) to (i).

Page 44 of 62

Clause 5
Obligations of the data importer2 
The data importer agrees and warrants:
		
	(a)
	to process the personal data only on behalf of the data exporter and in compliance with its instructions and the Clauses; if it cannot provide such compliance for whatever reasons, it agrees to inform promptly the data exporter of its inability to comply, in which case the data exporter is entitled to suspend the transfer of data and/or terminate the contract;

		
	(b)
	that it has no reason to believe that the legislation applicable to it prevents it from fulfilling the instructions received from the data exporter and its obligations under the contract and that in the event of a change in this legislation which is likely to have a substantial adverse effect on the warranties and obligations provided by the Clauses, it will promptly notify the change to the data exporter as soon as it is aware, in which case the data exporter is entitled to suspend the transfer of data and/or terminate the contract;

		
	(c)
	that it has implemented the technical and organisational security measures specified in Appendix 2 before processing the personal data transferred;

		
	(d)
	that it will promptly notify the data exporter about:

		
	(i)
	any legally binding request for disclosure of the personal data by a law enforcement authority unless otherwise prohibited, such as a prohibition under criminal law to preserve the confidentiality of a law enforcement investigation,

		
	(ii)
	any accidental or unauthorised access, and

		
	(iii)
	any request received directly from the data subjects without responding to that request, unless it has been otherwise authorised to do so;

		
	(e)
	to deal promptly and properly with all inquiries from the data exporter relating to its processing of the personal data subject to the transfer and to abide by the advice of the supervisory authority with regard to the processing of the data transferred;

		
	(f)
	at the request of the data exporter to submit its data processing facilities for audit of the processing activities covered by the Clauses which shall be carried out by the data exporter or an inspection body composed of independent members and in possession of the required professional qualifications bound by a duty of confidentiality, selected by the data exporter, where applicable, in agreement with the supervisory authority;

______________________
2    Mandatory requirements of the national legislation applicable to the data importer which do not go beyond what is necessary in a democratic society on the basis of one of the interests listed in Article 13(1) of Directive 95/46/EC, that is, if they constitute a necessary measure to safeguard national security, defence, public security, the prevention, investigation, detection and prosecution of criminal offences or of breaches of ethics for the regulated professions, an important economic or financial interest of the State or the protection of the data subject or the rights and freedoms of others, are not in contradiction with the standard contractual clauses. Some examples of such mandatory requirements which do not go beyond what is necessary in a democratic society are, inter alia, internationally recognised sanctions, tax-reporting requirements or anti-money-laundering reporting requirements.

Page 45 of 62

		
	(g)
	to make available to the data subject upon request a copy of the Clauses, or any existing contract for subprocessing, unless the Clauses or contract contain commercial information, in which case it may remove such commercial information, with the exception of Appendix 2 which shall be replaced by a summary description of the security measures in those cases where the data subject is unable to obtain a copy from the data exporter;

		
	(h)
	that, in the event of subprocessing, it has previously informed the data exporter and obtained its prior written consent;

		
	(i)
	that the processing services by the subprocessor will be carried out in accordance with Clause 11;

		
	(j)
	to send promptly a copy of any subprocessor agreement it concludes under the Clauses to the data exporter.

Clause 6
Liability
		
	1.
	The parties agree that any data subject, who has suffered damage as a result of any breach of the obligations referred to in Clause 3 or in Clause 11 by any party or subprocessor is entitled to receive compensation from the data exporter for the damage suffered.

		
	2.
	If a data subject is not able to bring a claim for compensation in accordance with paragraph 1 against the data exporter, arising out of a breach by the data importer or his subprocessor of any of their obligations referred to in Clause 3 or in Clause 11, because the data exporter has factually disappeared or ceased to exist in law or has become insolvent, the data importer agrees that the data subject may issue a claim against the data importer as if it were the data exporter, unless any successor entity has assumed the entire legal obligations of the data exporter by contract of by operation of law, in which case the data subject can enforce its rights against such entity. 

The data importer may not rely on a breach by a subprocessor of its obligations in order to avoid its own liabilities.
		
	3.
	If a data subject is not able to bring a claim against the data exporter or the data importer referred to in paragraphs 1 and 2, arising out of a breach by the subprocessor of any of their obligations referred to in Clause 3 or in Clause 11 because both the data exporter and the data importer have factually disappeared or ceased to exist in law or have become insolvent, the subprocessor agrees that the data subject may issue a claim against the data subprocessor with regard to its own processing operations under the Clauses as if it were the data exporter or the data importer, unless any successor entity has assumed the entire legal obligations of the data exporter or data importer by contract or by operation of law, in which case the data subject can enforce its rights against such entity. The liability of the subprocessor shall be limited to its own processing operations under the Clauses.

Page 46 of 62

Clause 7
Mediation and jurisdiction
		
	1.
	The data importer agrees that if the data subject invokes against it third-party beneficiary rights and/or claims compensation for damages under the Clauses, the data importer will accept the decision of the data subject:

		
	(a)
	to refer the dispute to mediation, by an independent person or, where applicable, by the supervisory authority;

		
	(b)
	to refer the dispute to the courts in the Member State in which the data exporter is established.

		
	2.
	The parties agree that the choice made by the data subject will not prejudice its substantive or procedural rights to seek remedies in accordance with other provisions of national or international law.

Clause 8
Cooperation with supervisory authorities
		
	1.
	The data exporter agrees to deposit a copy of this contract with the supervisory authority if it so requests or if such deposit is required under the applicable data protection law.

		
	2.
	The parties agree that the supervisory authority has the right to conduct an audit of the data importer, and of any subprocessor, which has the same scope and is subject to the same conditions as would apply to an audit of the data exporter under the applicable data protection law.

		
	3.
	The data importer shall promptly inform the data exporter about the existence of legislation applicable to it or any subprocessor preventing the conduct of an audit of the data importer, or any subprocessor, pursuant to paragraph 2. In such a case the data exporter shall be entitled to take the measures foreseen in Clause 5 (b).

Clause 9
Governing Law
The Clauses shall be governed by the law of the Member State in which the data exporter is established, namely the laws of the respective European Economic Area country where the data exporting entity is established.
Clause 10
Variation of the contract
The parties undertake not to vary or modify the Clauses. This does not preclude the parties from adding clauses on business related issues where required as long as they do not contradict the Clause.

Page 47 of 62

Clause 11
Subprocessing
		
	1.
	The data importer shall not subcontract any of its processing operations performed on behalf of the data exporter under the Clauses without the prior written consent of the data exporter. Where the data importer subcontracts its obligations under the Clauses, with the consent of the data exporter, it shall do so only by way of a written agreement with the subprocessor which imposes the same obligations on the subprocessor as are imposed on the data importer under the Clauses3. Where the subprocessor fails to fulfil its data protection obligations under such written agreement the data importer shall remain fully liable to the data exporter for the performance of the subprocessor’s obligations under such agreement.

		
	2.
	The prior written contract between the data importer and the subprocessor shall also provide for a third-party beneficiary clause as laid down in Clause 3 for cases where the data subject is not able to bring the claim for compensation referred to in paragraph 1 of Clause 6 against the data exporter or the data importer because they have factually disappeared or have ceased to exist in law or have become insolvent and no successor entity has assumed the entire legal obligations of the data exporter or data importer by contract or by operation of law. Such third-party liability of the subprocessor shall be limited to its own processing operations under the Clauses.

		
	3.
	The provisions relating to data protection aspects for subprocessing of the contract referred to in paragraph 1 shall be governed by the law of the Member State in which the data exporter is established, namely the laws of the European Economic Area country where the data exporting entity has its place of establishment.

		
	4.
	The data exporter shall keep a list of subprocessing agreements concluded under the Clauses and notified by the data importer pursuant to Clause 5 (j), which shall be updated at least once a year. The list shall be available to the data exporter’s data protection supervisory authority.

Clause 12
Obligation after the termination of personal data processing services
		
	1.
	The parties agree that on the termination of the provision of data processing services, the data importer and the subprocessor shall, at the choice of the data exporter, return all the personal data transferred and the copies thereof to the data exporter or shall destroy all the personal data and certify to the data exporter that it has done so, unless legislation imposed upon the data importer prevents it from returning or destroying all or part of the personal data transferred. In that case, the data importer warrants that it will guarantee the confidentiality of the personal data transferred and will not actively process the personal data transferred anymore.

		
	2.
	The data importer and the subprocessor warrant that upon request of the data exporter and/or of the supervisory authority, it will submit its data processing facilities for an audit of the measures referred to in paragraph 1.

______________________
3    This requirement may be satisfied by the subprocessor co-signing the contract entered into between the data exporter and the data importer under this Decision.

Page 48 of 62

On behalf of the data exporter:
Name (written out in full):    Matthew Craske
Position:    Global Category Manager
Address:    1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England
Other information necessary in order for the contract to be binding (if any):
	
					
	Signature
	 
	 
	 
	 

	 
	 
	 
	Date
	 

	 
	 
	(stamp of organisation)
	 

On behalf of the data importer:
Name (written out in full):    Christian LaPointe
Position:    General Counsel
Address:    2477 55th Street Suite 202 Boulder, CO 80301
Other information necessary in order for the contract to be binding (if any):
	
					
	Signature
	 
	 
	 
	 

	 
	 
	 
	Date
	 

Page 49 of 62

APPENDIX 1 TO THE STANDARD CONTRACTUAL CLAUSES
This Appendix forms part of the Clauses and must be completed and signed by the parties. 
The Member States may complete or specify, according to their national procedures, any additional necessary information to be contained in this Appendix.
Data exporter
The data exporter is (please specify briefly your activities relevant to the transfer):
AstraZeneca is one of the world ́s leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The activities relevant to this transfer involve patient data for clinical testing.
Data importer
The data importer is (please specify briefly activities relevant to the transfer):
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining patented Anchored Multiplexed PCR (AMPTM) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays to enable therapy selection and response as well as surveillance of disease recurrence. Learn more at archerdx.com. The activities relevant to this transfer involve patient data for clinical testing.
Data subjects
The personal data transferred concern the following categories of data subjects (please specify): Patients
Categories of data
The personal data transferred concern the following categories of data (please specify):
Medical records, blood samples, genetic data
Processing operations
The personal data transferred will be subject to the following basic processing activities (please specify):
		
	•
	Clinical Trials: conduct/coordinate clinical studies sponsored by Astra Zeneca for the development and testing of medicines, medical aids.

	
			
	DATA EXPORTER
	 
	DATA IMPORTER

	 
	 
	 

	Name: Matthew Craske
	 
	Name: Christian LaPointe

	 
	 
	 

	Authorised Signature
	 
	Authorised Signature

	 
	 
	 

	 
	 
	 

Page 50 of 62

APPENDIX 2 TO THE STANDARD CONTRACTUAL CLAUSES
This Appendix forms part of the Clauses and must be completed and signed by the parties.
Description of the technical and organisational security measures implemented by the data importer in accordance with Clauses 4(d) and 5(c) (or document/legislation attached): 
Importer shall take technical and organisational measures consistent with or higher than Good Industry Practice to protect Personal Data against accidental, unlawful or unauthorised destruction, loss, damage, alteration, copying, combination, disclosure, use and access. In particular, Personal Data shall not be downloaded onto any portable device or transmitted unless the device or transmission method are encrypted.

Page 51 of 62

APPENDIX 3 TO THE STANDARD CONTRACTUAL CLAUSES
EXPORTER AFFILIATES WITHIN THE EEA
The following Astra Zeneca Affiliates within the EEA + Switzerland are identified as data exporters for the purpose of the Standard Contractual Clauses.
	
				
	Name of AstraZeneca Affiliate
	Address (including country)
	Telephone Number
	Other Information (if applicable)

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	 
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

Page 52 of 62

	
				
	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	[**]
	 

	[**]
	[Intentionally Omitted]
	 
	 

	[**]
	[Intentionally Omitted]
	 
	 

Page 53 of 62

SCHEDULE 4 - SUMMARY OF ASTRAZENECA PROMOTIONAL POLICIES
This attachment summarizes a number of AstraZeneca policies that apply generally to how AstraZeneca promotes its products. These policies apply to employees of third parties engaged to provide services to AstraZeneca or its Affiliates, and compliance with these policies is mandatory. For further detail on AstraZeneca policies, please contact your AstraZeneca representative.
AstraZeneca will promote our Products only in accordance with the approved label
		
	•
	The full Prescribing Information or label sets out the approved conditions for use of a drug, including the indications, dosages, patient populations, warnings, contraindications and Adverse Events. Every promotional communication must be consistent with the label and you must not discuss off-label indications, uses or populations, even reactively.

		
	•
	Any promotional communication, however brief or informal, must contain balance between benefits and risks of a Product. Supplier must not diminish the warnings in the label or suggest an Adverse Event is a benefit.

		
	•
	AstraZeneca will only promote our Products to Health Care Professionals (“HCPs”) that are reasonably likely to prescribe them for labeled indications.  AstraZeneca has safeguards in place to ensure that we do not promote our Products to medical specialties that are unlikely to prescribe for on-label uses.  These safeguards include HCP blocking from promotional eligibility and sales incentive planning restrictions.

		
	•
	Supplier must offer a copy of the label for each Product discussion you initiate.  Any Product promotional materials you leave behind or send must include a copy of the label.

All materials used in promotion must be pre-approved
		
	•
	AstraZeneca maintains defined regulatory approval processes to ensure that all promotional materials are reviewed by qualified AstraZeneca personnel and are medically and scientifically accurate, objective and compliant with regulatory requirements.

		
	•
	No AstraZeneca employee or vendor can use, publish or communicate promotional materials that have not been approved through the appropriate regulatory approval process.

Supplier must maintain the confidentiality of sales and prescribing data
		
	•
	Although AstraZeneca can use patient de-identified sales and individual prescribing data for a variety of appropriate reasons, this data must be kept strictly confidential and cannot be shared with customers, competitors or anyone else outside of AstraZeneca or its Affiliates, unless expressly authorized by written agreement.

		
	•
	Supplier must not share or reference prescribing trends or details shown by the data (for example, changes in an HCP’s use of a product over time or use of competitor products).

Supplier must protect the privacy of patients, consumers and other third parties
		
	•
	Supplier should not intentionally engage in product discussions with patients and consumers. If Supplier comes into contact with patients or consumers at HCP offices, hospitals, health fairs and similar events, Supplier must not interfere, in any way, in the relationship between patients and their HCPs.

		
	•
	Supplier must not intentionally observe treatment of a patient without verifying that the HCP has obtained the patient’s written consent for your observation. Supplier must not examine patient or prescription files or similar records or otherwise obtain access to specific information about prescribing practices covering individual patients.

Page 54 of 62

		
	•
	Supplier must obtain an affirmative opt-in before initiating consumer communications and honor the requests of consumers.

		
	•
	Supplier must only collect personal information for legitimate business purposes and inform third parties of the purpose before or at the time of collection.

Supplier must report Adverse Events to Patient Safety
		
	•
	An Adverse Event is the development of an undesirable condition or deterioration of a pre-existing medical condition following or during exposure to a drug, regardless of whether the drug is believed to be the cause of the event.

		
	•
	Supplier must make every effort to report a death or life-threatening event on the same day you become aware of it by contacting AstraZeneca Information Center.  Supplier must report other safety events within one business day.

Supplier must not participate in scientific exchange if you are in a commercial role
		
	•
	The communication of objective, balanced and substantiated scientific information constitutes scientific exchange and is not regulated as promotional activity as long as the exchange does not occur in a promotional context and additional safeguards are in place. In order to preserve the separation between scientific exchange and promotional activities, only scientifically trained individuals outside of a commercial role may participate in scientific exchange.

Patient Assistance Programs must never be used to promote our Products
		
	•
	AstraZeneca’s Patient Assistance Programs (“PAPs”) provide patients with access to our medicines regardless of their ability to pay. To ensure that these programs are not misused for commercial purposes, discussion about our PAPs must be separated from product promotion to avoid any suggestion that our PAPs are intended to increase sales.

		
	•
	PAPs must never be provided as an incentive or reward for past, current or future prescribing, purchasing, use or dispensing of our products, or to help offset a payor’s cost of purchasing or reimbursing our products.

Page 55 of 62

SCHEDULE 5 – HUMAN BIOLOGICAL SAMPLES
To the extent the Services involve the sourcing, use or handling of Human Biological Samples (as defined below) the following provisions shall apply and shall form an integral part of the Agreement. 
Definitions
Unless otherwise specifically provided in any other parts of this Agreement, the following terms shall have the meanings set forth below. Any capitalized terms used in this Exhibit which are not defined herein shall have the meaning attributed thereto in the main body of the Agreement. In the event of a discrepancy between the terms set forth in this Exhibit and any other parts of the Agreement, the terms of this Exhibit shall govern all matters relating to Human Biological Samples and all other matters shall be governed by the relevant terms set forth in any other parts of this Agreement.
		
	1.1
	“Applicable Laws” means all national, supranational, federal, state, foreign or provincial and local laws (including case law), legislation, European regulations, statutes, statutory instruments, rules, regulations, edicts, by-laws or directions or guidance from government or governmental agencies, including any rules, regulations, guidelines or other requirements of Regulatory Authorities, which have the force of law and any industry codes of practice in effect from time to time.

		
	1.2
	“Approved Third Party Supplier” means a supplier of Human Biological Samples on AstraZeneca’s list of approved suppliers for the relevant type of HBS from time to time.

		
	1.3
	“De-identified” when used in relation to any data or information shall mean data or information which has been stripped of all subject information that could make an individual identifiable and where the party that shares the information or data has no reasonable knowledge which makes it possible to use the remaining information to identify the individual on its own or in combination with other information that could be reasonably obtained. This includes but is not limited to the removal, masking or generalization of all 18 HIPAA (the U.S. Health Insurance Portability and Accountability Act) identifiers. This means that there are no data points left that could be reasonably used to link the data set to a particular individual, such as age older than 89 years old; geographic location smaller than a State (or equivalent); exact elements of dates directly related to an individual (i.e., date of birth, date of death, dates of hospital visits, etc.); any unique identifying number, characteristic or code directly linked to an individual (i.e., national ID number, social security number, bank account number); contact details of any type; biometric identifiers (e.g., finger and voice prints); photos and comparable images; etc. and the parties supplying and receiving the information or data have no knowledge which makes it possible to use the remaining information to identify the individual.

		
	1.4
	“Diagnostic Samples” means any Human Biological Samples collected for purposes of diagnostics.

		
	1.5
	“Donor” means the individual from whom the Human Biological Sample(s) are  
acquired.

		
	1.6
	“Donor Information” means the following information relating to a Donor of Human Biological Samples and any additional information stipulated in Statement of Work:

		
	(a)
	year of birth of Donor;

Page 56 of 62

		
	(b)
	state of health of Donor and if applicable his/her agonal state;

		
	(c)
	the Donor’s medical history;

		
	(d)
	details of any restriction on the HBS in regard to Donor’s informed consent;

		
	(e)
	informed consent documentation template relating to the relevant HBS, along with true, complete, accurate and not misleading details of how the actual consent documentation signed by or on behalf of Donor varies from such template.

		
	1.7
	Good Clinical Practice” or “GCP” means the ICH ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects.

		
	1.8
	“Good Industry Practice” shall mean standards, practices, methods and procedures conforming to Applicable Laws, including as applicable, Good Clinical Practice and Good Laboratory Practice, and the degree of skill and care, diligence, prudence and foresight which would reasonably and ordinarily be expected from a skilled and experienced operator engaged in a similar undertaking under similar circumstances.

		
	1.9
	“Good Laboratory Practice” or “GLP” means the OECD ENV/MC/CHEM(98)17 quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported.

		
	1.10
	“Human Biological Samples” or “HBS” means biological materials acquired or derived from living or deceased human beings, which consist of or include human cells, subject to the following inclusions and exclusions:

		
	1.10.1
	Human Biological Samples or HBS include, but are not limited to:

		
	(a)
	solid specimens and certain materials processed directly from tissue, such as tissue sections on slides;

		
	(b)
	all primary tissue including primary cells, whole explant/biopsy cells, whole blood, plasma, serum, certain body fluids (including bile, excreta and sputum);

		
	(c)
	all samples and their derivatives, collected under informed consent on behalf of AstraZeneca during clinical trials/studies; and

		
	(d)
	DNA and other derivatives generated from the biological materials referred to above, where traceable to individual Donors (consent requirements apply).

		
	1.10.2
	Subject to Section 1.10.3 below (Sweden) Human Biological Samples or HBS exclude:

		
	(a)
	cells that have divided outside the body, including immortalized cell lines, as well as processed or acellular materials derived from human tissue, fluids or cells; such as proteins, lipids, assay controls, growth factors and other human molecules/substances;

		
	(b)
	biological samples of human origin (such as antibodies) that are not classified as HBS under the definition above shall be treated as laboratory reagents;

		
	(c)
	eggs, sperm, and human embryos (outside the body) (other restrictions apply);

		
	(d)
	cloned gene libraries (genomic and cDNA); and

		
	(e)
	RNA (unless for analysis technique to generate genomic DNA).

Page 57 of 62

		
	1.10.3
	Where sourced within Sweden, HBS shall additionally include cells that have been divided outside the body, including cell lines, processed or acellular materials derived from human tissue, fluids or cells, genes and parts of genes, and other types of biological materials – if traceable to a person, living or dead or a fetus.

		
	1.11
	“Remnant Samples” means the remnant of Human Biological Samples collected for routine clinical care or analysis that would otherwise have been discarded.

Requirements – Human Biological Samples
		
	2.1
	Supplier recognizes AstraZeneca’s commitment to working only with suppliers who embrace standards of ethical behavior that are consistent with AstraZeneca’s Global Policy on Bioethics, which can be found at: https://www.astrazeneca.com/content/dam/az/ourcompany/Sustainability/Bioethics-Policy-v60.pdf Supplier represents, warrants and undertakes that it shall perform the Services and operate its business in a manner which is consistent with said policy.

		
	2.2
	The Parties shall agree on each Party’s responsibility in respect of sourcing or providing Human Biological Samples to be used in the Services. To the extent this is not specifically set forth in this Agreement, such HBS shall be sourced or provided by Supplier unless AstraZeneca requires otherwise. The term Services as used in this Agreement shall be deemed to include Supplier process of collecting or preparing HBS.

		
	2.3
	Each Party shall ensure that any HBS sourced or provided by such Party conform to the requirements set forth in this Agreement. Supplier acknowledges and agrees that, the custody and control of, and to the extent permitted by law, title to, Human Biological Samples provided by AstraZeneca shall at all times remain with AstraZeneca (or its designee).

		
	2.4
	Supplier warrants and represents that all Human Biological Materials will be sourced or provided (insofar as they are sourced or provided by Supplier handled, retained, used, maintained, stored, transferred, transported and disposed of in accordance with the provisions set forth in this Agreement, all Applicable Laws, Good Industry Practice and any instructions or policies provided by or on behalf of AstraZeneca. Unless otherwise agreed with AstraZeneca in writing Supplier furthermore warrants and represents that it shall not use the HBS for any purpose other than in Supplier’s performance of Services and only in accordance with the provisions set forth in this Agreement.

		
	2.5
	Supplier shall ensure that all Human Biological Samples and any associated data or information sourced or provided by Supplier and used in the Services are of appropriate quality, are fit for purpose, suitable for the intended research purposes and in all respects, conform with the requirements specified in this Agreement.

		
	2.6
	Unless otherwise agreed to in writing by AstraZeneca, Supplier shall source or provide Human Biological Samples in accordance with the following order of precedence: (a) firstly from Supplier’s own internal biobank (if relevant to the nature of the relevant HBS), (b) secondly from an AstraZeneca Approved Third Party Supplier, and (c) thirdly, solely with AstraZeneca’s written consent, a supplier approved in advance by AstraZeneca. HBS may not be sourced from a third party without the prior written consent of AstraZeneca.

		
	2.7
	AstraZeneca may monitor Supplier’s acquisition process for Human Biological Samples and any associated data or information and has the right but not the obligation to audit the process to ensure compliance with this Agreement.

Page 58 of 62

		
	2.8
	Supplier acknowledges and agrees that the Human Biological Samples are experimental in nature. Under no circumstance shall Supplier use the HBS in humans.

		
	2.9
	Supplier acknowledges and agrees that, subject to Section 2.10, all Human Biological Samples provided by AstraZeneca are provided “as is”, and to the maximum extent permitted by applicable law AstraZeneca hereby disclaims and excludes any and all representations, warranties, conditions or other terms, whether written or oral, expressed or implied, with respect to such HBS, including any representation or warranty of quality, performance, merchantability or fitness for a particular use or purpose.

		
	2.10
	A Party sourcing or providing Human Biological Samples under this Agreement shall ensure it has obtained or is in the possession of all necessary ethical approvals as well as the appropriate informed consent of either the Donor or the person entitled under Applicable Laws required for: (a) the sourcing or provision (including via a third party) of such HBS and any associated data or information, (b) the use of such HBS and any associated data or information in the Services and (c) the assignment and transfer to and use by AstraZeneca or its designee of the Results and (if relevant) the HBS and any associated data or information. Said Party furthermore represents and warrants that the informed consent process and pro-forma used for sourcing or providing such HBS and any associated data or information as well as the informed consent:

is in writing;
is obtained before commencement of the relevant Services;
allows commercial use;
allows withdrawal of the informed consent;
specifies whether genetic use is allowed;
includes data privacy wording where a Donor is living;
includes no right to financial gain to Donor; and
includes whether the applicable HBS and any associated data or information can be retained for a finite or indefinite period.
		
	2.11
	Supplier shall not source or provide Human Biological Samples for which no informed consent has been obtained, Remnant Samples, Diagnostic Samples or HBS which contain human embryonic stem cells (“hESCs”) or human fetal tissues (“hFTs”), or any cells derived from any of the aforesaid, unless AstraZeneca has provided prior written consent to such supply and the source of such supply, such approvals to be given or withheld in AstraZeneca’s sole discretion.

		
	2.12
	A Party sourcing or providing Human Biological Samples under this Agreement shall promptly notify the other Party in writing of any restrictions on the transfer, shipment, storage, use or disposal of the Human Biological Samples and any associated data or information, including the relevant Donor Information, or if the Donor of any HBS withdraws the informed consent in whole or in part. If the informed consent to use a HBS in the Services is withdrawn, the Parties shall immediately discontinue using such HBS and shall handle it and ensure disposal is carried out in accordance with the process referred to in Section 2.17 and 2.18. Furthermore, AstraZeneca shall have the right, at its own option, to: (a) allow for the sourcing 

Page 59 of 62

or provision of new HBS in replacement of the HBS for which the informed consent has been withdrawn and for the Services to proceed using such replacement HBS, (b) terminate this Agreement, or (c) terminate those parts of the Services to which the HBS relate, in either case without liability to the Supplier except that AstraZeneca will pay for any part of the Services which have been successfully completed at the effect of such termination.
		
	2.13
	A Party sourcing or providing Human Biological Samples under this Agreement shall supply Donor Information and other information or data stipulated in this Agreement to the other Party. This obligation The Donor Information and any such other information or data shall be coded, De-identified or anonymised so that the receiving Party does not know the identity of the Donor.

		
	2.14
	To the extent the Services include the delivery of Human Biological Samples to AstraZeneca, any such HBS and any associated information or data shall be in coded and De-identified or anonymized form so that AstraZeneca does not know the identity of the Donor. AstraZeneca acknowledges the importance of data privacy of individuals to whom shared data may relate and it commits not to attempt to locate or re-identify individuals who are the subject of the data, not to combine the supplied data with other sources of data that could lead to the identification of any individual, and not to reverse engineer, reverse assemble or decompile the data.

		
	2.15
	Supplier shall, and shall ensure its suppliers and subcontractors have in place and maintain all the safety procedures and practices required by Applicable Law to adequately protect the quality of the Human Biological Samples and integrity of the Donor Information and any other associated data or information and shall ensure that its/their (as applicable) employees, agents, and other representatives comply with such safety procedures and practices.

		
	2.16
	Supplier shall, and shall ensure its suppliers and subcontractors have in place and maintain a tracking system and a chain-of-custody for all Human Biological Samples to allow traceability and enable the identification of the chronological history of the life cycle of the HBS.

		
	2.17
	Supplier shall, and shall ensure its suppliers and subcontractors have in place and maintain throughout the Term a documented and defined process in accordance with Applicable Laws and Good Industry Practice for the handling and disposal of excess, obsolete or rejected Human Biological Samples. To the extent any HBS are destroyed, Supplier shall keep records of destruction and shall provide copies thereof to AstraZeneca on AstraZeneca’s request.

		
	2.18
	At the completion of the Services, the early termination of this Agreement or the relevant Statement of Work, as the case may be, or at AstraZeneca’s earlier request, Supplier shall handle and dispose of the Human Biological Samples in accordance with AstraZeneca’s instructions and Supplier shall not make any further use thereof. In the event AstraZeneca requires destruction of any HBS, and in the absence of specific instructions from AstraZeneca, Supplier shall destroy the HBS within a prompt timeframe and in accordance with the process set forth in Section 2.17.

Page 60 of 62

SHEDULE 6 – KEY PERFORMANCE INDICATORS (SERVICE LEVELS)
	
				
	Service Level 
Description
	Conditions
	Service Level Measurement
	Service Measurement Period

	Service Level 1
Accuracy of reporting of patient results (reports or data) back to AZ or clinical sites.
Applies to prospective and retrospective sample analysis
	Pre-requisite:
AZ to provide biomarker eligibility rules to be programmed by Supplier
	Expected: 100% accurate data reported back to clinical sites for each patient.
Applicable to all SOWs
	Per each patient sample through duration of service

	Service Level 2
TATs for sample analysis and reporting of patient Results to clinical sites (positive or failed) or AZ
Applies to prospective and retrospective sample analysis
	No patient identification query or failure of DNA extraction hold
	Achieve contractually agreed TATs across all Project Schedules and associated SoWs each month.
To be calculated from sample being accessioned at Supplier
95% of samples monthly within expected TATs
	Monthly frequency

	Service Level 3
TATs for new drafting new SoW, or SOW amendment
	Pre-requisite: agreed prices for each activity and timelines required for their delivery
	SOW drafts to take between ten (10) and fifteen (15) days as agreed by the Parties depending on the complexity of the RFP
Same to apply to amendments
	Per each contract

Page 61 of 62

SCHEDULE 7 – DESIGN AND REPORTING OF ESSENTIAL AND EXPLORATORY RESEARCH OBJECTIVES.
Study Design Principles:
Supplier analyses may generate data that are essential to clinical study conduct/regulatory submission and exploratory data from the same samples.
AstraZeneca and Supplier will agree in advance which data are required for which purpose ie
clinical sites, clinical database and exploratory reporting.
All data may be disclosed to regulatory authorities if requested by them.
Data from tumour/plasma may include candidate predictive biomarkers, such as a EGFR mutation
status for example, and the tracking of other specific variants in plasma requested by AstraZeneca.
Failed analyses
AstraZeneca will not be charged for failed analyses
Vendor results to AstraZeneca: general
Primary and exploratory data will have different, pre-agreed reporting routes, frequency and format.
Vendor results to AstraZeneca: Identification and reporting of genomic variants from comparison of tumour and normal DNA including
		
	1.
	Sample adequacy assessment

		
	2.
	Identification/analysis of tumour specific variants

		
	3.
	Those chosen for tracking

		
	4.
	Those identified

		
	5.
	Pre-requests, for example tumour EGFRm status, (discuss if TMB & MSI pipeline/plans in place)

		
	6.
	Raw data files in an agreed format

Vendor Results to AstraZeneca: Tracking/analysis of plasma
For (i) selected a panel, for example MRD panel, and (ii) AZ requested customisable tracking
Standard report +/
Individual mutations AF
Overall tumour genome equivalent

Page 62 of 62Exhibit

Exhibit 10.16
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE ARCHERDX, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCHERDX, INC. IF PUBLICLY DISCLOSED.
Confidential – Execution version

IN VITRO DIAGNOSTICS
MASTER COLLABORATION AGREEMENT
between
ASTRAZENECA UK LIMITED
and
ARCHERDX, INC
Dated as of
22nd April 2020

TABLE OF CONTENTS
	
			
	Article 1
	DEFINITIONS
	1

	 
	 
	 

	Article 2
	PROJECTS
	15

	 
	 
	 

	2.1.
	Project Schedules
	15

	2.2.
	Adoption of Project Schedules
	15

	2.4.
	Amendments to Project Schedules
	17

	2.5.
	Project Delays
	18

	2.6
	Project Suspension
	20

	2.7.
	Conflicting Provisions
	21

	2.8
	KPIs
	22

	 
	 
	 

	Article 3
	MATERIALS
	22

	 
	 
	 

	3.1.
	Procurement of Materials
	22

	3.2.
	Delivery of AZ Materials
	22

	3.3.
	Use Restrictions
	23

	3.4.
	Materials Handling and Retention by Company
	23

	3.5.
	Return or Destruction of Materials
	23

	3.6.
	Samples
	23

	 
	 
	 

	Article 4
	TRANSFERS OF AZ CLINICAL DATA
	24

	 
	 
	 

	4.1.
	Overview
	24

	4.2.
	Data Transfer
	24

	4.3.
	Conditions on Transfer of Clinical Data
	24

	4.4.
	Conditions of Transfer of Samples
	25

	4.5
	Confidentiality
	25

	 
	 
	 

	Article 5
	DEVELOPMENT AND REGULATORY ACTIVITIES
	26

	 
	 
	 

	5.1.
	General Principles
	26

	5.2.
	Collaboration on Regulatory Strategy
	26

	5.3.
	Regulatory Approval of Company Assays
	27

	5.4.
	Regulatory Approval of AZ Products
	28

	5.5.
	Costs
	29

	5.6.
	Compliance Audit
	29

	5.7
	Regulatory Audits
	29

	 
	 
	 

	Article 6
	COMMERCIALIZATION
	29

	 
	 
	 

	6.1.
	Coordination on Commercialization Activities
	29

	6.2.
	Company’s Commercialization Obligations
	29

	6.3.
	Availability of Company Assays
	30

	6.4.
	Commercialization Terms
	30

	6.5.
	Compliance with Applicable Law
	30

i

	
			
	6.6.
	AZ Discontinuation in Markets
	30

	6.7.
	Failure to Commercialize a Company Assay
	31

	 
	 
	 

	Article 7
	COLLABORATION MANAGEMENT
	31

	 
	 
	 

	7.1.
	Joint Project Teams
	31

	7.2
	Joint Programme Committee
	34

	7.3.
	JPC Co-Chairs
	34

	7.4.
	Responsibilities of the JPC
	34

	7.5.
	General Provisions Applicable to the JPC
	35

	7.6.
	Joint Steering Committee
	36

	7.7.
	JSC Co-Chairs
	36

	7.8.
	Responsibilities of the JSC
	36

	7.9.
	General Provisions Applicable to the JSC
	36

	7.10.
	Limitations on Authority
	38

	7.11.
	Primary Contact Persons
	38

	 
	 
	 

	Article 8
	PAYMENTS AND RECORDS
	38

	 
	 
	 

	8.1.
	Fee Schedules
	38

	8.2.
	Invoices
	38

	8.3.
	Mode of Payment
	39

	8.4.
	Taxes
	39

	8.5.
	Financial Records
	40

	8.6.
	Financial Audit
	40

	8.7.
	No Right to Offset
	41

	 
	 
	 

	Article 9
	INTELLECTUAL PROPERTY OWNERSHIP AND LICENSE GRANTS
	41

	 
	 
	 

	9.1.
	Ownership
	41

	9.2.
	License Grants
	41

	9.3.
	Sublicenses
	43

	9.4.
	Rights Controlled by Third Parties
	43

	9.5.
	Disclosure of Foreground IP
	43

	9.6.
	Assignment
	43

	9.7.
	Assignment Obligation
	44

	9.8.
	Third Party Licenses
	44

	9.9.
	Rights of Reference
	45

	9.10.
	Retained Rights
	46

	 
	 
	 

	Article 10
	INTELLECTUAL PROPERTY PROSECUTION, ENFORCEMENT AND DEFENSE
	46

	 
	 
	 

	10.1.
	Patent Prosecution and Maintenance
	46

	10.2.
	Enforcement of Patents
	47

	10.3.
	Infringement Claims by Third Parties
	47

	10.4.
	Invalidity or Unenforceability Defenses or Actions
	48

	 
	 
	 

ii

	
			
	Article 11
	CONFIDENTIALITY AND NON-DISCLOSURE
	49

	 
	 
	 

	11.1.
	Confidentiality Obligations
	49

	11.2.
	Permitted Disclosures
	50

	11.3.
	Use of Name
	51

	11.4.
	Public Announcements
	52

	11.5.
	Publication
	52

	11.6.
	Return of Confidential Information
	53

	 
	 
	 

	Article 12
	REPRESENTATIONS, WARRANTIES AND COVENANTS
	53

	 
	 
	 

	12.1.
	Mutual Representations and Warranties
	53

	12.2.
	Representations and Warranties of Company
	54

	12.3.
	Representations and Warranties of AZ
	55

	12.4.
	Anti-Bribery
	55

	12.5
	DISCLAIMER OF WARRANTIES
	56

	 
	 
	 

	Article 13
	INDEMNITY
	57

	 
	 
	 

	13.1.
	Indemnification of Company
	57

	13.2.
	Indemnification of AZ
	57

	13.3.
	Indemnification Procedures
	58

	13.4.
	LIMITATIONS OF LIABILITY
	60

	13.5.
	Insurance
	61

	 
	 
	 

	Article 14
	TERM AND TERMINATION
	61

	 
	 
	 

	14.1.
	Term
	61

	14.2.
	Termination
	61

	14.3.
	Rights in Bankruptcy
	63

	14.4.
	Consequences of Termination
	64

	14.5
	Termination Fees
	65

	14.6.
	Return of Materials and Confidential Information
	66

	14.7.
	Remedies
	66

	14.8.
	Accrued Rights; Surviving Obligations
	66

	 
	 
	 

	Article 15
	MISCELLANEOUS
	66

	 
	 
	 

	15.1.
	Non-Exclusive Relationship
	66

	15.2.
	Subcontracting
	67

	15.3.
	Force Majeure
	67

	15.4.
	Export Control
	67

	15.5.
	Assignment
	67

	15.6.
	Severability
	68

	15.7.
	Dispute Resolution
	69

	15.8.
	Governing Law, Jurisdiction and Service
	69

	15.9.
	Notices
	70

	15.10.
	Entire Agreement; Amendments
	71

iii

	
			
	15.11.
	English Language
	71

	15.12.
	Equitable Relief
	71

	15.13.
	Waiver and Non-Exclusion of Remedies
	72

	15.14.
	No Benefit to Third Parties
	72

	15.15.
	Further Assurance
	72

	15.16.
	AZ Affiliates
	72

	15.17.
	Relationship of the Parties
	72

	15.18.
	References
	72

	15.19.
	Construction
	73

	15.20.
	Counterparts
	73

Attachment A – Form of RFP
Attachment B – Form of Project Schedule
Schedule 8.2 – Invoices to AstraZeneca

iv

IN VITRO DIAGNOSTICS
MASTER COLLABORATION AGREEMENT
This In Vitro Diagnostics Master Collaboration Agreement (this “Agreement”) is made and entered into effective as of                          2020 (the “Effective Date”), by and between AstraZeneca UK Limited, a company incorporated in England under no. 03674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England (“AZ”), and ArcherDX, INC ., a company incorporated in Delaware whose principal office is at 2477 55th Street, Suite 202 Boulder, CO 80301, USA (“Company”). AZ and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS
WHEREAS, AZ is a pharmaceutical company engaged in the research, development, manufacture and commercialization of pharmaceutical products;
WHEREAS, Company is engaged in diagnostics and research, development, obtaining regulatory approval, manufacture and commercialization of reagents, instruments, services, software and other products for diagnosis and laboratory processes, including development and commercialization of companion diagnostic products for pharmaceutical products; and
WHEREAS, from time to time, the Parties may wish to collaborate in one or more Projects for the Development and Commercialization of one or more Company Assays for use with one or more AZ Products, in each case as set forth in a Project Schedule (each capitalized term as defined below) and subject to the terms and conditions herein.
NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
ARTICLE 1
DEFINITIONS
Unless otherwise specifically provided herein, the following terms shall have the following meanings:
1.1    “Activities” means the activities to be performed by either Party in connection with this Agreement or an applicable Project Schedule.
1.2    “Additional Indication” has the meaning set forth in Section 2.3.2.
1.3    “Additional Markets” has the meaning set forth in Section 2.3.2.

1.4    “Additional Project Schedule” has the meaning set forth in Section 2.3.2.
1.5    “Affiliate” means any Person that (a) directly or indirectly controls a Party, (b) is directly or indirectly controlled by a Party, or (c) is controlled, directly or indirectly, by the ultimate parent company of a Party. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of an organization or otherwise having the power to govern the financial and operating policies or to appoint the management of an organization. For clarity, with respect to AZ, the term Affiliate includes any business entity that is controlled by AstraZeneca PLC, whether directly or indirectly through one or more intermediaries, including MedImmune LLC and MedImmune Limited.
1.6    “Analytical Validation Samples” means Samples provided by AZ or any of its Affiliates or otherwise obtained by Company, including through a Third Party supplier approved by AZ, for use in Analytical Validation Studies hereunder.
1.7    “Analytical Validation Studies” means studies conducted by Company pursuant to a Project Schedule to establish the analytical performance characteristics of a Company Assay such as accuracy, precision and reproducibility. Analytical Validation Studies are not intended, and shall not be construed, to include any Clinical Studies conducted by AZ or its Affiliates or other studies directed to the generation or interpretation of Clinical Outcomes Data.
1.8    “Anti-Corruption Laws” means all anti-corruption and anti-bribery laws and regulations, including, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the United Kingdom Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.
1.9    “Applicable Law” means laws, rules and regulations, including any rules, regulations, guidance or other requirements of Regulatory Authorities, that may be in effect from time to time and applicable to a particular activity hereunder, including those related to data privacy and the handling of genomic data. Applicable Law includes, as applicable, GCP, GLP and GMP.
1.10    “Approved IVD” means any IVD for use in the clinical diagnosis or evaluation of any disease or condition, excluding any RUO or IUO labelled diagnostic product, or other IVD solely for research or investigational purposes, and with respect to which any necessary Regulatory Approval has been obtained in an applicable country, including, for example, any required PMA Approval by the FDA in the United States and any required declaration of conformity by a Notified Body permitting CE marking for the member states of the EU.
1.11    “Approved Sample Supplier” has the meaning set forth in Section 3.6.2.
1.12    “Assay Validation Data” means Data from Analytical Validation Studies conducted with respect to a Company Assay that relate to the performance characteristics of such 

Page 2 of 84

Company Assay, including without limitation, such Company Assay’s ability to reliably and reproducibly detect a given Biomarker..

Page 3 of 84

1.13    “Associated Company Assay” means the Company Assay Developed in association with an applicable AZ Product that is the subject of termination under this Agreement or Project Schedule or portion thereof.
1.14    “Authorized Person” means any individual, employee, subcontractor, assistant or advisor who will support Company in the performance of the Purpose and who will have access to the Clinical Data.
1.15    “AZ Background IP” means (a) any Know-How Controlled by AZ or its Affiliates, whether prior to the Effective Date or during the Term, that is necessary or useful for the making, using, selling, offering for sale or importation of any AZ Product, and (b) any Patent Controlled by AZ or its Affiliates whether prior to the Effective Date or during the Term that covers or claims (i) any AZ Product or (ii) the making, using, selling, offering for sale or importation of such AZ Product, in each case ((a) and (b)), excluding any Foreground IP.
1.16    “AZ Data” means any (a) Clinical Outcomes Data, (b) Data provided to Company by or on behalf of AZ or its Affiliates in relation to a Project (including any Clinical Data so provided), and (c) AZ Sample Data Files.
1.17    “AZ Foreground IP” means (a) AZ Foreground Know-How, (b) AZ Foreground Patents and (c) any intellectual property rights other than AZ Foreground Patents (e.g., copyrights) with respect to AZ Foreground Know-How.
1.18    “AZ Foreground Know-How” means any Foreground Know-How (a) relating solely to any AZ Product (but excluding Raw Data and Company Improvements), (b) that is AZ Data, (c) that arises from the AZ Sample Data Files, or (d) Response Prediction Know-How.
1.19    “AZ Foreground Patent” means any Foreground Patent that claims or covers AZ Foreground Know-How.
1.20    “AZ Group” has the meaning set forth in Section 15.16.
1.21    “AZ Materials” means any Materials or Samples (a) delivered to Company by or on behalf of AZ or its Affiliates pursuant to a Project Schedule or (b) procured by Company pursuant to a Project Schedule hereunder using funds specifically provided by AZ or its Affiliates for such procurement as set forth in a Project Schedule.
1.22    “AZ Product” means a Therapeutic Product identified in a Project Schedule for which a Company Assay identified in such Project Schedule will be Developed or Commercialized, and all dosages, formulations and presentations of such Therapeutic Product.
1.23    “AZ Sample Data Files” means the final report files (including CSV and digital BAM files) delivered by Company to AZ setting forth the genetic sequence variation data and information generated from the analysis of AZ Materials and/or Samples (a) provided to Company by AZ or its Affiliates or (b) obtained by Company using funding provided by AZ or its Affiliates in connection with a Project Schedule, excluding any [**], including a full summary of results for each complete gene panel applicable to a given Project Schedule 

Page 4 of 84

including Sample ID and details of each mutation found, including [**], but excluding any [**].
1.24    “Biomarker” means a biological characteristic that (a) can be measured and evaluated objectively and acts as an indicator of a normal or pathogenic biological process, or (b) enables assessment of an actual or anticipated pharmacological response to a therapeutic intervention. Biomarkers include molecular, anatomic, physiologic and biochemical characteristics, including, in the case of molecular characteristics, all types of nucleic acid variants, such as mutations, insertions/deletions, copy number changes, and frame-shift events.
1.25    “Biomarker Detection Know-How” means Foreground Know-How with respect to the methods and reagents used by Company to detect or determine the mutation profile of a Sample, including the characterisations of gene fusions, CNVs and other variants.
1.26    “Breaching Party” has the meaning set forth in Section 14.2.1.
1.27    “Business Day” means a day other than a Saturday or Sunday or a day on which banking institutions in New York, New York or London, England or Stockholm, Sweden are permitted or required to be closed.
1.28    “Calendar Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date and the last Calendar Quarter shall end on the last day of the Term.
1.29    “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.
1.30    “Change of Control” means a transaction occurring after the Effective Date in which a Party or a Person directly or indirectly controlling such Party: (a) sells, conveys or otherwise disposes of all or substantially all of its property or business; or (b)(i) merges or consolidates with any other Person (other than a wholly-owned subsidiary of such Party) or (ii) effects any other transaction or series of related transactions, in each case ((i) or (ii)), such that the stockholders of such Party immediately prior thereto, in the aggregate, no longer own, directly or indirectly, beneficially or legally, at least fifty percent (50%) of the outstanding voting securities or capital stock of the surviving Person or the ultimate parent of the surviving Person following the closing of such merger, consolidation, other transaction or series of related transactions.
1.31    “CLIA” means Clinical Laboratory Improvement Amendments of 1988, its implementing regulations and guidance or any corresponding or similar foreign laws, regulations or guidance.

Page 5 of 84

1.32    “Clinical Data” has the meaning set forth in Section 4.2.1.
1.33    “Clinical Outcomes Data” means Data from Clinical Studies conducted by or on behalf of AZ or any of its Affiliates or under a Project Schedule with respect to a Therapeutic Product that is useful to (a) select patients that will benefit from the use of such Therapeutic Product; (b) de-select patients that will not benefit from the use of such Therapeutic Product or for whom the risks of use of such Therapeutic Product would outweigh the benefits; (c) determine or predict disease prognosis from the use of such Therapeutic Product; or (d) otherwise assess health outcomes associated with such Therapeutic Product.
1.34    “Clinical Studies” means studies conducted in human subjects to obtain or maintain Regulatory Approval for a Therapeutic Product for an Indication, including studies conducted to expand the labeling for a Therapeutic Product with respect to an Indication.
1.35    “Commercialization” means any and all activities directed to the preparation for sale of, offering for sale of, or sale of a product (including a Product), including activities related to marketing, promoting, distributing and importing such product, interacting with Regulatory Authorities regarding any of the foregoing and manufacturing activities in support of any of the foregoing. When used as a verb, “to Commercialize” and “Commercializing” mean to engage in Commercialization and “Commercialized” has a corresponding meaning.
1.36    “Commercially Reasonable Efforts” means, with respect to a Party, such efforts that are consistent with the efforts and resources normally associated with good business practice and standards in the diagnostic or pharmaceutical industry, as the case may be, relating to the research, development or commercialization of an IVD or a Therapeutic Product, as the case may be, with similar product characteristics, which is of similar market potential at a similar stage in its development or product life.
1.37    “Companion Diagnostic” means an Approved IVD that provides information that is essential for the safe and effective use of a corresponding Therapeutic Product.
1.38    “Company Assay” means any diagnostic product (including an assay) identified in a Project Schedule for Development or Commercialization as an IVD for use with an AZ Product identified in such Project Schedule.
1.39    “Company Background IP” means (a) any Know-How Controlled by Company or its Affiliates, whether prior to the Effective Date or during the Term, that is necessary or useful for the making, using, selling, offering for sale or importation of any Company Assay being Developed or Commercialized under an applicable Project Schedule for use with an AZ Product, and (b) any Patent Controlled by Company or its Affiliates whether prior to the Effective Date or during the Term that covers or claims (i) any Company Assay being Developed or Commercialized under an applicable Project Schedule for use with an AZ Product or (ii) the making, using, selling, offering for sale or importation of such Company Assay, in each case ((a) and (b)), excluding any Foreground IP.
1.40    “Company Data” means any (a) Assay Validation Data, (b) Biomarker Detection Know-How, or (c) all data provided to AZ by or on behalf of Company or its Affiliates in relation to a Project, except for AZ Data and Response Prediction Know-How. Company Data 

Page 6 of 84

includes data provided to AZ by or on behalf of Company or its Affiliates that was not (x) generated from analysis of AZ Materials and/or Samples or (y) obtained by Company using funding provided by AZ or its Affiliates in connection with this Agreement. For example, Company Data may include data in a regulatory submission that is derived from a clinical study performed outside the scope of this Agreement.
1.41    “Company Foreground IP” means (a) Company Foreground Know-How, (b) Company Foreground Patents, and (c) any intellectual property rights other than Company Foreground Patents (e.g., copyrights) with respect to Company Foreground Know-How.
1.42    “Company Foreground Know-How” means any Foreground Know-How (a) that is a Company Improvement, provided that such Company Improvement does not rely upon the continued use of or incorporate AZ’s Confidential Information (for clarity, a Company Improvement shall only be deemed to “rely upon the continued use of or incorporate” AZ’s Confidential Information in the event that such Company Improvement relies upon the continued use of such Confidential Information after the date of its creation, but not by the mere fact that such Company Improvement was developed, improved or discovered through the use of, or in the course of generating, AZ’s Confidential Information), (b) that is Company Data, (c) that comprises or arises from the Assay Validation Data or Raw Data, (d) that is Biomarker Detection Know-How, or (e) that is developed solely by or on behalf of Company or its affiliates and does not constitute AZ Foreground Know-How under Section 1.18.
1.43    “Company Foreground Patent” means any Foreground Patent that claims or covers Company Foreground Know-How.
1.44    “Company Improvement” means any improvement or modification to Company Background IP or the Company Technology Platform that is developed by the Parties, solely or jointly, in connection with performance pursuant to a Project Schedule.
1.45    “Company Technology Platform” means Company’s proprietary instruments, analytical methods, procedure and techniques, algorithms, databases, and software designed for use and used by Company as of the applicable Project Schedule Effective Date, or as subsequently modified outside the scope of the applicable Project Schedule, to test Samples to identify somatic alterations.
1.46    “Competing Product” has the meaning set forth in Section 15.5.3.
1.47    “Complementary Diagnostic” means an Approved IVD that provides information useful to the safe and effective use of a corresponding Therapeutic Product but that is not a Companion Diagnostic.
1.48    “Confidential Information” has the meaning set forth in Section 11.1.1.
1.49    “Conformity Assessment and CE Marking” means completion of all applicable conformity assessment procedures required under the EU IVD Legislation, including obtaining any necessary certifications by a Notified Body of the conformity of an in vitro diagnostic medical device with the requirements of the EU IVD Legislation and applicable 

Page 7 of 84

harmonized standards necessary for the manufacture and use of such device to permit a CE mark to be affixed to the device and place such device on the market in the EU.
1.50    “Control” means, with respect to any item of information, Regulatory Documentation, material, Patent or other intellectual property right, and subject to Section 15.5.2, possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by operation of the licenses and other grants in Sections 9.2 or 9.9), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such information, Regulatory Documentation, material, Patent or other intellectual property right as provided for herein without violating the terms of any agreement with any Third Party.
1.51    “Controlling Party” has the meaning set forth in Section 10.4.4.
1.52    “Data” means all results, information, documentation, writings and reports recorded in any form (together with the results of analyses thereof) generated pursuant to or shared under a Project Schedule.
1.53    “Defending Party” has the meaning set forth in Section 10.3.2.
1.54    “Deliverables” means the work product that Company agrees to provide to AZ with respect to a Project, in each case, as specified in the applicable Project Schedule.
1.55    “Development” means activities relating to the development, optimization, validation or clinical testing of any product (including any Product), including activities relating to obtaining or maintaining Regulatory Approval of such product and manufacturing activities in support of any of the foregoing. When used as a verb, “Develop” means to engage in Development.
1.56    “Diagnostic Field” means products and services for diagnostic use, including (a) the diagnosis of a disease or condition in a subject; (b) predicting or monitoring the response of a disease or condition to a Therapeutic Product; or (c) selecting or stratifying patients for treatment with a Therapeutic Product, including in vitro testing using an IVD to detect one or more Biomarkers.
1.57    “Disclosing Party” has the meaning set forth in Section 11.1.
1.58    “Dispute” has the meaning set forth in Section 15.7.1.
1.59    “Dollars” or “$” means United States Dollars.
1.60    “Drug Approval Application” means an NDA, a biologics license application as defined in the FFDCA, or any corresponding foreign applications in any country or territory, including, with respect to the EU, a marketing authorization application filed with the EMA pursuant to the centralized approval procedure or with the applicable Regulatory Authority of a member state of the EU with respect to the mutual recognition procedure, the decentralized procedure, or any other national approval.

Page 8 of 84

1.61    “EMA” means the European Medicines Agency and any successor agency thereto.
1.62    “Enforcing Party” has the meaning set forth in Section 10.2.3.
1.63    “EU IVD Legislation” means Directive 98/79/EC on in vitro diagnostic medical devices, as implemented by the national laws of the individual EU member states, and Regulation (EU) 2017/746 on in vitro diagnostic medical devices, each as applicable and as amended from time to time and any equivalent legislation in the United Kingdom.
1.64    “European Union” or “EU” means the economic, scientific and political organization of member states of the European Union as it may be constituted from time to time, including the United Kingdom.
1.65    “Exploit” means to make, have made, import, use, sell or offer for sale, including to research, Develop, Commercialize, register, manufacture, have manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market or have sold or otherwise dispose of. “Exploitation” means the act of Exploiting.
1.66    “FDA” means the United States Food and Drug Administration and any successor agency thereto.
1.67    “Fee Schedule” has the meaning set forth in Section 8.1.
1.68    “FFDCA” means the United States Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto).
1.69    “Foreground IP” means (a) Foreground Know-How, (b) Foreground Patents and (c) any intellectual property rights other than Foreground Patents (e.g., copyrights) with respect to Foreground Know-How.
1.70    “Foreground Know-How” means any Know-How conceived, reduced to practice, generated or otherwise developed solely or jointly as part of a Project by or on behalf of a Party or its Affiliates,
1.71    “Foreground Patent” means any Patent or Patent application filed by or on behalf of a Party with respect to any Foreground Know-How. Foreground Patent shall exclude, for clarity, any Patent or Patent application filed prior to the Effective Date, or with respect to Know-How arising outside of the scope of a Project.
1.72    “FTE” means the equivalent of the work of one qualified Company employee (or employee of a Company Subcontractor) working on a dedicated full-time basis in performing work in support of a Project. The applicable FTE rates will be detailed and agreed in the Project Schedules where it is agreed the application of an FTE rate is applicable.
1.73    “GCP” means the current standards for the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of clinical trials required by FDA or any 

Page 9 of 84

other applicable Regulatory Authority, including 21 C.F.R. Parts 11, 50, 54, 56, 312, 314, and 812 Directive 2005/28/EC laying down principles and detailed guidelines for good clinical practice, the ICH Guideline for Good Clinical Practice (E6), and the World Medical Association Declaration of Helsinki entitled “Ethical Principles for Medical Research Involving Human Subjects” (1996 version), each as amended from time to time.
1.74    “GDPR” means the General Data Protection Regulation (EU) 2016/679.
1.75    “GLP” means the current standards of good laboratory practice for the conduct of non-clinical health and environmental safety studies required by FDA or any other applicable Regulatory Authority, including the requirements of 21 C.F.R. Part 58 and the OECD Principles of Good Laboratory Practice (OECD ENV/MC/CHEM(98)17), as amended from time to time.
1.76    “GMP” means, with respect to a Product, the current standards of good manufacturing practice for such Product required by FDA or any other applicable Regulatory Authority, including the requirements of 21 C.F.R. Parts 210-211 and 610, the requirements of FDA’s QSR and the requirements of Directive 2003/94/EEC laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and Volume 4 of the European Commission’s Rules governing medicinal products in the European Union, as amended from time to time.
1.77    “Good Industry Practices” means the exercise of that degree of skill, diligence, prudence and foresight which would reasonably and ordinarily be expected from a skilled and experienced operator engaged in the same type of undertaking under the same or similar circumstances.
1.78    “Government Official” means any person employed by or acting on behalf of a government, government-controlled entity or public international organization; any political party, party official or candidate; any person who holds or performs the duties of an appointment, office or position created by custom or convention; and any person who holds himself out to be the authorized intermediary of any of the foregoing.
1.79    “HDE” means a humanitarian device exemption filing made with the FDA or an analogous filing outside the United States made with a Regulatory Authority for the applicable jurisdiction.
1.80    “IDE” means an investigational device exemption filing made with the FDA or an analogous filing outside the United States made with a Regulatory Authority for the applicable jurisdiction.
1.81    “IND” means (a) an investigational new drug application filed with the FDA for authorization to commence Clinical Studies or any corresponding or similar application in other countries or regulatory jurisdictions, and (b) all supplements and amendments that may be filed with respect to the foregoing.
1.82    “Indemnification Claim Notice” has the meaning set forth in Section 13.3.1.

Page 10 of 84

1.83    “Indemnified Party” has the meaning set forth in Section 13.3.1.
1.84    “Indication” means a disease or condition that an AZ Product treats, prevents or cures (or is intended or investigated to treat, prevent or cure), as specified in an applicable Project Schedule.
1.85    “IUO” or “Investigational Use Only” means an IVD for investigational use only that meets certain clinical and manufacturing standards and that is used in clinical studies (that are exempt from FDA’s Investigational Device Exemption or IDE regulations, 21 C.F.R. 812) to gather data for submission as required by the FDA or another Regulatory Authority to obtain Regulatory Approval of such IVD as an Approved IVD.
1.86    “IVD” or “In Vitro Diagnostic” means a product or service for in vitro testing of patient or subject specimens, or other biological materials, for use in the diagnosis or evaluation of a disease, medical condition or state of health, including to identify any genomic alterations or signatures, or for the prediction or monitoring of a response to any Therapeutic Product (or other treatment) or other prognostic use, whether used for research, exploratory purposes, or as a clinical diagnostic. For clarity, the term IVD includes IUOs, RUOs, Companion Diagnostics, Complementary Diagnostics and other IVDs.
1.87    “Joint Programme Committee” or “JPC has the meaning set forth in Section 7.2.
1.88    “Joint Project Team” or “JPT” has the meaning set forth in Section 7.1.1.
1.89    “Joint Steering Committee” or “JSC” has the meaning set forth in Section 7.6.
1.90    “JPC Co-Chairs” has the meaning set forth in Section 7.3.
1.91    “JSC Co-Chairs” has the meaning set forth in Section 7.7.
1.92    “Key Performance Indicator” or “KPI” means a defined metric in a Project Schedule that is used to monitor achievement of strategic or operational goals for the performance of the Company.
1.93    “Know-How” means all tangible and intangible: (a) information, techniques, technology, practices, trade secrets, inventions (whether patentable or not),
discoveries, methods, know-how, data, results (including pharmacological, toxicological and clinical test data and results), analytical and quality control data, descriptions, software and algorithms, reports, formulae, processes and techniques; and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material, excluding, in each case ((a) and (b)), any Regulatory Documentation.
1.94    “Losses” has the meaning set forth in Section 13.1.
1.95    “Markets” means the countries and territories specified in an applicable Project Schedule for which a Company Assay will be Developed or Commercialized for use with

Page 11 of 84

the AZ Product identified in such Project Schedule. Such Markets to be agreed between the Parties in good faith for each individual Project Schedule.
1.96    “Material Breach” means a failure to perform under this Agreement (or, as applicable, a Project Schedule) whereby the failure to perform defeats the essential purpose of this Agreement (or as applicable Project Schedule) or deprives the Non-Breaching Party of a significant portion of the benefit that it reasonably expected to receive under this Agreement or a Project Agreement as applicable; provided, however, the Parties agree that failure to meet an estimated timeline in a Project Schedule is not, in and of itself, a Material Breach.
1.97    “Materials” means the biological or chemical materials, including Samples, that (a) one Party delivers, or causes to be delivered, to the other Party or (b) one Party obtains using funds provided by the other Party expressly for such purpose, in each case, ((a) and (b)), in connection with this Agreement or any Project Schedule.
1.98    “NDA” means a new drug application as defined in the FFDCA.
1.99    “Non-Breaching Party” has the meaning set forth in Section 14.2.1.
1.100    “Non-Controlling Party” has the meaning set forth in Section 10.4.4.
1.101    “Non-Defending Party” has the meaning set forth in Section 10.3.2.
1.102    “Non-Enforcing Party” has the meaning set forth in Section 10.2.3.
1.103    “Notice Period” has the meaning set forth in Section 14.2.1.
1.104    “Notified Body” means an entity licensed, authorized or approved by the applicable government agency, department or other authority to assess and certify the conformity of an in vitro diagnostic medical device with the requirements of the EU IVD Legislation and applicable harmonized standards.
1.105    “Officer Resolution Period” has the meaning set forth in Section 15.7.1.
1.106    “Party” and “Parties” have the meanings set forth in the preamble hereto.
1.107    “Patents” means (a) all national, regional and international patents and patent applications, including provisional patent applications; (b) all patent applications filed claiming priority from any such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, innovation patents and design patents and certificates of invention; (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations, reviews and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)); and (e) any similar rights, including so-called

Page 12 of 84

pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of the foregoing patent applications and patents.
1.108    “Payment” has the meaning set forth in Section 8.4.
1.109    “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.
1.110    “Personal Data” has the meaning in the GDPR and includes any information that directly or indirectly identifies or singles out a living person, such as and not limited to, age, birth date, race or ethnicity and medical history.
1.111    “PMA” means (a) a premarket approval application filed with the FDA or any corresponding or similar application in other countries or regulatory jurisdictions; and (b) all supplements and amendments that may be filed with respect to the foregoing.
1.112    “PMA Approval” means approval of a Premarket Approval (PMA) Application in accordance with Section 515 of the FFDCA and 21 C.F.R. Part 814, each as amended from time to time, of a PMA by the FDA for a Class III device or similar approval in other countries or regulatory jurisdictions.
1.113    “Primary Contact Person” has the meaning set forth in Section 7.11.
1.114    “Prior CDA” means any confidentiality or non-disclosure agreement entered into by the Parties prior to the Effective Date with respect to the transactions contemplated by this Agreement.
1.115    “Product” means, in the case of AZ, any AZ Product and, in the case of Company, any Company Assay, in each case as designated in an applicable Project Schedule.
1.116    “Project” means the program of Activities to be performed under an agreed Project Schedule with the goal of Developing or Commercializing a Company Assay for use as an IVD in connection with a specified AZ Product.
1.117    “Project Delay” has the meaning set forth in Section 2.5.1
1.118    Project Leader” has the meaning set forth in Section 7.1.2.
1.119    “Project Schedule” means a plan executed by the Parties under this Agreement that details a Project and the applicable AZ Product, Company Assay, Selected Biomarker(s), and Indication(s) that are the subject of such Project and that includes the Activities, Deliverables, Materials, Markets and other terms applicable to such Project in the form provided as Attachment A. Each Project Schedule shall, if applicable, include a Fee Schedule setting forth the Payments under such Project Schedule.

Page 13 of 84

1.120    “Project Suspension” has the meaning set forth in Section 2.6.2.
1.121    “Purpose” has the meaning set forth in Section 4.2.1.
1.122    “Quality System Regulation” or “QSR” means the requirements applicable to manufacturers of finished medical devices (including design control and current good manufacturing practices) pertaining to the methods used in, and the facilities and controls used for, the design, manufacture, packaging, labeling, storage, installation and servicing of all finished devices intended for human use, as specified in 21 C.F.R. Part 820 and FDA’s guidance documents, and all applicable successor regulations and guidance documents thereto.
1.123    “Raw Data” means all data and results generated by Company in connection with the services up to the point of creation of the AZ Sample Data Files, including Biomarker Detection Know-How.
1.124    “Receiving Party” has the meaning set forth in Section 11.1.
1.125    “Regulatory Approval” means any and all clearances, approvals, licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a product (including a Product), in a country or territory, including, in the case of a Company Assay, any required CE Marking Approval in Markets where required.
1.126    “Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities or Notified Bodies regulating or otherwise exercising authority with respect to the Exploitation of Therapeutic Products or IVDs (including Products) in any country or territory, including the FDA for the United States and the EMA for the EU, and any Notified Body for any country or territory that has responsibility for the regulation of any IVD, and any successor(s) to any of the foregoing.
1.127    “Regulatory Documentation” means all (a) applications (including all INDs, Drug Approval Applications, IDEs, 510(k)s, de novo determinations, HDEs and PMAs), registrations, licenses, authorizations and approvals (including Regulatory Approvals); and (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority), including all adverse event files and complaint files, in each case ((a) and (b)) relating to a Product.
1.128    “Response Prediction Know-How” means Foreground Know-How with respect to the correlation between one or more Selected Biomarkers and the response to the AZ Product arising from the Clinical Outcomes Data.
1.129    “Retention Period” has the meaning set forth in Section 3.4.
1.130    “RFP” has the meaning set forth in Section 2.3.3.
1.131    “RUO” or “Research Use Only” means an IVD for research use only that meets certain manufacturing standards and which is intended to be used in non-clinical studies,

Page 14 of 84

including to gather data for submission as required by the FDA or another Regulatory Authority in support of an IUO or an Approved IVD.
1.132    “Samples” means biological materials, including human tissue and its derivatives or components (e.g., cell lines and DNA), as may be further identified in an applicable Project Schedule obtained and used for the purpose of Clinical Validation Studies and Analytical Validation Studies.
1.133    “Selected Biomarkers” means the one or more Biomarkers identified in an applicable Project Schedule for inclusion in a Company Assay as relevant to an AZ Product and Indication.
1.134    “Senior Officer” means, with respect to AZ, its Senior VP, Head of Precision Medicine and, with respect to Company, its Chief Executive Officer, or their respective designees.
1.135    “Service Levels” means the levels of performance of the Project set out in a Project Schedule and agreed by the Parties which include quality of the AZ Sample Data Files delivered to AZ or its clinical sites as applicable, and delivery of data and results to mutually agreed timelines, which levels will in any event be consistent with Good Industry Practices.
1.136    “Specifications” means product performance requirements for a Company Assay as set forth in the applicable Project Schedule.
1.137    “Subcontractor” has the meaning set forth in Section 15.2.
1.138    “Term” has the meaning set forth in Section 14.1.
1.139    “Termination Notice” has the meaning set forth in Section 14.2.1.
1.140    “Therapeutic Field” means the prevention, treatment or cure of a disease or condition in a subject, including by administering a Therapeutic Product.
1.141    “Therapeutic Product” means any product containing one or more chemical or biologic substances investigated or approved for the prevention, treatment or cure of a disease or condition.
1.142    “Third Party” means any Person other than AZ, Company and their respective Affiliates.
1.143    “Third Party Claims” has the meaning set forth in Section 13.1.
1.144    “Third Party Infringement Claim” has the meaning set forth in Section 10.3.1.
1.145    “Third Party Licenses for AZ Technology” has the meaning set forth in Section 9.8.2.

Page 15 of 84

1.146    “Third Party Licenses for Company Technology” has the meaning set forth in Section 9.8.1.
1.147    “Third Party Licenses” has the meaning set forth in Section 9.8.3.
1.148    “Trademark Rights” means any word, name, symbol, color, shape, designation or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration, program name, delivery form name, certification mark, collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered, and all statutory and common law rights therein and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.
1.149    “United States” or “U.S.” means the United States of America and its territories and possessions (including the District of Columbia and Puerto Rico).
ARTICLE 2
PROJECTS
2.1    Project Schedules. This Agreement, together with any applicable Project Schedule(s), shall constitute the entire agreement between the Parties with respect to the Project(s) identified in such Project Schedule(s). Each Party shall use Commercially Reasonable Efforts to perform the Activities assigned to such Party in each Project Schedule and to provide the Materials and Deliverables set forth therein, in each case according to the estimated timelines specified therein and subject to the assumptions set forth therein. The Parties shall carry out Activities in accordance with this Agreement and Applicable Law, including applicable GCP, GLP and GMP. Company shall use Commercially Reasonable Efforts to ensure that, when performing activities in relation to any Project, it shall meet or exceed the applicable Service Levels in accordance with Section 2.8.
2.2    Without limiting the effect of Section 2.5, in the event that either Party anticipates or experiences a delay in the completion of any Activities assigned to it under a Project Schedule, or any suspected breach of Applicable Law, such Party will inform the other Party promptly but, in any case, within fifteen (15) days of becoming aware of such anticipated delay or breach or actual delay or breach.
2.3    Adoption of Project Schedules
2.3.1    During the Term, the Parties may enter into one or more Project Schedules in the form attached to this Agreement as Attachment B. Once executed by the Parties, each Project Schedule shall be incorporated in its entirety into this Agreement. Each Project Schedule will specify the applicable Markets, and specify the commitments to be made by the Company to Develop, obtain Regulatory Approval, and Commercialize the applicable Company Assay in each such Market. Project Schedules for Development and Regulatory Approval and Commercialization activities will be set forth in separate Project Schedules including when such Project relates to the same Company Assay, AZ Product and/or Indication.

Page 16 of 84

2.3.2    If, during the Term, the Parties agree to add to this Agreement and any Project Schedules (a) a new Project in relation to any additional AZ Products (an “Additional AZ Product”), (b) in relation to an existing AZ Product, a disease or condition that such AZ Product treats, prevents or cures (or is intended or investigated to treat, prevent or cure) that is not already an Indication for such AZ Product in an applicable Project Schedule (an “Additional Indication”), including activities directed to obtaining Regulatory Approval of a Company Assay with respect to such Additional Indication, (c) switching from one Company Assay technology platform to another or (d) in relation to an existing AZ Product, any countries and territories that are not already Markets for such Product in an applicable Project Schedule (“Additional Markets”), including activities directed to obtaining Regulatory Approval of a Company Assay for use in such Additional Market(s), the Parties shall follow the procedures set forth in Section 2.3.3, 2.3.4 and Section 2.3.5 with respect to entering into a new Project Schedule (each such new Project Schedule, an “Additional Project Schedule”) in order to effect one or more of the modifications set forth in (a)-(c) of this Section 2.3.2. For clarity, the execution of this Agreement alone will not obligate either Party to enter into any Additional Project Schedule and nothing herein will obligate either Party to perform any Services hereunder except as set forth in a duly executed Project Schedule.
2.3.3    If AZ desires for the Parties to enter into any Additional Project Schedule(s) pursuant to Section 2.3.2(a) (Additional AZ Product), AZ shall provide Company’s Primary Contact Person with a request for proposal (“RFP”), using the form provided in Attachment A. Company shall consider such RFP in good faith. Within ten (10) Business Days of receipt of such RFP Company shall contact the AZ Primary Contact Person to discuss the scope and complexity of the proposed Additional Project Schedule and agree on a timeline for Company to negotiate and provide a detailed and finalized proposal which shall be within an agreed timeframe of between an additional ten (10) and thirty (30) Business Days depending upon the complexity of such proposed Additional Project Schedule. If the Parties agree to negotiate such Additional Project Schedule, then the Parties shall negotiate in good faith and attempt to finalise the terms with respect to such Additional Project Schedule, using the form provided in Attachment  B, within a further fifteen (15) Business Days.
2.3.4    If AZ desires for the Parties to enter into any Additional Project Schedule(s) pursuant to Section 2.3.2(b) (Additional Indication), AZ shall provide Company’s Primary Contact Person with an RFP, using the form provided in Attachment A. Company shall consider such RFP in good faith and within ten (10) Business Days of first receiving such RFP, provide a response to AZ’s Primary Contact Person as to whether Company is willing to negotiate such Additional Project Schedule and, if so, the Company’s proposal for the Project. If the Parties agree to negotiate such Additional Project Schedule, then the Parties shall negotiate in good faith and attempt to agree upon mutually acceptable terms with respect to such Additional Project Schedule, using the form provided in Attachment B, within an additional fifteen (15) Business Days following Company’s response to the RFP.
2.3.5    If AZ desires for the Parties to enter into an Additional Project Schedule(s) pursuant to Section 2.3.2(c) (Additional Market), AZ shall notify the Company of such intention specifying the proposed additional countries or territories, and the Company shall consider such request in good faith. Company shall contact the AZ Primary Contact Person within ten (10) Business Days to discuss the possibility of such Additional Market and within thirty (30)

Page 17 of 84

Business Days of first receiving such RFP, provide a response to AZ’s Primary Contact Person as to whether Company is willing to negotiate such Additional Project Schedule and, if so, the Company’s proposal for the Project. If the Parties agree to negotiate such Additional Project Schedule, then the Parties shall negotiate in good faith and attempt to agree upon mutually acceptable terms with respect to such Additional Project Schedule, using the form provided in Attachment B, within fifteen (15) Business Days following Company’s response to the RFP.
2.4    Amendments to Project Schedules.
2.4.1    AZ and Company shall each have the right to propose amendments to any Project Schedule through the JPT, other than the inclusion of additional AZ Products, Additional Indications or Additional Markets, which shall be governed by Section 2.3. The JPT shall promptly, and in any event within fifteen (15) days after either Party proposes an amendment, discuss in good faith the terms and conditions of the proposed amendment. If the Parties reach agreement with respect to the proposed amendment, then the Parties shall prepare and execute a written amendment to such Project Schedule. If the JPT is unable to agree upon such proposed amendment within fifteen (15) days or if such amendment is outside the scope of the JPT’s ability to approve as set out in Section 2.4, then the JPT shall refer the amendment to the JPC, or if the JPC has not then been established, direct to the JSC. If the members of the JPC are unable to agree or ratify the amendment, it will be referred to the JSC for resolution. If the JSC is unable to agree or ratify the amendment it will be referred to Senior Officers for resolution. No amendment shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties as provided in Section 15.10. Such amended or modified Project Schedule and payment plan shall not become effective unless agreed upon in writing and signed by authorized representatives of AZ and Company.
2.4.2    Notwithstanding anything to the contrary herein, if either Party proposes to amend any Project Schedule to (a) account for new information or data with respect to the performance of an AZ Product or Company Assay; (b) address requests or requirements of a Regulatory Authority relating to an AZ Product or Company Assay; or (c) account for changes to any of the Key Assumptions or other aspects of such Project Schedule, then, in each case ((a)-(c)), the other Party shall not unreasonably withhold or delay its consent to such amendment, provided that, in the case of such a proposal by AZ, AZ agrees to reimburse Company for all reasonable costs and expenses associated with implementing such proposal. For clarity, in the event that any such amendment would require Company to obtain Regulatory Approval for the Company Assay or perform additional Development activities, in each case with respect to any Additional AZ Product(s), Additional Indication(s) or Additional Market(s), the Parties shall negotiate in good faith the scope of an Additional Project Schedule in accordance with Section 2.3, but neither Party will be obligated to enter into any Additional Project Schedule.
2.5    Project Delays
2.5.1    Each Party shall through the JPT, notify the other promptly in the event of an actual or predicted material Project Delay, due to circumstances outside either Party’s control. A “Project Delay” means a material delay to the timelines of the applicable Project Schedule. Such Project Delay will be discussed by the Joint Project Team and if required the JSC to agree upon the impact and potential appropriate remedial action. 

Page 18 of 84

2.5.2    A Project Delay will not be deemed to be a Project Suspension regardless of the amount of time the Project Delay lasts, unless AZ separately initiates a Project Suspension at its sole discretion.
2.6    Project Suspension
2.6.1    Unless otherwise provided in any applicable Project Schedule, each Project shall be carried out by Company in stages, as set forth in each Project Schedule, in furtherance of the achievement of specific milestones set forth in such applicable Project Schedule. Company shall notify AZ in writing as soon as practicable but in any event at least thirty (30) days prior to the date that Company intends to commence Activities with respect to each stage of a Project, which notice shall specify the date that Company intends to commence such Activities.
2.6.2    AZ shall have the right, in its discretion, and upon written notice to Company’s Primary Contact Person on or before the start of Activities with respect to a stage in a Project Schedule, to temporarily suspend any Activities with respect to any stage of a Project (each such suspension, a “Project Suspension”).
2.6.3    In the event that AZ exercises its right to initiate a Project Suspension with respect to any Project, then, without limiting any other rights or obligations of AZ under this Agreement, within twenty (20) Business Days following receipt of the notice of such Project Suspension, Company shall provide to AZ a written overview of options for such Project, including (a) costs for maintaining the availability of Company resources; (b) options for temporary, partial or complete cessation of Activities with respect to such Project; (c) estimated delays to the timeline set forth in the applicable Project Schedule as a result of such Project Suspension; (d) additional costs with respect to such Project if such Project is resumed at a later date; and (e) any other information that AZ may reasonably request in order to determine whether to maintain such Project Suspension or to resume such Project in part or in its entirety.
2.6.4    Within twenty (20) days after receiving Company’s written overview of options under Section 2.6.3, AZ shall notify Company in writing as to whether to (a) maintain such Project Suspension in its entirety, (b) proceed with one or more options set forth in such written overview or (c) consider other options suggested by AZ or such Affiliate. AZ shall pay to Company an amount equal to all documented non-cancellable costs incurred at the time of such Project Suspension for resources and services that cannot practicably be re-deployed or put on hold pending use without additional cost.
2.6.5    In the event that, (a) the Parties are unable to agree upon the amount of the fee payable pursuant to Section 2.6.4 within thirty (30) days after AZ’s receipt of Company’s written overview of options under Section 2.6.3 the matter will be referred to the JSC for resolution. If the JSC are unable to resolve such dispute, the dispute resolution procedure set forth in Section 15.7 will be triggered solely with regard to the fee payable by AZ to Company.
2.6.6    To restart the conduct of Activities with respect to a Project following a Project Suspension, AZ shall provide at least thirty (30) days’ written notice to Company. In the event that the Project is projected not to restart, or if the Project in actuality does not restart

Page 19 of 84

within twelve (12) months from the date of the Project Suspension, then the Parties shall discuss the feasibility of any such re-start in the Joint Project Team.
2.6.7    For clarity, Company shall be excused from any failure or delay in performing Company’s Activities under a Project Schedule during a Project Suspension, including during the Parties’ discussions related thereto.
2.7    Conflicting Provisions. In the event there is a conflict between the terms or conditions of this Agreement and the terms or conditions of any Project Schedule, the terms and conditions of this Agreement shall govern, unless such Project Schedule specifically and expressly supersedes this Agreement on that specific matter and then only with respect to such Project Schedule and such matter.
2.8    KPIs and Service Levels. The Parties shall together perform ongoing measurement of KPIs and periodic assessment of Service Levels, as further described in the applicable Project Schedule. The formulation of the Service Levels will be proposed for each Project Schedule drafted and agreed between the Project Team Leads. The satisfaction of each such Service Level will be determined by quantitative metrics collected by Parties. Satisfaction of the Service Levels by Company will be monitored by the Joint Project Team with escalation to the Joint Programme Committee and/or JSC as appropriate. A breach of a Service Level of KPI may result in liquidated damages being due or a reduction in a milestone payment. The amounts of any liquidated damages/reduced milestone payments will be agreed on a Project by Project basis by the JPT and reflected in the Project Schedule by amendment. Persistent and continued breaches of the Service Levels agreed and set forth in a Project Schedule may be deemed a Material Breach of such Project Schedule and will give AZ the right to terminate such Project Schedule in accordance with Sections 14.2.5 and 14.4.3.
ARTICLE 3
MATERIALS
3.1    Procurement of Materials Except as otherwise expressly provided in the applicable Project Schedule, either Company shall be responsible for procuring or supplying the Materials required for performance of its Activities under each Project Schedule or Company will use AZ Materials provided to it by AZ. As between the Parties, all AZ Materials are owned by AZ and all Company Materials are owned by Company. Company agrees to source and keep sufficient reagents to complete a Project Schedule and to protect against significant delays to a Project due to the required reagents becoming unavailable or subject to delay in delivery. Unless otherwise set forth in the applicable Project Schedule, all AZ Materials will be provided at AZ’s sole cost and expense.
3.2    Delivery of AZ Materials AZ shall provide the AZ Materials designated in any applicable Project Schedule to Company as set forth in a Project Schedule, including with respect to the timelines set forth therein. Company will acknowledge receipt of the AZ Materials and notify AZ as to whether such Materials conform to the applicable written specifications, described in the Project Schedule, as set forth in this Section 3.2. Prior to providing AZ Materials to Company or its approved Subcontractors, AZ shall cause such AZ Materials to be coded in a 

Page 20 of 84

manner that does not allow for identification of the patient or their personally-identifiable Protected Health Information (as such term is defined under HIPAA) by Company or its Subcontractors. If Company discovers that any AZ Materials provided by AZ or its Affiliate do not conform to their descriptions or are unsuitable for the Activities set forth with respect to such AZ Materials under the applicable Project Schedule, then (a) Company shall notify AZ within ten (10) Business Days of discovering the non-conformity or unsuitability, explaining in detail why such Materials do not conform or are unsuitable and (b) if there is no Dispute regarding the non-conformity or unsuitability of such AZ Materials, then (i) AZ shall provide new or replacement AZ Materials or (ii) if providing new or replacement AZ Materials is not possible, AZ shall propose and discuss with Company in good faith the use of alternative AZ Materials. Company shall be excused from any failure or delay in performing Company’s Activities under a Project Schedule to the extent caused by AZ Materials not conforming to the specification of such AZ Materials or being otherwise unavailable or receipt of such AZ Materials by Company being delayed. Notwithstanding the foregoing, if such non-conformity or unsuitability results from Company’s failure to use, handle or store such AZ Materials with the information provided by AZ, then any new or replacement AZ Materials, or alternative AZ Materials, shall be acquired at Company’s sole cost and expense.
3.3    Use Restrictions. Company shall use the AZ Materials in accordance with the provisions of this Agreement, the applicable Project Schedule and all Applicable Law relating to the classification and use of such AZ Materials. Company shall use best efforts to handle the AZ Materials in accordance with any applicable documentation, reasonable handling procedures for similar materials, applicable common scientific standards of care, and any written instructions of AZ, in each case as expressly set forth in a Project Schedule. Company shall use Commercially Reasonable Efforts to ensure that any approved Subcontractors shall, use the AZ Materials only in connection with the Activities described in the applicable Project Schedule and for no other purpose. Company shall not transfer or sell any AZ Materials to any Third Party, except to Subcontractors in accordance with Section 15.2. Company acknowledges and agrees that the AZ Materials are experimental in nature and that AZ shall not be liable for any loss, claim, damage or liability which may arise from Company’s use, storage or handling of the AZ Materials, except to the extent resulting from (a) Company’s compliance with the applicable documentation, handling procedures, scientific standards of care, and written instructions of AZ, in each case as expressly set forth in a Project Schedule, or (b) AZ’s failure to include in a Project Schedule applicable documentation, handling procedures, scientific standards of care, or written instructions, which if followed by Company, would have avoided the loss, claim, damage or liability.
3.4    Materials Handling and Retention by Company. Company shall segregate all AZ Materials from all other materials held by Company; provided that such all AZ Materials are clearly identified or marked by AZ as the property of AZ. To the extent that any AZ Materials are not fully utilized during the performance of Activities under a Project Schedule, and not returned to AZ or destroyed in accordance with Section 3.5, Company shall at AZ’s reasonable cost and expense (such costs, where applicable to set forth in the relevant Project Schedule) retain such AZ Materials for three (3) years, or for such longer period as may be required by Applicable Law (the “Retention Period”). Without limiting the foregoing, in the event that Company desires to destroy any AZ Materials, or any portion thereof, after the expiration of the Retention Period, Company shall notify AZ sufficiently in advance of any such proposed destruction (and in any event at least sixty (60) days prior to any such proposed destruction) to provide AZ with an

Page 21 of 84

opportunity to request the return of such AZ Materials, at the cost set forth in the Project Schedule, or at AZ’s sole cost and expense if no such cost is set forth in the Product Schedule.
3.5    Return or Destruction of Materials. Company shall, upon AZ’s request and at AZ’s cost and expense, either return to AZ, or destroy any AZ Materials within a reasonable period of time following such request, but, unless otherwise agreed by the Parties in writing, no later than forty-five (45) days after such request.
3.6    Samples
3.6.1    AZ hereby represents and warrants to Company that at the time of delivery by AZ to Company of any Samples: (a) such Samples will have been collected, stored, handled, transported and delivered in compliance with all Applicable Law relating to human research specimens; (b) it shall cause such Samples to be coded in a manner that does not allow for identification of the patient or their personally identifiable Protected Health Information (PHI) (as such term is defined under HIPAA), or in the case of Samples received from the European Union, Personal Data as defined by the GDPR, by Company or its approved Subcontractors; (c) it (or a Third Party acting on its behalf) has obtained all necessary approvals and informed consents for the collection and use of such Samples as contemplated by this Agreement and the applicable Project Schedule; and (d) Company may use such Samples as specified in the applicable Project Schedule without any obligations of compensation to the donors from whom such Samples were obtained or any other Third Party. With respect to any Samples it supplies hereunder, AZ will, upon reasonable request, provide Company with either (i) a copy of any necessary institutional review board or other ethics committee approvals and form of informed consent with respect to such Samples or (ii) written confirmation in an appropriate form, that all necessary approvals and informed consents have been obtained with respect to such Samples. If the collection and use of any Samples supplied under this Agreement is subject to the informed consent or approval of the donor or any other Third Party, then Company shall ensure that the use of such Samples in accordance with this Agreement and any applicable Project Schedule is consistent with the terms of such informed consent or approval, including in the event such consent is withdrawn and notified to Company by AZ.
3.6.2    Company may, from time to time, obtain Samples for use in connection with Analytical Validation Studies under any Project Schedule from any Third Party. To facilitate Company’s ability to utilize Third Party suppliers of Samples, AZ shall maintain a list of approved sample suppliers (each, an “Approved Sample Supplier”) and provide to Company confirmation that the intended provider is compliant with AZ human biological sample requirements. In the event company wishes to use a provider of human tissue that is not currently on the AZ approved provider list, AZ will complete due diligence of the provider prior to approving their use.
ARTICLE 4
TRANSFERS OF AZ CLINICAL DATA
4.1    Overview The Parties do not envisage the transfer of Personal Data from AZ or its Affiliates to Company, but in the event a Project requires the transfer of Personal Data,

Page 22 of 84

the Parties shall set forth the details of such Personal Data in an appendix to the applicable Project Schedule, and in addition the EU model clauses will be added if applicable.
4.2    Data Transfer.
4.2.1    AZ shall provide Company with (a) de-identified patient-level data; and/or (b) de-identified results of analysed patient data from the Clinical Studies as listed in an Exhibit A of the applicable Project Schedule ( the “Clinical Data”) for the sole purpose of conducting the Activities that require such Clinical Data (the “Purpose”), as specifically set forth in the exhibit to the Project Schedule. As used herein, “de-identified” means to be coded in a manner that does not allow for identification of the patient or their personally-identifiable PHI of Personal Data, by Company or any Authorized Person(s). Company shall not use the Clinical Data for any other purpose unless authorized by AZ in writing. Company agrees that Clinical Data provided by AZ are Confidential Information of AZ and constitute AZ Data hereunder. AZ shall obtain all consents, permissions and authorizations necessary to provide Company with Clinical Data and for Company to use such Clinical Data for the Purpose.
4.2.2    Company represents and warrants that any Authorized Person(s) shall at all times comply with the terms of this Article 4 and the applicable Project Schedule with respect to such Clinical Data, and that Company shall duly notify any Authorized Person(s) of all applicable requirements under this Article 4 and such Project Schedule with respect to such Clinical Data. Company shall be liable for any acts or omissions of any Authorized Person with respect to any Clinical Data.
4.3    Conditions on Transfer of Clinical Data.
4.3.1    The Clinical Data (a) shall be used by Company and any Authorized Person(s) solely and exclusively to conduct the Purpose; (b) shall not be used, delivered or transmitted by any means by Company or any Authorized Person(s) to or for the benefit of any Third Party (other than to an Authorized Person) without the prior written consent of AZ; (c) shall not be used by Company or any Authorized Person(s) in combination with any other data other than those explicitly set forth in the applicable Project Schedule for use with such Clinical Data (whether commercially available or otherwise); (d) shall not be reverse engineered, reverse assembled or decompiled by Company or any Authorized Person(s); and (e) shall not be used by Company or any Authorized Person to re-identify, locate or single out any individual who is the subject of the data.
4.3.2    The transfer of the Clinical Data by AZ to Company or any Authorized Person(s) under this Agreement shall not transfer any rights to or in the Clinical Data to Company or any Authorized Person(s).
4.3.3    Company shall use, and shall cause any Authorized Person(s) to use, the Clinical Data in compliance with all Applicable Laws, including the GDPR.
4.3.4    Company shall notify AZ in writing of any use, access or disclosure of Clinical Data not permitted by this Agreement and the applicable Project Schedule within twenty-four (24) hours of becoming aware of such unpermitted access, use or disclosure. Company agrees to use its best efforts to mitigate any harmful effect known to Company that is 

Page 23 of 84

caused by any unpermitted access, use or disclosure and to remedy the causes of the incident. Company shall not report any details of the incident to any Third Party unless authorized in writing by AZ or required by Applicable Law.
4.4    Conditions of Transfer of Samples. In addition to its obligations under Sections 3.4 and 14.5, Company shall, (a) upon request from AZ, or (b) if this Agreement or the applicable Project Schedule terminates, or (c) if a subject withdraws consent to use of his or her Sample(s), promptly return to AZ or destroy, at AZ’s sole option and instruction, any related Samples and shall provide written confirmation to AZ promptly following any such destruction of Samples.
4.5    Confidentiality. In addition to the Confidentiality obligations under Article 11:
4.5.1    Company shall apply technical and organizational safeguards consistent with or higher than Good Industry Practices to protect the Clinical Data and shall not use the Clinical Data for any purpose other than as expressly permitted.
4.5.2    At any time upon the request of AZ, all tangible expressions, in any media, of the Clinical Data in Company’s or any Authorized Person(s)’s possession or control shall be delivered to AZ or, at AZ’s option, irretrievably destroyed within the timeframes specified in this Section 4.5.2. In any event, upon completion of the Purpose or earlier termination or expiration of for any reason, Company shall, and shall cause any Authorized Person(s) to, irretrievably destroy all copies of the Clinical Data within Company’s or an Authorized Person(s)’s possession or control. Company shall complete such destruction within one hundred and eighty (180) days of completion of the Purpose specified in the applicable Project Schedule or expiration or termination of such Project Schedule, as applicable. Company shall issue corresponding deletion instructions to any Third Parties authorized by AZ to have access to the Clinical Data for the Purpose.
ARTICLE 5
DEVELOPMENT AND REGULATORY ACTIVITIES
5.1    General Principles. The Parties agree that the ultimate goal of each Project conducted under this Agreement is the Development and Commercialization of a Company Assay for use in connection with an AZ Product. Company shall use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for each Company Assay, in each applicable Market, for each applicable Indication, for use with the applicable AZ Product, in each case in accordance with this Agreement and the requirements of any applicable Project Schedule. The determination of whether and to which extent and in which countries or territories the AZ Product shall be Commercialized shall be within AZ’s sole discretion; provided, however that the Parties will work together in good faith to agree upon and include within a Project Schedule, the timelines of jurisdictions for Regulatory Approval and Commercialization of the Company Assay and AZ Product. As agreed by the Parties, from time to time, the Parties shall execute Project Schedules in accordance with Section 2.3, to include for the applicable Company Assay, Additional Markets or Additional Indications, as applicable, with respect to which such Company Assay shall be

Page 24 of 84

Developed and Commercialized. Each of Company and AZ shall, and shall cause its Affiliates, and shall require its Subcontractors, to comply with all Applicable Law with respect to its Activities under this Agreement and any Project Schedule, which may set forth additional requirements on the Parties with respect to Commercialization in the applicable Markets.
5.1.1    Until commercial launch of a Company Assay, Company shall use Commercially Reasonable Efforts to ensure that Company has arranged adequate laboratory capacity in accordance with Company’s generally applicable commercial terms and any forecast, order, payment, delivery and shipment terms mutually agreed between the Parties. Subject to receiving sufficient prior written notice of required capacity from AZ, Company shall use Commercially Reasonable Efforts to ensure that it maintains sufficient capacity for the Company Assay as is necessary for the complete conduct of the Clinical Studies of the respective AZ Product, provided that Company shall not engage a Third Party for the development of a Company Assay without AZ’s prior written consent with respect to such Third Party (such consent not to be unreasonably withheld or delayed). Company shall inform AZ in the event it becomes aware of any issues with regard to laboratory capacity that may impact the timelines in a Project Schedule.
5.2    Collaboration on Regulatory Strategy. The Parties shall (acting through the applicable JPT(s) and Joint Steering Committee(s)) reasonably collaborate on the strategy for obtaining Regulatory Approvals for the use of each Company Assay with the applicable AZ Product, for the applicable Indication(s), in the applicable Market(s) and shall agree upon the Activities to be completed in support of the achievement of each milestone and the regulatory strategy overall, including with respect to: (i) the regulatory meetings and interactions to take place, including subject matter thereof and objectives of the meetings and interactions, and which Party will attend/participate; (ii) the studies to be carried out, including protocols, acceptance criteria, analysis methods; (iii) regulatory submissions and filings to be made statistical analysis plans and data to be provided in connection in support of those plans; (iv) statistical analysis plans and data to be provided in support of those plans; (v) Data and documentation necessary to support any applications for such Regulatory Approvals in the applicable Market(s); (vi) systems and methods to be used; and (vii) risk determinations and communications thereof, in each case, as further agreed to by the Parties in the applicable Project Schedule. Without limiting the obligations of AZ herein, in the event that AZ ceases for any reason to Develop, pursue Regulatory Approval, or Commercialize the AZ Product in one or more Markets set forth in a Project Schedule, then it shall provide written notice of such cessation to Company, and Company shall have no further obligation under the Project Schedule and this Agreement to Develop, seek Regulatory Approval for, and Commercialize the applicable Company Assay in any of the Markets identified in the applicable Project Schedule.
5.3    Regulatory Approval of Company Assays.
5.3.1    Subject to the principles set forth more specifically in each applicable Project Schedule and the other terms and conditions of this Agreement, Company shall, at its own expense, have the sole right to prepare, obtain and maintain Regulatory Approvals for, and to conduct communications with Regulatory Authorities regarding, any Company Assay (which may include filings of or with respect to IDEs and other filings or communications with Regulatory Authorities with respect to Company’s Development activities). All Regulatory Documentation (including all Regulatory Approvals) generated by Company or its Affiliates with

Page 25 of 84

respect to any Company Assay shall be owned by, and shall be the sole property and held in the name of, Company or its designated Affiliate. Company shall use Commercially Reasonable Efforts to obtain and maintain Regulatory Approval for each Company Assay as an Approved IVD (in the form(s) designated in the applicable Project Schedule) for use with the applicable AZ Product, for the Indication(s) and in the Markets specified in such Project Schedule. At Company’s reasonable request and in accordance with Section 4.2, AZ shall provide Company with any data in the Control of AZ or any of its Affiliates that is necessary or useful in support of Company’s obtaining and maintaining Regulatory Approvals for the use of the Company Assay with the applicable AZ Product.
5.3.2    Company shall provide AZ with a reasonable opportunity to review and comment on (i) any statistical analysis plan that includes AZ Data in support of regulatory filings that are intended to be submitted to Regulatory Authorities, and (ii) relevant portions of all regulatory filings that are made to obtain Regulatory Approval of any Company Assay for use with an AZ Product to the extent that any such filing involves a discussion of any AZ Product, or any AZ Data, that has not been the subject of a prior opportunity for review and comment by AZ or that has been changed, or is being used for a different purpose, since AZ’s previous review and comment. Upon AZ’s request, Company shall provide to AZ information regarding the Company Assay for use as an Approved IVD to an AZ Product as reasonably necessary in connection with AZ’s review and comment on such relevant portions of regulatory filings. Company shall consider in good faith AZ’s comments with respect thereto to the extent relating to the applicable AZ Product; provided that in no event shall Company be obligated to delay the submission of any such regulatory filing due to AZ’s failure to provide its comments in a timely manner. However, if such AZ comments are directly related to the avoidance of a negative impact to the AZ Product, such as but not limited to, regulatory labelling, the AZ comments must be taken into account by Company.
5.3.3    To the extent legally permissible, Company shall provide AZ with an opportunity to attend any scheduled meeting with a Regulatory Authority regarding obtaining Regulatory Approval of a Company Assay for use with an AZ Product, to the extent such meeting includes (or is reasonably anticipated to include) a discussion of such AZ Product or any AZ Data; provided that Company may require that AZ be excused from any such meeting (or portion of meeting) involving discussions of proprietary or confidential information of Company or a third party, and from any portion of any meeting during which there is no discussion of the AZ Product or AZ Data, and provided further that AZ may be excused from any discussions at the request of a Regulatory Authority. Notwithstanding the foregoing, Company shall have ultimate decision-making authority in relation to the content of any regulatory filings, including Regulatory Documentation, that are made to obtain Regulatory Approval of any Company Assay for use with an AZ Product. However, if such AZ comments are directly related to the avoidance of a negative impact to the AZ Product, such as but not limited to, regulatory labelling, the AZ comments must be taken into account by Company.
5.3.4    At least once per Calendar Quarter, each Party shall provide the applicable JPT and the Joint Steering Committee with an update regarding its Development activities with respect to the applicable Company Assay or AZ Product Developed under each Project Schedule conducted since the last report to such JPT and Joint Steering Committee respectively (or with respect to the first report, since the Effective Date). Company shall promptly

Page 26 of 84

notify AZ with respect to any material communication or notifications received from a Regulatory Authority with respect to the Development of each Company Assay and shall provide copies of such communications and/or notices within three (3) Business Days.
5.4    Regulatory Approval of AZ Products
5.4.1    AZ shall, at its own expense, have the sole right to prepare, obtain and maintain Regulatory Approvals for, and to conduct communications with Regulatory Authorities regarding, any AZ Product (which may include filings of or with respect to INDs and other filings or communications with Regulatory Authorities with respect to AZ’s Development activities). All Regulatory Documentation (including all Regulatory Approvals) generated by AZ or its Affiliates with respect to any AZ Product shall be owned by, and shall be the sole property and held in the name of, AZ or its designated Affiliate. Subject to compliance with the countries agreed in the applicable Project Schedule, AZ shall have the sole discretion to determine the countries in which it will seek to obtain and maintain Regulatory Approval for each AZ Product. At AZ’s reasonable request, Company shall provide AZ with any documents or other materials in the Control of Company or any of its Affiliates with respect to the applicable Company Assay as necessary or useful for AZ to obtain or maintain Regulatory Approvals for each AZ Product for which such Company Assay is Developed under a Project Schedule for use with such AZ Product, for the Indication(s) and in the Markets specified in such Project Schedule.
5.4.2    AZ shall provide Company with a reasonable opportunity to review and comment on relevant portions of all regulatory filings that are made to obtain Regulatory Approval of any AZ Product to the extent that any such filing involves technical content related to the applicable Company Assay, solely in relation to the Company Assay that has not been the subject of a prior regulatory review or opportunity for review and comment by Company or that has been changed, or is being used for a different purpose, since Company’s previous review and comment. To the extent legally permissible, AZ shall provide Company with an opportunity to attend any scheduled meeting with a Regulatory Authority regarding obtaining Regulatory Approval of a Company Assay for use with an AZ Product, to the extent such meeting includes (or is reasonably anticipated to include) a discussion of such Company Assay; provided that AZ may require that Company be excused from any meetings involving discussions of proprietary or confidential information of AZ, and from any portion of any meeting during which there is no discussion of the Company Assay, and provided further that Company may be excused from any discussions at the request of a Regulatory Authority. Notwithstanding the foregoing, AZ shall have ultimate decision-making authority in relation to the content of any regulatory filings, including Regulatory Documentation, that are made to obtain Regulatory Approval of any AZ Product.
5.5    Costs. Except as expressly agreed in an applicable Project Schedule, each Party shall be responsible for its own costs and expenses incurred relation to the activities described in Sections 5.3, 5.4 and 5.5, including travel costs.
5.6    Compliance Audit. Subject to the Parties’ confidentiality obligations under Article 11, AZ or its authorized representatives or designees shall have the right, once per calendar year, unless AZ determines an extraordinary reason to carry out a further compliance audit outside of such once per year restriction, with reasonable advance notice (but in no event less than twenty

Page 27 of 84

(20) Business Days’ notice) and at AZ’s cost and expense, during regular business hours, to: (a) audit any facility used in the performance of the Activities assigned to Company under any Project Schedule; (b) review licenses, certificates and accreditations of Company related to such Activities; and (c) audit any recordkeeping, data collection and processing, information and other electronic and non-electronic systems and business processes used by Company in the performance of such Activities related to the Project Schedule. Company shall ensure timely access to facilities and documentation. If any such audit reveals deficiencies, AZ shall promptly notify Company and the Parties will discuss through the JPT whether such deficiencies need to be addressed and if so, the remedial steps to be taken. Any additional audit rights relevant to specific Activities will be set forth in the applicable Project Schedule.
5.7    Regulatory Audits. If a Regulatory Authority desires to conduct an inspection or audit of Company’s facility, or any other facility used in connection with Company’s performance of any Project (including the facilities of Company’s Affiliates or Subcontractors), with regard to a Project, then Company shall promptly notify AZ, and shall permit and cooperate with such inspection and audit. Following receipt of the inspection or audit observations of such Regulatory Authority (a copy of which Company shall immediately provide to AZ), Company shall prepare the response to any such observations and shall provide a copy of such response to AZ provided that Company may redact any portions thereof that do not relate to the applicable Project Schedule. Company shall also provide to AZ a summary of the findings of any other inspection or audit by a Regulatory Authority of Company’s facility, or any facility of Company’s Affiliates or Subcontractors used in connection with Company’s performance of any Project, if and to the extent that such findings are relevant to or may otherwise have an impact on the Commercialization of any Company Assay or any AZ Product.
ARTICLE 6
COMMERCIALIZATION
6.1    Coordination on Commercialization Activities. Within the timeframe set forth in the applicable Project Schedule (but, where launch of the applicable AZ Product in the applicable Indication is dependent on the Company Assay being available for use, no later than twelve (12) months prior to AZ’s planned launch date for the applicable AZ Product and Indication in each Market), the JSC shall commence discussions of the high-level strategy for Commercialization of each Company Assay for use with the corresponding AZ Product and Indication in the Markets.
6.2    Company’s Commercialization Obligations. Upon receiving the required Regulatory Approvals with respect to each Company Assay in each Market, for each Indication, subject to any limitations on Company’s obligations set forth in the applicable Project Schedule, Company shall make such Company Assay commercially available in the applicable Market, for such Indication, for use with the corresponding AZ Product, within a timeframe to be agreed within each Project Schedule of (a) receipt of the required Regulatory Approvals for the Company Assay, if such AZ Product is already marketed, or (b) launch of the AZ Product. Company will use Commercially Reasonable Efforts to ensure that such Company Assay is made commercially available for so long as the Regulatory Approval for the corresponding AZ Product is maintained by or on behalf of AZ or its Affiliates, or its or their (sub)licensees in such Market for the

Page 28 of 84

Indication. Within the timeframe set out in the applicable Project Schedule, Company shall submit to the applicable JPT a proposed written plan for the launch and Commercialization of each Company Assay in each Market for each Indication (“Commercialization Plan”) and the Parties shall coordinate in good faith to finalize and adopt such Commercialization Plan, and upon written agreement it shall be appended to and made part of the applicable Project Schedule.
6.3    Availability of Company Assays. Subject to the terms of this Article 6, Company shall be solely responsible, at Company’s expense (unless otherwise negotiated in a Project Schedule), for making available the Company Assay in compliance with Applicable Law in each Market, including the requirements of CLIA, CAP, QSR, ISO 13485, ISO15189 and GLP, as applicable.
6.4    Commercialization Terms. As between the Parties, Company shall have the sole right to establish the terms of sale for, and otherwise Commercialize, the Company Assay, in each case, anywhere in the world. As between the Parties, AZ shall have the sole right to establish the terms of sale for, and otherwise Commercialize, the AZ Product, in each case, anywhere in the world.
6.5    Compliance with Applicable Law. Company shall and shall cause its Affiliates and Subcontractors to, comply with all Applicable Law with respect to the Commercialization of each Company Assay for use with the applicable AZ Product.
6.6    AZ Discontinuation in Markets. Without expanding the termination rights of either Party under Article 14, if AZ elects to (a) discontinue selling any AZ Product in any Market or (b) not maintain Regulatory Approval for any AZ Product in any Market, then AZ shall notify Company in writing as far in advance of such discontinuation or non-maintenance as possible, and Company shall have no obligation to continue to Commercialize the applicable Company Assay in such Market following the date of discontinuation of such Product or expiration of such Regulatory Approval.
6.7    Failure to Commercialize a Company Assay. If with respect to any AZ Product and Market, Company breaches its obligation pursuant to Section 6.2 to (a) launch such Company Assay; or (b) post launch make commercially available any Company Assay, (in each case subject to any limitations on Company’s obligations set forth in the Commercialization Plan and Project Schedule), and does not cure such failure for (a) within ninety (90) days ahead of intended launch date; or (b) within sixty (60) days to commercialize the applicable Company Assay, then at AZ’s request, and discretion, and provided that any such failure to commercialise is not the result of AZ failing to meet its applicable obligations under this Agreement and the Project Schedule, Company shall promptly make the applicable Company Assay commercially available through alternate channels (e.g., by engaging a Third Party) solely for the applicable Indication or in the applicable Market. This Section 6.7 is not intended, and shall not be construed, to limit any other right or remedy of AZ under this Agreement or at law or equity.
ARTICLE 7
COLLABORATION MANAGEMENT
7.1    Joint Project Teams 

Page 29 of 84

7.1.1    Composition of the Joint Project Team. Within thirty (30) days after execution of any Project Schedule for a Project, each Party shall appoint an agreed number of representatives to a joint project team for such Project (each, a “Joint Project Team” or “JPT”). A Party may change its designated representatives to any JPT as required for any applicable project. JPT members may also be members of other governance teams depending upon the resource available and the structure of each Party and the resources applied to any particular Project for example. Project Team Leads (may also be referred to as “Alliance Managers” within Company). However, each Party’s representatives to a JPT shall have appropriate technical expertise and experience in disciplines relevant to the applicable Project, including, as applicable, expertise and experience in (a) project management, (b) laboratory operations, (c) clinical study operations or (d) regulatory strategy and submissions
7.1.2    Project Leaders. Each Party shall designate one of its representatives to each JPT as its primary point of contact and lead representative for matters related to the Project for which such JPT has responsibility (each, a “Project Leader”). The Parties acknowledge the different structures of support in each of Company and AZ and that such a Project Leader for the purposes of this Agreement may be an Alliance Manager of Company. Meetings of each JPT shall be jointly chaired by the Project Leaders. A Party may change its designated Project Leader by providing written notice to the other Party. The Project Leaders will be responsible for establishing meeting schedules and agendas for the applicable JPT, for generating mutually acceptable minutes of meetings of such JPT and for any other administrative matters related to meetings of such JPT. The Project Leaders may elect to delegate such responsibilities to other members of the JPT, or to alternate or otherwise allocate such responsibilities amongst themselves.
7.1.3    Sub-Teams. Each JPT may establish sub-teams as necessary or useful to carry out any responsibilities of such JPT. Each Party’s representatives to each sub-team shall have appropriate technical expertise and experience in disciplines relevant to the responsibilities of such sub-team. A Party may change its designated representatives to any sub-team by providing written notice to the other Party.
7.1.4    Responsibilities of the Joint Project Teams. The primary responsibility of each JPT is to promote successful completion of the applicable Project in accordance with the applicable Project Schedule. Specific JPT responsibilities shall include:
a)    managing the resources necessary to perform the Activities with respect to each Company Assay under the Project Schedule for the applicable Project;
b)    facilitating communications and exchange of data and information related to the Project, and coordinating interpretation of such data;
c)    assessing the status and direction of the Project and determining approaches needed to carry out the Project with respect to each Company Assay;

Page 30 of 84

d)    reviewing overall strategy and ongoing risks with respect to the Project, including by preparation of risk mitigation reports on a quarterly basis related to timely performance of the Activities required under the Project Schedule for the Company Assay with respect to each Project;
e)    communicating Project status, issues, resolutions and progress to the JSC and other stakeholders, as appropriate, including with respect to any improvement plans agreed by the Parties which may effect an applicable Project;
f)    promptly notifying the relevant Joint Programme Committee, or if such committee has not been established yet, the JSC in the event that issues arise that are likely to impact a Project’s scope, timeline or budget as set forth in an applicable Project Schedule with respect to each Company Assay, and providing recommendations for amending such Project Schedule, if applicable, to account for such issues. Changes to the budget and/or development programme that trigger an increase in fees, if applicable, will be discussed by the Joint Project Team and may be agreed to trigger an amendment to the applicable Project Schedule.;
g)    communicating summaries and preparatory information to the relevant Joint Programme Committee , prior to scheduled JPC meetings, special JPC meetings, or any action by the JPC in writing without a meeting, or as otherwise requested by the JPC;
h)    communicating summaries and preparatory information to the JSC, as applicable, prior to scheduled JSC meetings, special JSC meetings, or any action by the JSC in writing without a meeting, or as otherwise requested by the JSC;
i)    resolving any Disputes that arise with respect to matters within the responsibilities assigned to the sub-teams, in accordance with Section 7.1.6;
j)    supporting the preparation and submission of Regulatory Documentation and Regulatory Approvals relevant to each Project with respect to each Project Schedule; and
k)    preparing and, subject to having the right to approve certain amended or modified Project Schedules under Section 2.4.1, seeking approval for and execution of amendments to Project Schedules in accordance with Article 2; provided that final agreement and signature shall remain subject to an authorized representative of each Party.
7.1.5    Joint Project Team Communication and Meetings. The Parties shall collaborate through a JPT to carry out each Project. Each JPT shall plan and manage its applicable resources, as well as those of any sub-teams, to ensure performance of the Activities set forth in the applicable Project Schedule in accordance with the estimated timelines specified

Page 31 of 84

therein. Each JPT shall interact on an ongoing basis through email, teleconferencing, phone calls and other communication modes, as needed. Each JPT also will meet according to a schedule to be established by such JPT. Each JPT will determine its meeting locations, and whether to conduct a meeting in-person, by teleconference, by videoconference or by other electronic means. Each Party may invite its employees that are not members of a JPT to attend and participate in relevant portions of any JPT meeting. A Party shall notify the other Party’s Project Leader in writing in the event that it wishes to invite a non-employee Third Party to attend a JPT meeting. Any such notice shall be provided at least two (2) Business Days prior to the relevant JPT meeting and shall identify the relevant Third Party and briefly describe the reasons that the requesting Party wishes to include such Third Party in such meeting. The attendance and participation of such Third Party shall be subject to the prior written consent of the Party receiving such notice (such consent not to be unreasonably withheld or delayed). Any such consent granted by a Party shall be conditioned upon such Third Party being bound by a written confidentiality and non-use agreement that is reasonably acceptable to the consenting Party. Notice and approval of the attendance of a Third Party at a subsequent JPT meeting shall not be required for any Third Party who was previously approved by the other Party and remains bound by such confidentiality and non-use agreement at the time of such subsequent JPT meeting. The Parties’ respective Project Leaders shall be responsible for ensuring compliance with the provisions of this Section 7.1.5. Upon request, either Party shall provide evidence in writing that any Third Party that it wishes to invite to any JPT meeting is bound by such confidentiality and non-use agreement. The Parties respective Project Leaders shall be responsible for ensuring compliance with the provisions of this Section 7.1.5. Each Party shall be responsible for all costs and expenses incurred by it in connection with its participation in the meetings of the JPTs.
7.1.6    Joint Project Team Decisions-Making and Dispute Resolution. Each JPT shall make decisions with respect to the matters falling within its jurisdiction by unanimous consent of its designated representatives, with each Party having a single vote. All decisions of each JPT shall be documented in such JPT’s meeting minutes. If a JPT is unable to resolve a Dispute regarding any matter within its authority, or the authority of any applicable sub-team, within twenty (20) days of first considering such matter, then the matter shall be referred to either the Joint Programme Committee for resolution in accordance with Section 7.5.3 or, in the event that an Joint Programme Committee has not been established, to the JSC for resolution in accordance with Section 7.9.3.
7.2    Joint Programme Committee. In the event there are four (4) or more Project Schedules put in place and correspondingly more than one Joint Project Team, and such Project Schedules are ongoing at the same time the Parties shall establish a joint programme committee to be responsible for supervising and coordinating the activities of both Parties under this Agreement with respect to all Indications and Markets, and correspondent Project Schedules, pertaining to the relevant AZ Product (the “Joint Programme Committee” or “JPC”). Each JPC shall consist of an equal number of representatives from each of the Parties (but in any event not less than two (2) representatives from each of the Parties), each with the requisite experience and seniority to enable such person to make decisions on behalf of the Party such person represents with respect to the matters falling within the jurisdiction of the Joint Programme Committee. From time to time, each Party may substitute one or more of its representatives to the JPC by providing written notice to the other Party. It is acknowledged that Company members of the JPC may also be Project Team Leads may also be referred to as “alliance managers” at Company.

Page 32 of 84

7.3    JPC Co-Chairs. The JPC shall be jointly chaired by one representative of each Party to be designated from among such Party’s appointed representatives to the JPC (the “JPC Co-Chairs”). A Party may change its designated JPC Co-Chair by providing written notice to the other Party.
7.4    Responsibilities of the JPC. The primary purpose of the JPC will be to provide oversight and strategic planning for all Project Schedules that pertain to a single AZ Product under this Agreement. The JPC’s responsibilities shall include the following functions:
7.4.1    leading the direction and strategic planning for the Development and Commercialization of each Company Assay for the relevant AZ Product;
7.4.2    resolving any Disputes referred to the JPC by a JPT in accordance with Section 7.5.3 and reviewing progress against any improvement plans that effect two or more Projects;
7.4.3    subject to the JPT having the right to approve certain amended or modified Project Schedules under Section 2.4.1, approving any significant amendments or modifications to the Project Schedule submitted to the JPC by the JPT pursuant to Section 2.4.1, including any associated financial terms or modifications to the payment plan (provided that final agreement and signature shall remain subject to an authorized representative of each Party);
7.4.4    communicating summaries and preparatory information to the JSC, as applicable, prior to scheduled JSC meetings, special JSC meetings, or any action by the JSC in writing without a meeting, or as otherwise requested by the JSC;
7.4.5    facilitating coordination of planned Commercialization activities with respect to each Company Assay for the relevant AZ Product; and
7.4.6    such other responsibilities as may be assigned to the JPC in or pursuant to this Agreement or as may be mutually agreed by the Parties in writing.
7.5    General Provisions Applicable to the JPC.
7.5.1    Meetings and Minutes. The JPC Co-Chairs shall be responsible for establishing meeting schedules and agendas, and for ensuring the generation of mutually acceptable minutes of JPC meetings. Each Party’s JPC Co-Chair may delegate such administrative responsibilities with respect to JPC meetings to one of such Party’s members on the JPC or a JPT, or the JPC Co-Chairs may elect to alternate or otherwise allocate such administrative responsibilities between themselves. The JPC shall meet (either in-person, telephonically or via video conference) not less than once per Calendar Quarter or at such greater frequency as agreed by the respective JPC members. Meetings of the JPC shall be at such locations as the JPC members agree. Each Party shall have the right to request a special meeting of the JPC at any time as necessary to address Disputes or other matters within the scope of the JPC’s responsibilities by providing the other Party with written notice. The Parties shall schedule and convene such JPC meeting as soon as practicable following such notice, but in any event within ten (10) working days of such notice.

Page 33 of 84

7.5.2    Procedural Rules. A quorum of the JPC shall exist whenever there is present at a meeting at least one (1) representative appointed by each Party. Representatives of the Parties on the JPC may attend a meeting either in-person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the other participants. Representation by proxy shall be allowed. Each Party may, from time-to-time and with prior written notice to the JPC members of the other Party, invite Primary Contact Persons, JPT members or any of its employees to attend relevant portions of a JPC meeting, as necessary. If a Party wishes to invite a non-employee Third Party to attend a JPC meeting, then such party shall notify the other Party in writing at least ten (10) Business Days prior to the relevant JPC meeting, which notice shall identify the relevant Third Party, and briefly describe the reasons that the requesting Party wishes to include the Third Party in the meeting. The attendance and participation of such Third Party shall be subject to the prior written consent of the Party receiving such notice (such consent not to be unreasonably withheld or delayed). Any such consent granted by a Party shall be conditioned upon such Third Party being bound by a written confidentiality and non-use agreement that is reasonably acceptable to the consenting Party. Notice and approval of the attendance of such Third Party at a subsequent JPC meeting shall not be required for any Third Party who was previously approved by the other Party and remains bound by such confidentiality and non-use agreement at the time of such subsequent JPC meeting. Upon request, either Party shall provide evidence in writing that any Third Party that it wishes to invite to any JPT meeting is bound by such confidentiality and non-use agreement. The Parties respective JPC Co-Chairs shall be responsible for ensuring compliance with the provisions of this Section 7.5.2. Each Party shall be responsible for all costs and expenses incurred by it in connection with its participation in the meetings of the JPC.
7.5.3    JPC Decisions and Dispute Resolution. The JPC shall make decisions with respect to the matters falling within its jurisdiction by unanimous consent of the Parties’ representatives, with each Party having a single vote. All decisions of the JPC shall be documented in the JPC’s meeting minutes. Except as otherwise set forth in this Agreement, if the JPC is unable to reach agreement on any matter within its jurisdiction within thirty (30) days after the matter is first referred to the JPC then, except as set forth in Section 7.9.4, the matter will be referred to the JSC for resolution pursuant to Section 7.9.3.
7.6    Joint Steering Committee. Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or “JSC”), which shall consist of an equal number of representatives from each of the Parties as agreed, each with the requisite experience and seniority to enable such person to make decisions on behalf of the Party such person represents with respect to the matters falling within the jurisdiction of the JSC; provided, however, that a member of the JSC may not simultaneously serve as a member of any JPT or JPC. From time to time, each Party may substitute one or more of its representatives to the JSC by providing written notice to the other Party.
7.7    JSC Co-Chairs. The JSC shall be jointly chaired by one representative of each Party to be designated from among such Party’s appointed representatives to the JSC (the “JSC Co-Chairs”). A Party may change its designated JSC Co-Chair by providing written notice to the other Party.

Page 34 of 84

7.8    Responsibilities of the JSC. The primary purpose of the JSC will be to provide oversight and strategic planning for all Projects carried out under this Agreement. The JSC’s responsibilities shall include the following functions:
7.8.1    supervising the JPC’s direction and strategic planning of the Development and Commercialization of each Product;
7.8.2    resolving any Disputes referred to the JSC by a JPT or by the JPC in accordance with Sections 7.1.6, 7.5.3 and 7.9.3 and reviewing progress against any improvement plan agreed by the Parties;
7.8.3    facilitating coordination of all planned Commercialization activities; and
7.8.4    such other responsibilities as may be assigned to the JSC in or pursuant to this Agreement or as may be mutually agreed by the Parties in writing.
7.9    General Provisions Applicable to the JSC.
7.9.1    Meetings and Minutes. The JSC Co-Chairs shall be responsible for establishing meeting schedules and agendas, and for ensuring the generation of mutually acceptable minutes of JSC meetings. Each Party’s JSC Co-Chair may delegate such administrative responsibilities with respect to JSC meetings to one of such Party’s members on the JSC or a JPT, or the JSC Co-Chairs may elect to alternate or otherwise allocate such administrative responsibilities between themselves. The JSC shall meet (either in-person, telephonically or via video conference) not less than once per year or at such greater frequency as agreed by the respective JSC members. Meetings of the JSC shall be at such locations as the JSC members agree. Each Party shall have the right to request a special meeting of the JSC at any time as necessary to address Disputes or other matters within the scope of the JSC’s responsibilities by providing the other Party with written notice. The Parties shall schedule and convene such JSC meeting as soon as practicable following such notice, but in any event within fifteen (15) working days of such notice.
7.9.2    Procedural Rules. A quorum of the JSC shall exist whenever there is present at a meeting at least one (1) representative appointed by each Party. Representatives of the Parties on the JSC may attend a meeting either in-person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the other participants. Representation by proxy shall be allowed. Each Party may, from time-to-time and with prior written notice to the JSC members of the other Party, invite Primary Contact Persons, JPT members or any of its employees to attend relevant portions of a JSC meeting, as necessary. If a Party wishes to invite a non-employee Third Party to attend a JSC meeting, then such party shall notify the other Party in writing at least ten (10) Business Days prior to the relevant JSC meeting, which notice shall identify the relevant Third Party, and briefly describe the reasons that the requesting Party wishes to include the Third Party in the meeting. The attendance and participation of such Third Party shall be subject to the prior written consent of the Party receiving such notice (such consent not to be unreasonably withheld or delayed). Any such consent 

Page 35 of 84

granted by a Party shall be conditioned upon such Third Party being bound by a written confidentiality and

Page 36 of 84

non-use agreement that is reasonably acceptable to the consenting Party. Notice and approval of the attendance of such Third Party at a subsequent JSC meeting shall not be required for any Third Party who was previously approved by the other Party and remains bound by such confidentiality and non-use agreement at the time of such subsequent JSC meeting. Upon request, either Party shall provide evidence in writing that any Third Party that it wishes to invite to any JPT meeting is bound by such confidentiality and non-use agreement. The Parties respective JSC Co-Chairs shall be responsible for ensuring compliance with the provisions of this Section 7.9.2. Each Party shall be responsible for all costs and expenses incurred by it in connection with its participation in the meetings of the JSC.
7.9.3    JSC Decisions and Dispute Resolution. The JSC shall make decisions with respect to the matters falling within its jurisdiction by unanimous consent of the Parties’ representatives, with each Party having a single vote. All decisions of the JSC shall be documented in the JSC’s meeting minutes. Except as otherwise set forth in this Agreement, if the JSC is unable to reach agreement on any matter within its jurisdiction within thirty (30) days after the matter is first referred to the JSC then, except as set forth in Section 7.9.4, the matter will be referred to the Parties’ Senior Officers for resolution pursuant to Section 15.7.
7.9.4    Resolution of Selected Matters. Notwithstanding Section 7.9.3, the Parties agree that the following matters shall not be referred to the Parties’ Senior Officers for resolution pursuant to Section 15.7, and instead shall be resolved as follows:
a)    AZ shall have the right to resolve finally and definitively any matters related exclusively to the Development and Commercialization of any AZ Product; provided, however, that (i) AZ’s final decision-making authority with respect to such matters is not intended, and shall not be construed, to relieve AZ of compliance with the terms and conditions of this Agreement or any Project Schedule, and (ii) in exercising its final decision-making authority under this clause (a), AZ may not impose any additional financial or other obligations on Company under this Agreement or any Project Schedule; and
b)    Company shall have the right to resolve finally and definitively any matters related exclusively to the Development or Commercialization of any Company Assay; provided, however, that (i) Company’s final decision-making authority with respect to such matters is not intended, and shall not be construed, to relieve Company of compliance with the terms and conditions of this Agreement or any Project Schedule, including any Specifications set forth in any Project Schedule with respect to any Company Assay, and (ii) in exercising its final decision-making authority under this clause (b), Company may not impose any additional financial or other obligations on AZ under this Agreement or any Project Schedule.
7.10    Limitations on Authority. Each Party shall retain the rights, powers, and discretion granted to it under this Agreement and no such rights, powers, or discretion shall be delegated to or vested in a JPT, a JPC, or the JSC unless such delegation or vesting of rights is expressly provided for in this Agreement or a Project Schedule, or the Parties otherwise expressly so agree in writing. No JPT, JPC or the JSC shall have the power to amend, modify, or waive 

Page 37 of 84

compliance with any provision of this Agreement, which may only be amended or modified as provided in Section 15.10 or compliance with which may only be waived in accordance with Section 15.13.
7.11    Primary Contact Persons. Each Party shall appoint a person who shall oversee contact between the Parties for all matters between meetings of the JSC (except to the extent that this Agreement or a Project Schedule provides that communications shall be submitted through the JPTs) and shall have such other responsibilities as the Parties may agree in writing after the Effective Date (the “Primary Contact Person”). From time to time, each Party may substitute its Primary Contact Person by providing written notice to the other Party. The Primary Contact Persons shall work together to manage and facilitate the communication between the Parties under this Agreement and any Project Schedules, including the resolution (in accordance with the terms of this Agreement) of Disputes that arise in connection with this Agreement. The Primary Contact Person shall not have decision-making authority with respect to any matter under this Agreement or any Project Schedule. Each Party’s Primary Contact Person may, if elected by such Party, also serve as a representative of such Party on the JSC.
ARTICLE 8
PAYMENTS AND RECORDS
8.1    Fee Schedules. The Project Schedule for each Project shall include fee schedule(s) for the Activities for such Project (each, a “Fee Schedule”).
8.2    Invoices. AZ shall pay to Company all amounts properly due and payable under each invoice submitted under a Project Schedule within seventy-five (75) days following the receipt and approval of such invoice. For clarity invoices shall be sent to AZ after Company has provided the required Deliverables.
8.2.1    Each Project Schedule shall include the invoicing schedule applicable to the fees payable for the applicable Project.
8.2.2    In the case of a milestone-based invoicing schedule, Company shall submit to AZ written documentation regarding the evidence of milestone achievement prior to invoicing AZ, as set forth in the applicable Project Schedule, and AZ will confirm to Company its satisfaction (not to be unreasonably withheld, conditioned or delayed, but in no case longer than fifteen (15) days) that the milestone has been met pursuant to the evidence provided.
8.2.3    Each invoice submitted by Company shall include (a) the applicable AZ purchase order number, which number shall be provided by AZ upon Company’s request, (b) a reference to this Agreement and the applicable Project Schedule and (c) the information set forth in Schedule 8.2 hereto, which information may be updated from time to time, upon written notice by AZ. Each invoice, along with all applicable supporting documentation, shall be submitted electronically, in.pdf, .doc, .xls, or .ppt format, to:
[**]
and addressed to:

Page 38 of 84

[**]
AstraZeneca UK Ltd
[Intentionally Omitted]
Phone: [**]
		
	with cc to:
	AZ’s Project Leader for the applicable JPT Contact

Any inquiries with respect to the status of any invoices or purchase orders shall be submitted electronically to:
[**]
		
	with cc to:
	AZ’s Project Leader for the applicable JPT

8.3    Mode of Payment. Payments to Company under this Agreement shall be made in Dollars in the requisite amount by electronic bank transfer to such bank as Company may designate to AZ in the applicable invoice, in accordance with the invoicing requirements under Schedule 8.2.
8.4    Taxes. The milestones and other amounts payable by AZ to Company pursuant to this Agreement and the applicable Project Schedule (each, a “Payment”) shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law. Except as otherwise provided in this Section 8.4, Company shall be solely responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by AZ) levied on account of, or measured in whole or in part by reference to, any Payments it receives. AZ shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if Company is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to AZ or the appropriate governmental authority (with the assistance of AZ to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve AZ of its obligation to withhold such tax and AZ shall apply the reduced rate of withholding or dispense with withholding, as the case may be. If, in accordance with the foregoing, AZ withholds any amount, it shall pay to Company the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to Company proof of such payment within ten (10) days following such payment.
8.5    Financial Records. As and to the extent necessary for the verification of payments under the applicable Project Schedule, Company shall, and shall cause its Affiliates to, keep accurate books and records pertaining to the Payments received under this Agreement until the later of (a) five (5) years after the end of the period to which such books and records pertain 

Page 39 of 84

and (b) the expiration of the applicable tax statute of limitations (or any extensions thereof) or for such longer period as may be required by Applicable Law.
8.6    Financial Audit.
8.6.1    Procedures. At the request of AZ and, subject to Section 8.6.2, at AZ’s expense, Company shall, and shall cause its Affiliates to, permit an independent auditor designated by AZ and reasonably acceptable to Company, at reasonable times during normal business hours and upon reasonable notice, to audit the books and records maintained pursuant to Section 8.5 to ensure the accuracy of Payments invoiced by Company hereunder. Such examinations may not (a) be conducted more than two (2) years after Company invoices AZ for such Payment or (b) be conducted more than once with respect to achievement of any milestone unless a previous audit revealed a material error in determining whether such milestone was achieved or the timing of achievement of such milestone.
8.6.2    Audit Dispute. In the event of a Dispute with respect to any audit under Section 8.6.1, the Parties shall work in good faith to resolve the Dispute. If the Parties are unable to reach a mutually acceptable resolution of any such Dispute within thirty (30) days after first considering such Dispute, then such Dispute shall be submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree. The decision of such Person shall be final and the costs of review by such Person and the initial audit shall be borne between the Parties in such manner as such Person shall determine. Not later than ten (10) days after such decision, and in accordance with such decision, AZ shall pay any additional amounts owed or Company shall reimburse any excess payments made, as applicable.
8.6.3    Confidentiality. The auditing Party shall treat all information subject to review under this Article 8 in accordance with the confidentiality provisions of Article 11 and shall cause the Person performing the audit to enter into a confidentiality and non-use agreement with the audited Party with respect to such information, which agreement shall be reasonably acceptable to the audited Party.
8.7    No Right to Offset. Neither Party shall have the right to offset any amount owed by the other Party to such first Party under or in connection with this Agreement, including pursuant to Article 13 or in connection with any breach, against any payments owed by such first Party to such other Party under this Agreement without the prior agreement of the Party benefitting from such amount.
ARTICLE 9
INTELLECTUAL PROPERTY OWNERSHIP, DATA AND LICENSE GRANTS
9.1    Ownership.
9.1.1    Background IP. Subject to the license grants provided by a Party to the other Party hereunder, neither Party grants to the other any right, title or interest in or to, in the case of AZ, any AZ Background IP, and in the case of Company, any Company Background IP and, as between the Parties, AZ shall retain all of its right, title and interest in and to AZ 

Page 40 of 84

Background IP and Company shall retain all of its right, title and interest in and to the Company Background IP.
9.1.2    Foreground IP. Without limiting the effect of Section 9.1.1, as between the Parties, (a) AZ shall own all right, title and interest in and to the AZ Foreground IP and (b) Company shall own all right, title and interest in and to the Company Foreground IP.
9.1.3    Data. Without limiting the effect of Sections 9.1.1 and 9.1.2, AZ shall own all right, title and interest in and to the AZ Data and (b) Company shall own all right, title and interest in and to the Company Data.
9.2    License Grants.
9.2.1    Grants to Company.
a)    AZ, on behalf of itself and its Affiliates, hereby grants to Company and its Affiliates during the Term a non-exclusive, worldwide, non-transferable (except as expressly permitted in Section 15.5) and royalty-free license, with the right to grant sublicenses solely in accordance with Section 9.3, under the AZ Background IP and AZ Foreground IP, solely as necessary to Develop each Company Assay for use with the applicable AZ Product for the applicable Indication, in accordance with the applicable Project Schedule. For clarity, nothing contained in this Section 9.2.1.a) is intended, or shall be construed, to grant to Company or its Affiliates any license to Develop or Commercialize any AZ Product.
b)    AZ, on behalf of itself and its Affiliates, hereby grants to Company and its Affiliates a non-exclusive, worldwide, non-transferable (except as expressly permitted in Section 15.5) and royalty-free license, with the right to grant sublicenses solely in accordance with Section 9.3, under the AZ Data, as necessary to Commercialise each Company Assay developed under a Project Schedule for use with the applicable AZ Product in the Market(s) and for the Indication(s) set forth in such Project Schedule . For clarity, nothing contained in this Section 9.2.1.b) is intended, or shall be construed, to grant to Company or its Affiliates any license to Commercialize any AZ Product.
c)    AZ may in its discretion agree, on terms to be negotiated in an applicable Project Schedule, to grant to Company, a licence to use AZ Data for example relating to diagnosis and prognosis to the extent such AZ Data is not related to an AZ Product in a clinical trial.
9.2.2    Grants to AZ.
a)    Company, on behalf of itself and its Affiliates, hereby grants to AZ and its Affiliates during the Term a non-exclusive, worldwide, non-transferable (except as expressly permitted in Section 15.5) and royalty-free license, with the right to grant sublicenses solely in accordance with Section 9.3, under the Company Data to the extent the same is incorporated into the AZ Sample Data 

Page 41 of 84

Files, as necessary to carry out the activities under the Agreement. For clarity, nothing contained in this Section 9.2.2.a) is intended or shall be construed to grant to AZ or its Affiliates, or its sublicensee(s) any license to Develop or Commercialize any Company Assay, any IVD or any other product in the Diagnostic Field.
b)    Company, on behalf of itself and its Affiliates, hereby grants to AZ and its Affiliates during the Term a non-exclusive, worldwide, non-transferable (except as expressly permitted in Section 15.5) and royalty-free license, with the right to grant sublicenses solely in accordance with Section 9.3, under the (x) Company Background IP and (y) Company Improvements, in each case (of (x) and (y)) solely to the extent the same is incorporated into the AZ Sample Data Files, as solely required to Develop each Company Assay for use with an AZ Product as set forth in each Project Schedule. For clarity, nothing contained in this Section 9.2.2.b) is intended or shall be construed to grant to AZ or its Affiliates, or its Sublicensee(s), any license to Commercialize any Company Assay, any IVD or any other product in the Diagnostic Field.
9.3    Sublicenses.
9.3.1    To the extent a Party shall have the right to grant sublicenses under the licenses granted in Section 9.2.1, or 9.2.2, such right shall be exercisable without the consent of the other Party solely (a) to any Affiliate of the applicable Party; (b) to Subcontractors to perform activities on behalf of the applicable Party hereunder; (c) in the case of AZ, to any Third Party to which AZ or any of its Affiliates grants a license under intellectual property owned or Controlled by AZ to Exploit an AZ Product for use with the applicable Company Assay; and (d) in the case of Company, to any Third Party to which Company grants a license under intellectual property owned or Controlled by Company to Exploit a Company Assay for use with the applicable AZ Product. Each Party shall be responsible for its respective sublicensee(s)’ compliance with this Agreement.
9.4    Rights Controlled by Third Parties. Notwithstanding the foregoing, if intellectual property controlled by a Third Party is included in either, AZ Background IP or Company Background IP, by an agreement with a Party then the other Party agrees to comply with the terms of such agreement, provided such terms are notified to the other Party. Notwithstanding any such agreement between a Third Party and a Party that provides rights in intellectual property controlled by a Third Party to flow through to the other Party, the Party in agreement with the Third Party is responsible for any payments under any such agreement unless otherwise agreed in the relevant Project Schedule.
9.5    Disclosure of Foreground IP. Each Party shall promptly disclose to the other Party in writing the conception, reduction to practice, generation or other development of any invention included in the Foreground IP that such Party has an obligation to assign to the other Party under Section 9.6 and 9.7. Notwithstanding anything to the contrary herein, but without limiting Company’s obligation to provide to AZ the AZ Sample Data Files, Company shall not in 

Page 42 of 84

any event be required to disclose to AZ any Raw Data, Assay Validation Data, Company Background IP or Company Improvement.
9.6    Assignment. Each Party shall, and does hereby, assign, and shall cause its Affiliates and its and their (sub)licensees to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Foreground IP as is necessary to fully effect ownership as provided in Section 9.1.2.
9.7    Assignment Obligation. Each Party shall use Commercially Reasonable Efforts to cause all Persons who (a) perform Development Activities on behalf of such Party under or in connection with this Agreement or any applicable Project Schedule, or (b) conceive, reduce to practice, generate or otherwise develop any Foreground IP on behalf of such Party or its Affiliates, or its or their (sub)licensees, to be, in each case ((a) and (b)), under an obligation to assign (or, if such Party is unable to cause such Person to agree to such assignment obligation despite such Party’s using Commercially Reasonable Efforts to negotiate such assignment obligation, provide an exclusive license under) their rights in any Foreground IP resulting therefrom to such Party for the purpose of fully effecting ownership as provided for in Section 9.1.2.
9.8    Third Party Licenses. Each Party shall promptly provide written notice to the other Party upon becoming aware of any potential or actual infringement of any intellectual property controlled by a Third Party arising from the Exploitation of any Company Assay Developed or Commercialized under any Project Schedule, including any potential or actual infringement arising from the Exploitation of any Company Assay for use with the applicable AZ Product.
9.8.1    Company Assays and Company Technology Platform. Company shall use Commercially Reasonable Efforts to negotiate and obtain any license, at its own expense, to any intellectual property controlled by a Third Party that is necessary for the Exploitation of any Company Assay or the Company Technology Platform under this Agreement (the “Third Party Licenses for Company Technology”). Unless otherwise set forth in the applicable Project Schedule or otherwise agreed upon by the Parties in writing, Company shall be responsible for the costs in connection with obtaining any Third-Party Licenses for Company Technology that are necessary for the Exploitation of the Company Technology Platform and Company Assay pursuant to this Agreement.
9.8.2    Company shall use Commercially Reasonable Efforts to obtain the right to grant a sublicense under any Third Party License for Company Technology, as applicable, to AZ to the extent necessary to include such sublicense rights in the licenses granted by such Party in Section 9.2. Company (a) shall consult with AZ in connection with such negotiations and shall consider any comments with respect thereto, and (b) shall not enter into any Third Party License for Company Technology pursuant to which AZ would have any payment-related obligations or any other obligations (other than to comply with the terms and conditions of such Third Party License if receiving a sublicense thereunder) without AZ’s prior written consent.
9.9    Rights of Reference.

Page 43 of 84

9.9.1    With respect to each Company Assay Developed for use with an applicable AZ Product pursuant to a Project Schedule, AZ shall, and shall ensure that its Affiliates shall, upon request provide Company (and Company’s designated Affiliates and (sub)licensees) with any appropriate letters or other similar documentation necessary to authorize such Person to cross-reference and rely (on a non-exclusive basis) upon the contents of any of AZ’s or its Affiliates’ (or, to the extent Controlled by AZ or any of its Affiliates, its (sub)licensees’) Regulatory Documentation for each AZ Product for the sole purposes of (i) performing Company’s obligations under this Agreement or any Project Schedule or (ii) filing, obtaining and maintaining of Regulatory Approvals for the Company Assay for use with the applicable AZ Product in the Markets and for the Indications.
9.9.2    With respect to each AZ Product with respect to which any Company Assay is or will be Developed for use pursuant to a Project Schedule, Company shall, and shall ensure that its Affiliates shall, upon request provide AZ (and AZ’s designated Affiliates and (sub)licensees) with any appropriate letters or other similar documentation necessary to authorize such Person to cross-reference and rely (on a non-exclusive basis) upon the contents of any of Company’s or its Affiliates’ (or, to the extent Controlled by Company or any of its Affiliates, its (sub)licensees’) Regulatory Documentation (including any device master files or equivalent) for each Company Assay Developed for use with an applicable AZ Product, for the sole purposes of (i) performing AZ’s obligations under this Agreement or (ii) filing, obtaining and maintaining of Regulatory Approvals for the AZ Product for use with the applicable Company Assay in the Markets and for the Indications.
9.10    Retained Rights. Neither Party grants to the other Party any intellectual property licenses or other rights, express or implied, by estoppel or otherwise, other than those licenses or rights explicitly set forth in this Agreement.
ARTICLE 10
INTELLECTUAL PROPERTY PROSECUTION, ENFORCEMENT AND DEFENSE
10.1    Patent Prosecution and Maintenance.
10.1.1    AZ Patents. As between the Parties, AZ shall have the sole right, but not the obligation, using counsel of its own choice, to prepare, file, prosecute and maintain (a) Patents included in the AZ Background IP and (b) AZ Foreground Patents worldwide, and to be responsible for any related interference, re-issuance, re-examination, review, opposition proceedings and patent term extensions, in each case, at its sole cost and expense.
10.1.2    Company Patents. As between the Parties, Company shall have the sole right, but not the obligation, using counsel of its own choice, to prepare, file, prosecute and maintain (a) Patents included in the Company Background IP and (b) Company Foreground Patents worldwide, and to be responsible for any related interference, re-issuance, re-examination, review, opposition proceedings and patent term extensions, in each case, at its sole cost and expense.
10.1.3    Cooperation. The non-prosecuting Party shall use reasonable efforts, and shall cause its Affiliates to use reasonable efforts, to, assist and cooperate with the

Page 44 of 84

prosecuting Party, as the prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the Foreground Patents, including by providing access to relevant documents and other evidence and making its employees available at reasonable business hours, in each case, solely to the prosecuting Party’s outside counsel, who will not make such documents, evidence and information directly available to the prosecuting Party; provided that neither Party shall be required to provide legally privileged information unless and until procedures reasonably acceptable to such Party are in place to protect such privilege; and provided, further, that the prosecuting Party shall reimburse the non-prosecuting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith.
10.1.4    Common Ownership Under Joint Research Agreements. Notwithstanding anything to the contrary in this Section 10.1, neither Party shall have the right to make an election under 35 U.S.C. § 102(c) when exercising its rights under this Section 10.1 without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed). With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in 35 U.S.C. § 100(h).
10.2    Enforcement of Patents.
10.2.1    Enforcement of AZ Intellectual Property Rights. As between the Parties, AZ shall have the sole right, but not the obligation, to prosecute infringement or misappropriation with respect to the AZ Background IP and AZ Foreground IP.
10.2.2    Enforcement of Company Intellectual Property Rights. As between the Parties, Company shall have the sole right, but not the obligation, to prosecute infringement or misappropriation with respect to the Company Background IP and Company Foreground IP.
10.2.3    Cooperation. The Parties agree to cooperate fully in any infringement or misappropriation action with respect to any Foreground IP pursuant to this Section 10.2, including by making applicable records and documents available upon the reasonable request of the Party having the right to enforce such Foreground IP (the “Enforcing Party”). The other Party (the “Non-Enforcing Party”) shall use reasonable efforts, and shall cause its Affiliates to use reasonable efforts, to, assist and cooperate with the Enforcing Party, as such Enforcing Party may reasonably request from time to time, in connection with its activities under this Section 10.2, including by providing access to relevant documents and other evidence and making its employees available at reasonable business hours, in each case to the Enforcing Party’s outside counsel, who shall not make such documents, evidence and information directly available to the Enforcing Party; provided that the Enforcing Party shall reimburse the Non-Enforcing Party (or its Affiliate) for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith.
10.2.4    Recovery. Any recovery realized as a result of an enforcement action with respect to any Foreground IP under this Section 10.2 (whether by way of settlement or otherwise) shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of 

Page 45 of 84

such expenses). Any remainder after such reimbursement is made shall be retained by the Enforcing Party.
10.3    Infringement Claims by Third Parties.
10.3.1    In General. If the Exploitation of an AZ Product or a Company Assay pursuant to this Agreement results in, or is reasonably expected to result in, any claim, suit or proceeding by a Third Party alleging infringement by AZ or Company, or any of their Affiliates, (sub)licensees, distributors or customers (a “Third Party Infringement Claim”), including as a defense or counterclaim in connection with an enforcement action initiated pursuant to Section 10.2, then the Party having information regarding the Third Party Infringement Claim will promptly notify the other Party in writing, and the Parties shall have the following rights and obligations:
a)    Defense of AZ Product. As between the Parties, AZ shall have the sole right, but not the obligation, to defend and control the defense of any Third Party Infringement Claim with respect to any AZ Product, at its sole cost and expense, using counsel of its own choice. For the avoidance of doubt, this shall include the sole right, but not the obligation, to defend and control the defense of any Third Party Infringement Claim which specifically relates to a method of treating patients with the AZ Product by using the Company Assay in accordance with the applicable Project Schedule.
b)    Defense of Company Assay or Company Technology Platform. As between the Parties, Company shall have the sole right, but not the obligation, to defend and control the defense of any Third Party Infringement Claim with respect to any Company Assay or the Company Technology Platform, using counsel of its own choice. Company shall be responsible for its costs arising from the defense and control of any Third Party Infringement Claim with respect to the Company Technology Platform and the Company Assay. AZ shall be responsible for Company’s costs arising from the defense and control of any other Third Party Infringement Claim with respect to any Company Assay to the extent such Third Party Infringement Claim directly relates to a method of treating patients with the AZ Product using the Company Assay in accordance with the applicable Project Schedule; provided that AZ shall have the right to provide comments with respect to such defense and control, which Company shall consider in good faith.
10.3.2    Cooperation. Where a Party controls the defense of a Third Party Infringement Claim as set forth in Sections 10.3.1.a) or 10.3.1.b) (as applicable, the “Defending Party”), the other Party (the “Non-Defending Party”) shall use reasonable efforts, and shall cause its Affiliates to use reasonable efforts, to, assist and cooperate with the Defending Party, as such Defending Party may reasonably request from time to time, in connection with such defense including, where necessary, joining in or being named as a necessary party to such action (or furnishing a power of attorney for such purpose); provided that, except in connection with a Third Party Infringement Claim with respect to a Company Assay for which AZ is responsible for Company’s costs as described in Section 10.3.1.b), the Defending Party shall reimburse the Non-

Page 46 of 84

Defending Party (or its Affiliate) for its documented and verifiable out-of-pocket costs and expenses actually incurred in connection therewith. Each Party shall keep the other Party reasonably informed of all material developments in connection with any Third Party Infringement Claim. The Defending Party shall have the sole and exclusive right to settle any Third Party Infringement Action; provided that the Defending Party shall not have the right to settle any such claim in a manner that imposes any costs or liability on, or involves any admission by, the other Party, without the express written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed).
10.4    Invalidity or Unenforceability Defenses or Actions.
10.4.1    Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or unenforceability of any Foreground Patent by a Third Party, including as a defense or counterclaim in connection with an infringement action initiated pursuant to Section 10.2, in each case of which such Party becomes aware.
10.4.2    AZ Patents. As between the Parties, AZ shall have sole right, but not the obligation, to defend and control the defense of the validity and enforceability of (a) Patents included in the AZ Background IP and (b) AZ Foreground Patents, in each case ((a) and (b)), at its sole cost and expense and using counsel of its own choice.
10.4.3    Company Patents. As between the Parties, Company shall have sole right, but not the obligation, to defend and control the defense of the validity and enforceability of (a) Patents included in the Company Background IP and (b) Company Foreground Patents, in each case ((a) and (b)), at its sole cost and expense and using counsel of its own choice.
10.4.4    Cooperation. Upon the request from time to time by the Party allocated the right to defend and control the defense of the validity and enforceability of such Foreground Patent (the “Controlling Party”), the other Party (the “Non-Controlling Party”) shall use reasonable efforts, and shall cause its Affiliates to use reasonable efforts, to, assist and cooperate with the Controlling Party, as the Controlling Party may reasonably request from time to time in connection with its activities under this Section 10.4; provided that the Controlling Party shall reimburse the Non-Controlling Party for its documented and verifiable out-of-pocket costs and expenses actually incurred in connection therewith.
10.4.5    Settlements. Each Party shall have the sole and exclusive right to settle a claim under this Section 10.4 with respect to any Patents it owns; provided that neither Party shall have the right to settle any such claim in a manner that imposes any costs or liability on, or involves any admission by, the other Party, without the express written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed).
ARTICLE 11
CONFIDENTIALITY AND NON-DISCLOSURE
11.1    Confidentiality Obligations.

Page 47 of 84

11.1.1    At all times during the Term and for a period of ten (10) years following termination or expiration hereof in its entirety or perpetually with respect to trade secrets, the Receiving Party shall and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any Confidential Information of the Disclosing Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is necessary for the performance of a Party’s obligations hereunder. “Confidential Information” of a Party means any confidential or proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) that are provided by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) in connection with this Agreement, whether prior to, on or after the Effective Date, including any Know-How or other proprietary information relating to the Disclosing Party’s past, present or future marketing activities, financial activities, or development activities with respect to any product or potential product or technology of the Disclosing Party or the pricing thereof.
11.1.2    Notwithstanding Section 11.1.1, (a) the terms of this Agreement shall be deemed the Confidential Information of both Parties (and both Parties shall be deemed to be the Receiving Party and the Disclosing Party with respect thereto); (b) Confidential Information consisting of Biomarker Detection Know-How, Assay Validation Data or other Company Foreground IP shall be deemed the Confidential Information of Company (and Company shall be deemed the Disclosing Party and AZ shall be deemed the Receiving Party with respect thereto); and (c) Confidential Information consisting of AZ Data or other AZ Foreground IP shall be deemed the Confidential Information of AZ (and AZ shall be deemed the Disclosing Party and Company shall be deemed the Receiving Party with respect thereto).
11.1.3    Notwithstanding the foregoing provisions of this Section 11.1, Section 11.1.1 shall not apply to the Receiving Party with respect to any Confidential Information of the Disclosing Party to the extent it can be established by the Receiving Party that such Confidential Information:
a)    was in the Receiving Party’s possession prior to disclosure by the Disclosing Party without any obligation of confidentiality with respect to such information; provided that the foregoing exception shall not apply to the Receiving Party with respect to the terms of this Agreement or any applicable Project Schedule, or with respect to Confidential Information that a Party possesses but is deemed to be the Receiving Party with respect thereto pursuant to Section 11.1.2;
b)    is subsequently received by the Receiving Party from a Third Party who is not bound by any obligation of confidentiality with respect to such information;
c)    has been or hereafter is published by a Third Party or has become or hereafter otherwise becomes publicly available through no fault of the Receiving Party, but solely from and after the time the Confidential Information becomes publicly available; or

Page 48 of 84

d)    is independently developed by or for the Receiving Party without reference to the Disclosing Party’s Confidential Information; provided that the foregoing exception shall not apply to the Receiving Party with respect to the terms of this Agreement or any applicable Project Schedule, or with respect to Confidential Information that a Party independently develops but is deemed to be that of the Receiving Party with respect thereto pursuant to Section 11.1.2.
Specific aspects or details of Confidential Information shall not be deemed to be publicly available or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information that is publicly available or in the possession of the Receiving Party. Further, any combination of Confidential Information shall not be considered publicly available or in the possession of the Receiving Party merely because individual elements of such Confidential Information are publicly available or in the possession of the Receiving Party unless the combination and its principles are publicly available or in the possession of the Receiving Party.
11.2    Permitted Disclosures. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such disclosure is:
11.2.1    made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial or local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the Receiving Party’s legal counsel, such disclosure is otherwise required by Applicable Law, including by the U.S. Securities Exchange Commission, or (solely in the case of disclosure of the terms of this Agreement) by any stock exchange upon which such Party’s securities are listed or to which an application for listing has been submitted; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and provided, further, that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order;
11.2.2    subject to the Disclosing Party’s prior written consent, not to be unreasonably withheld, conditioned or delayed, made by or on behalf of the Receiving Party to a patent authority for purposes of obtaining, maintaining or enforcing a Foreground Patent, in each case, in a manner not inconsistent with Article 9 and Article 10; provided, however, that the Receiving Party shall take reasonable measures to assure confidential treatment of such information, to the extent such protection is available;
11.2.3    limited to a disclosure of the terms of this Agreement, and is made by or on behalf of the Receiving Party to bona fide potential or actual investors or acquirers as may be necessary in connection with their evaluation of such potential or actual investment or acquisition; provided, however, that such Persons shall be subject to written obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to

Page 49 of 84

the obligations of confidentiality and non-use of the Receiving Party pursuant to this Article 11 (with a duration of confidentiality and non-use at least as long as the duration of the Receiving Party’s obligations);
11.2.4    subject to the Disclosing Party’s prior written consent, made by or on behalf of the Receiving Party as may be reasonably necessary in connection with any filing, application or submission made in support of obtaining or maintaining any Regulatory Approval (a) in the case of AZ, for any AZ Product for which any Company Assay is Developed or Commercialized under this Agreement, and (b) in the case of Company, for any Company Assay for use with the applicable AZ Product specified in an applicable Project Schedule; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; or
11.2.5    made by or on behalf of the Receiving Party to a Third Party as may be necessary or useful in connection with the performance of such Party’s obligations as contemplated by this Agreement or any applicable Project Schedule, including to existing or potential agents, Affiliates, subcontractor(s); provided, however, that such Third Party or existing or potential agents, Affiliates, or (sub)licensees shall be subject to written obligations of confidentiality and non-use with respect to such Confidential Information at least as restrictive as the obligations of confidentiality and non-use of the receiving Party pursuant to this Article 11 (with a duration of confidentiality and non-use at least as long as the duration of the Receiving Party’s obligations).
11.3    Use of Name. Except as expressly provided under this Agreement, neither Party shall mention or otherwise use the name, logo or Trademark Rights of the other Party or any of its Affiliates or any of its or their (sub)licensees (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material or other form of publicity without the prior written approval of such other Party. The restrictions imposed by this Section 11.3 shall not be construed to limit or prevent a Party from (a) making any disclosure identifying the other Party to the extent required in connection with its exercise of its rights or obligations under this Agreement or (b) making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted).
11.4    Public Announcements. The Parties agree that Company will be permitted to issue a press release announcing this Agreement , the date and content of which must be mutually agreed in advance by the Parties. Notwithstanding the foregoing, neither Party shall otherwise issue any public announcement, press release or other public disclosure regarding the terms of this Agreement without the other Party’s prior written consent, except for any such disclosure that is, in the opinion of the disclosing Party’s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). In the event a Party is, in the opinion of its counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than five (5) Business Days prior to the anticipated date of disclosure or such shorter period as may be necessary under the circumstances) so as to provide a 

Page 50 of 84

reasonable opportunity to comment thereon. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement or any Project Schedule, or any amendment hereto or thereto, that has already been publicly disclosed by such Party or by the other Party, in accordance with this Section 11.4 provided that such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable. Further, the restrictions imposed on each Party under this Section 11.4 are not intended, and shall not be construed, to prohibit a Party from identifying the other Party in its internal business communications.
11.5    Publication. Each Party recognizes that collaborative publication of papers, including peer reviewed journal articles, abstracts and posters, as well as oral presentations, regarding the activities and results under this Agreement, may be beneficial to both Parties. Each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation, which includes Confidential Information of the reviewing Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a complete copy of the paper or materials for oral presentation to the other Party at least forty-five (45) days prior to submitting the paper to a publisher or fifteen (15) days prior to submitting an abstract or making a presentation. The other Party shall review any such paper and give its comments to the publishing Party within thirty (30) days of receipt. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the presenting Party with appropriate comments, if any, but in no event later than seven (7) days from the date of receipt. If approval is not given, either Party may refer the matter to the JSC for discussion together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper or presentation and will withhold publication of any such paper or any presentation for an additional sixty (60) days in order to allow such other Party to obtain patent protection if such other Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate.
11.6    Return of Confidential Information. Upon expiration or termination of this Agreement or an applicable Project Schedule for any reason, or at any time during the Term, either Party may request in writing and the non-requesting Party shall either, with respect to Confidential Information of the requesting Party to which such non-requesting Party does not retain rights under the surviving provisions of this Agreement or any Project Schedule: (a) promptly destroy all copies of such Confidential Information in the possession or control of the non-requesting Party and confirm such destruction in writing to the requesting Party; or (b) promptly deliver to the requesting Party, at the requesting Party’s sole cost and expense, all copies of such Confidential Information in the possession or control of the non-requesting Party. Notwithstanding the foregoing, the non-requesting Party shall be permitted to retain such (i) Confidential Information to the extent necessary for purposes of performing any continuing obligations or exercising any ongoing rights hereunder or under any Project Schedule or with respect to which a Party has a continuing license or ownership right hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (ii) any computer records or files containing such Confidential Information that have been created solely by such non-

Page 51 of 84

requesting Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 11.1.1.
ARTICLE 12
REPRESENTATIONS, WARRANTIES AND COVENANTS
12.1    Mutual Representations and Warranties. AZ and Company each represents, and warrants to the other Party, as of the Effective Date, and covenants to the other Party during the Term that:
12.1.1    it is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement;
12.1.2    the execution and delivery of this Agreement and each Project Schedule and the performance by it of the transactions contemplated hereby have been, or in the case of a Project Schedule, will be as of the Project Schedule Effective Date, duly authorized by all necessary corporate action on its part;
12.1.3    this Agreement is, and, in the case of each Project Schedule, will be as of the Project Schedule Effective Date, a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);
12.1.4    it is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement or the applicable Project Schedule;
12.1.5    it has the right to grant the applicable rights and licenses provided for under this Agreement; and
12.1.6    neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of its Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described in such section. It agrees to inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of its or its Affiliates’ knowledge, is threatened, relating to the debarment or conviction of it or any such Person performing services hereunder.
12.2    Representations and Warranties of Company. Company represents and warrants to AZ, as of the Effective Date, and, in the case of any representation and warranty as it 

Page 52 of 84

relates to Activities under any Project Schedule, any Company Assay to be Developed or Commercialized under any Project Schedule or a Project Schedule, as of the Project Schedule Effective Date, and covenants to AZ during the Term, that:
12.2.1    Company shall conduct the Exploitation of each Company Assay in compliance with Applicable Law;
12.2.2    to the Company’s knowledge, after reasonable inquiry, it owns or controls all rights or has a licence as necessary to Exploit the Company Technology Platform and as required under this Agreement
12.2.3    it has enforceable written agreements with all of its employees who receive Confidential Information of AZ or perform activities under this Agreement assigning to Company ownership of all intellectual property rights created in the course of their employment, except to the extent that such assignment obligations would not be consistent with Applicable Law;
12.2.4    to the Company’s knowledge, there are no claims or litigation pending or threatened against Company or its Affiliates alleging that the Exploitation of any Company Assay that is the subject of a Project Schedule, infringes or otherwise misappropriates any intellectual property of any Third Party; and
12.2.5    it shall not, and shall cause any Authorized Person(s) not to, attempt to re-identify patient subjects, and not to combine accessed data with other sources of data, whether publicly available or otherwise, in a way that would lead to the identification or recognition of any patient subject and shall comply with all applicable data privacy legislation.
12.2.6    to the Company’s knowledge, the performance of Company’s activities as contemplated under this Agreement or the applicable Project Schedule will not infringe the intellectual property rights of any Third Party.
12.3    Representations and Warranties of AZ. AZ represents to Company, as of the Effective Date, and, in the case of any representation as it relates to Activities under any Project Schedule, as of the Project Schedule Effective Date, any AZ Product to be Developed or Commercialized under any Project Schedule that:
12.3.1    it has enforceable written agreements with all of its employees who receive Confidential Information of Company or perform activities under this Agreement assigning to AZ ownership of all intellectual property rights created in the course of their employment, except to the extent that such assignment obligations would not be consistent with Applicable Law;
12.3.2    to AZ’s knowledge, the Exploitation of the applicable AZ Product will not infringe or otherwise misappropriate any intellectual property of any Third Party to the extent that Commercialization of the applicable AZ Product would be prevented.

Page 53 of 84

12.4    Anti-Bribery.
12.4.1    Each Party agrees, on behalf of itself and its Affiliates and its and their respective officers, directors and employees, that in connection with the performance of its obligations hereunder, it shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to (a) any Government Official in order to influence official action; (b) any person (whether or not a Government Official) (i) to influence such person to act in breach of a duty of good faith, impartiality or trust, (ii) to reward such person for acting improperly, or (iii) where such person would be acting improperly by receiving the money or other thing of value; or (c) any person while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit a Government Official in order to improperly influence official action for or against any Party in connection with the matters that are the subject of this Agreement.
12.4.2    In connection with the performance of its obligations hereunder, each Party and its Affiliates (a) shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws, (b) undertakes to comply with the Anti-Corruption Laws in its performance of this Agreement and (c) shall not take any action in furtherance of this Agreement that will, or would reasonably be expected to, cause it to be in violation of any such laws.
12.4.3    Each Party shall promptly provide the other Party with written notice upon becoming aware of any breach or violation by such Party or any of its Affiliates or any of their respective officers, directors, employees, of any of the representation, warranty or undertaking set forth in this Section 12.4.3 and/or (ii) upon receiving a formal notification that it is the target of a formal investigation by a governmental authority for an Anti-Corruption Law violation.
12.4.4    On the occurrence of any of the following events: (A) AZ becomes aware of, whether or not through an Audit, that Company (or any other Company Representative) is in breach or violation of any representation, warranty or undertaking in Sections of the Anti-Corruption Laws; or (B) AZ receives notice relating to any suspected or actual violation of Anti-Corruption Laws by Company or any other Company Representative, in either case ((A) or (B)), AZ shall have the right, in addition to any other rights or remedies under this Agreement or to which AZ may be entitled in law or equity, to take such steps, including by requiring Company to agree to such additional measures, representations, warranties, undertakings and other provisions, in each case, as are reasonably necessary in order to avoid a potential violation or continuing violation by AZ, Company or any of its Affiliates of the Anti-Corruption Laws (“Provisions”).
12.4.5    Each Party acknowledges and agrees that its breach of the obligations set forth in this Section 12.4 shall constitute a Material Breach of this Agreement and that the non-breaching Party may terminate this Agreement if the other Party breaches such obligations.
12.5    DISCLAIMER OF WARRANTIES

Page 54 of 84

12.5.1    Unless expressly set forth in an applicable Project Schedule, neither Party makes any representations or grants any warranties, express or implied, (a) in the case of AZ, with respect to whether any AZ Product will be approved from commercial sale by the applicable Regulatory Authorities in the applicable Indication, and b) in the case of Company, with respect to whether any Company Assay will be approved for commercial sale by the applicable Regulatory Authorities. The warranty in this Section 12.5.1 does not relieve Company or AZ from its obligations under Article 5 to seek Regulatory Approval for each Company Assay or AZ Product, as applicable; provided, however, that, in the event that it ceases to be commercially practicable for AZ to continue to seek Regulatory Approval for an AZ Product, it shall provide written notice of such fact to Company, and following delivery of such notice, each Party shall be relieved of its obligations under the Project Schedule and this Agreement to Develop, seek Regulatory Approval for, and Commercialize such AZ Product and any Company Assay that was intended for use in connection with such AZ Product, as set forth in Article 5.
12.5.2    EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT OR IN AN APPLICABLE PROJECT SCHEDULE, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE.
12.5.3    EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT OR IN AN APPLICABLE PROJECT SCHEDULE, ALL DATA AND MATERIALS PROVIDED BY EITHER PARTY TO THE OTHER PARTY PURSUANT TO A PROJECT SCHEDULE ARE PROVIDED “AS IS” AND, TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, THE PROVIDING PARTY HEREBY DISCLAIMS AND EXCLUDES ANY AND ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR OTHER TERMS, WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED, WITH RESPECT TO THE CLINICAL DATA, INCLUDING ANY REPRESENTATION OR WARRANTY OF QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE.
ARTICLE 13
INDEMNITY
13.1    Indemnification of Company. AZ shall indemnify Company, its Affiliates and its and their respective (sub)licensees, directors, officers, employees and agents and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) to the extent arising from or occurring as a result of: (a) the Material Breach by AZ under this Agreement; (b) the negligence, fraud, or willful misconduct on the part of AZ or its Affiliates or its or their respective directors, officers, employees or agents in performing its or their obligations under this Agreement (including any Project Schedule); (c) the Exploitation 

Page 55 of 84

of any AZ Product by or on behalf of either Party or any of its Affiliates, (sub)licensees or distributors, including claims arising from or occurring as a result of personal injury or death of any Person resulting from the use of any AZ Product; except in each case of (a) through (c) for any Losses to the extent arising from or occurring as a result of (i) the breach by Company of its obligations under this Agreement (including any Project Schedule); (ii) the negligence, fraud, or willful misconduct on the part of Company or its Affiliates or its or their respective directors, officers, employees or agents in performing its or their obligations under this Agreement (including any Project Schedule); or (iii) a Third Party Claim to which an AZ indemnitee is otherwise entitled to indemnification by Company under Section 13.2 as to which Losses each Party shall indemnify the other to the extent of their respective liability for the Losses.
13.2    Indemnification of AZ. Company shall indemnify AZ, its Affiliates, and its and their respective (sub)licensees, directors, officers, employees and agents and defend and hold each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a result of: (a) the Material Breach by Company under this Agreement; (b) the negligence, fraud, or willful misconduct on the part of Company or its Affiliates or its or their respective directors, officers, employees or agents in performing its or their obligations under this Agreement (including any Project Schedule); (c) the Exploitation of any Company Assay or the Company Technology Platform by or on behalf of Company or any of its Affiliates, (sub)licensees, distributors or contractors, including claims arising from or occurring as a result of personal injury or death of any Person resulting from the use of a Company Assay or the Company Technology Platform; except in each case (of (a) through (c)) for any Losses to the extent arising from or occurring as a result of (i) the breach by AZ of an obligation under this Agreement (including any Project Schedule); (ii) the negligence, fraud, or willful misconduct on the part of AZ or its Affiliates or its or their respective directors, officers, employees or agents in performing its or their obligations under this Agreement (including any Project Schedule); or (iii) a Third Party Claim to which an Company indemnitee is otherwise entitled to indemnification by AZ under Section 13.1 as to which Losses each Party shall indemnify the other to the extent of their respective liability for the Losses.
13.3    Indemnification Procedures.
13.3.1    Notice of Claim. All indemnification claims in respect of a Party, its Affiliates, or its or their (sub)licensees, respective directors, officers, employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this Article 13, but in no event shall the indemnifying Party be liable for any Losses that result from any unreasonable delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims.
13.3.2    Control of Defense. At its option, the indemnifying Party may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within thirty (30) days after the indemnifying Party’s receipt of an Indemnification Claim Notice.

Page 56 of 84

The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall promptly deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in Section 13.3.3, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically requested in writing by the indemnifying Party. In the event that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any Losses incurred by the indemnifying Party in its defense of the Third Party Claim.
13.3.3    Right to Participate in Defense. Any Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s sole cost and expense unless (a) the employment thereof has been specifically authorized in writing by the indemnifying Party, (b) the indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 13.3.2 (in which case the Indemnified Party shall control the defense), or (c) the interests of the Indemnified Party and the indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles.
13.3.4    Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that shall not result in the applicable indemnitees becoming subject to injunctive or other relief and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 13.3.2, the indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, then the Indemnified Party may defend against such Third Party Claim; provided that the Indemnified Party shall not settle any Third Party Claim without the prior written consent of the indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).

Page 57 of 84

13.3.5    Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable and verifiable out-of-pocket expenses in connection therewith.
13.3.6    Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.
13.4    LIMITATIONS OF LIABILITY
13.4.1    EXCEPT (A) IN THE EVENT OF THE GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD OF A PARTY OR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 11, (B) FOR LOSSES ASSERTED BY THIRD PARTIES IN CLAIMS THAT ARE SUBJECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 13, AND (C) AS PROVIDED UNDER SECTION 15.12, NEITHER PARTY NOR ANY OF ITS AFFILIATES OR (SUB)LICENSEES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY.
13.5    Insurance. Company shall have and maintain such types and amounts of insurance covering its activities and obligations under this Agreement as is normal and customary for diagnostic companies in the life sciences industry for parties similarly situated or otherwise required by Applicable Law. AZ shall have and maintain such types and amounts of insurance covering its activities and obligations under this Agreement as is normal and customary for pharmaceutical companies in the life sciences industry, or otherwise required by Applicable Law. Upon request by the other Party, each Party shall provide to the other Party evidence of its insurance coverage. The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to maintain such insurance after the expiration or termination of this Agreement in its entirety for a period of seven (7) years. Notwithstanding the foregoing, AZ may self-insure in whole or in part the insurance requirements described above.

Page 58 of 84

ARTICLE 14
TERM AND TERMINATION
14.1    Term. The term of this Agreement (the “Term”) commences on the Effective Date and continues until terminated in accordance with this Article 14; provided, however, that each Project Schedule shall become effective as of the applicable Project Schedule Effective Date and with respect to any Project Schedule entered into prior to expiration or termination of this Agreement, this Agreement shall remain in effect with respect to such Project Schedule until the earlier of (a) the completion of the Activities to be performed pursuant to such Project Schedule or (b) termination of such Project Schedule pursuant to Section 14.2. If the Parties wish to enter into a new Project Schedule during the time this Agreement is undergoing re-negotiation such new Project Schedule may be commenced under this Agreement and the Term of this Agreement will be extended until the new Agreement has been executed.
14.2    Termination
14.2.1    Material Breach of the Agreement. If either Party (the “Breaching Party”) has committed a Material Breach of this Agreement (not the terms of a specific Project Schedule), in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may terminate this Agreement in its entirety (including all Project Schedules then in effect) by providing ninety (90) days’ (the “Notice Period”) prior written notice (the “Termination Notice”) to the Breaching Party and specifying the Material Breach and its claim of right to terminate this Agreement; provided that any proposed termination shall not become effective at the end of the Notice Period if the Breaching Party cures the Material Breach specified in the Termination Notice during the Notice Period (or, if such Material Breach cannot be cured within the Notice Period, if the Breaching Party commences actions to cure such Material Breach within the Notice Period and thereafter diligently continues such actions, provided that the Material Breach is cured to the satisfaction of the Non-Breaching Party within a period not exceeding ninety (90) days). Notwithstanding the foregoing, if either Party initiates a dispute resolution procedure under Section 15.7 to resolve a Dispute regarding the Material Breach for which termination is being sought and is diligently pursuing such procedure, then the cure period set forth in this Section 14.2.1 will be tolled during the pendency of such dispute resolution procedure.
14.2.2    Mutual Agreement and Convenience. The Parties may terminate this Agreement in its entirety (including all Project Schedules then in effect) at any time by mutual written agreement. Company may terminate this Agreement in its entirety if no Project Schedule is active and there has been no active Project Schedule for two (2) years and no new Project Schedules are contemplated or in discussion as at the date of termination.
14.2.3    Insolvency. If either Party: (a) files for protection under bankruptcy or insolvency laws; (b) makes an assignment for the benefit of creditors; (c) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged within ninety (90) days after such filing; (d) proposes a written agreement of composition or extension of its debts; (e) proposes or is a party to any dissolution or liquidation; or (f) files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within sixty (60) days of the filing thereof, then the other Party may terminate this 

Page 59 of 84

Agreement in its entirety (including all Project Schedules then in effect) effective immediately upon written notice to such Party.
14.2.4    Anti-Bribery. Either Party may terminate this Agreement in its entirety (including all Project Schedules then in effect) at any time, immediately upon written notice to the other Party, if such other Party breaches its obligations under Section 12.4.
14.2.5    Material Breach of a Project Schedule. Without limitation to Section 14.2.1, if the Breaching Party has committed a Material Breach of a Project Schedule, then in addition to any other right and remedy the Non-Breaching Party may have, the Non-Breaching Party may terminate such Project Schedule by providing a Termination Notice to the Breaching Party and specifying the Material Breach and its claim of right to terminate such Project Schedule; provided that any proposed termination shall not become effective at the end of the Notice Period if the Breaching Party cures the Material Breach specified in the Termination Notice during the Notice Period (or, if such Material Breach cannot be cured within the Notice Period, if the Breaching Party commences actions to cure such Material Breach within the Notice Period and thereafter diligently continues such actions, provided that the Material Breach is cured to the satisfaction of the Non-Breaching Party within a period not exceeding ninety (90) days). Notwithstanding the foregoing, if either Party initiates a dispute resolution procedure under Section 15.7 to resolve a Dispute regarding the Material Breach for which termination is being sought and is diligently pursuing such procedure, then the cure period set forth in this Section 14.2.5 will be tolled during the pendency of such dispute resolution procedure.
14.2.6    Termination of a Project Schedule for Mutual Agreement. The Parties may terminate any Project Schedule in its entirety or any portion thereof at any time by mutual written agreement.
14.2.7    Termination of a Project Schedule for Lack of Feasibility. AZ may terminate a Project Schedule in its entirety or any portion thereof by providing thirty (30) days’ prior written notice to Company, in the event that AZ determines in good faith, after consultation with the Company, that the continuation of the conduct of Activities under a Project Schedule are technically/or clinically not feasible. The list below is a non-exhaustive list of reasons why a project may not continue to be feasible:
a)    the Company Assay being developed under such Project Schedule is no longer necessary (or likely to be necessary) for use with the AZ Product;
b)    there is a reasonable likelihood that the Company Assay being developed under such Project Schedule would not meet the requirements of a Regulatory Authority that apply to the Development or Commercialization of the AZ Product in any applicable Market;
c)    the clinical data does not support market entry for the drug due to efficacy, safety or issues with any clinical trial or clinical data; or

Page 60 of 84

d)    the Company Assay may fail due to technical feasibility such as analytical performance, assay success rates, sensitivity, testing TAT and/or clinical validation.
e)    a required Third Party License is not obtainable which renders the use of the Assay no longer feasible.
If Company determines in good faith that the continuation of the conduct of Activities under a Project Schedule is technically or clinically not feasible, then Company shall refer the matter to the JPT for discussion. If the JPT do not agree on a resolution Company shall have the right to refer the matter to the JSC for resolution. If no resolution is reached by the JSC within thirty (30) days after such referral, then the applicable Project Schedule can be terminated by mutual agreement of the Parties.
14.2.8    Termination of a Project Schedule for Convenience by AZ. AZ may terminate a Project Schedule in its entirety or any portion thereof by providing ninety (90) days’ prior written notice to Company. The following list are examples of termination for convenience for the purpose of assisting the Parties to determine causation of any termination provision by AZ but such list is not exhaustive:
a)    AZ determines in its sole discretion to discontinue the internal program specified in the Project Schedule with respect to the relevant AZ Product;
b)    AZ divests or out-licenses the applicable AZ Product to a Third Party with respect to any applicable Market;
c)    the applicable AZ Product is withdrawn from any applicable Market for any reason other than as a result of negative clinical data.
14.3    Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement or a Project Schedule by AZ or Company are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement or the applicable Project Schedule, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party hereto that is not subject to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under clause (a) above, following the rejection of this 

Page 61 of 84

Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.
14.4    Consequences of Termination.
14.4.1    If this Agreement is terminated in its entirety for any reason then the following terms and conditions shall apply (without limitation to Section 14.8):
a)    the Parties shall promptly meet to prepare and enter into a mutually-agreeable close-out Project Schedule with respect to all Projects for which the Parties are then conducting Activities. Company shall cease performing any work not necessary for the orderly close-out of the applicable Projects, for the fulfillment of any requirements of applicable Regulatory Authorities, or that is otherwise required by such close-out Project Schedule.
b)    Without limiting any of AZ’s payment obligations as set forth in this Agreement and any applicable Project Schedule, AZ shall in any event pay Company for its fees under the applicable Project Schedules for: (i) all Activities performed up to the effective date of such termination, provided that such Activities have been conducted in accordance with this Agreement or the applicable Project Schedule; and (ii) any other reasonable, non-cancellable costs incurred by Company in performance of Company’s obligations under this Agreement or (iii) where payments under a terminated Project Schedule are solely milestone-based, and this Agreement is terminated after costs have been incurred by Company toward achieving a milestone, but that milestone has not yet been completed, AZ will pay a pro rata portion of the next applicable milestone fee (according to its percentage completion), and shall reimburse Company for any reasonable non-cancellable costs incurred towards that milestone prior to termination.
14.4.2    In the event of termination of this Agreement in its entirety by AZ for any reason; or by Company (except pursuant to Sections 14.2.1 (AZ Material Breach of the Agreement), 14.2.3 (Insolvency), 14.2.4 (Anti-Bribery)),
a)    Company shall conclude all applicable on-going Project(s) or, if instructed by AZ, shall transfer the applicable Project(s) to a Third Party, as instructed by AZ and pursuant to the close-out Project Schedule, as expeditiously as reasonably possible and in accordance with all applicable requirements of Regulatory Authorities.
b)    If payments under a terminated Project Schedule are milestone-based, and the Project Schedule is terminated (except for termination by AZ pursuant to Sections 14.2.1, 14.2.3 or 14.2.4) after costs have been incurred by Company toward achieving a milestone, but that milestone has not yet been completed, AZ will pay Company’s standard FTE rate as set forth in the applicable Project Schedule for actual work performed and reasonable non-cancellable costs incurred towards that milestone prior to termination instead of any amounts due upon achievement of such milestone up to a maximum amount not to exceed the milestone achievement payment amount.
14.4.3    In the event of termination of this Agreement in its entirety or a Project Schedule by AZ pursuant to Sections 14.2.1 (Company Material Breach of the Agreement) or 14.2.5 (Company Material Breach of a Project Schedule), or 14.2.3 (Insolvency) or 

Page 62 of 84

14.2.4 (Anti-Bribery), (i) Company shall, and hereby does, grant to AZ a worldwide, fully paid-up, royalty free, non-exclusive, non-transferable license for the remainder of the Term, to the Assay Validation Data generated during the Term or during an applicable Project Schedule (and any issued Foreground Patent that claims such Assay Validation Data), with the right to grant sublicenses through multiple tiers, to carry out a bridging study in a successor assay technology, and (ii) any license granted to AZ under this Agreement shall survive pursuant to its terms.
14.4.4    In the event of termination of a Project Schedule by Company at any time in accordance with 14.2.5 (AZ Material Breach of a Project Schedule), the Parties shall promptly meet to prepare and enter into a mutually-agreeable close-out Project Schedule for which the Parties are then conducting Activities. Company shall cease performing any work not necessary for the orderly close-out of the Project, for the fulfillment of any requirements of applicable Regulatory Authorities, or that is otherwise required by such close-out Project Schedule. Without limiting any of AZ’s payment obligations as set forth in any applicable Project Schedule, AZ shall in any event pay Company for its fees under the applicable Project Schedule for: (i) all Activities performed up to the effective date of such termination, provided that such Activities have been conducted in accordance with this Agreement or the applicable Project Schedule; and (ii) any other reasonable, documented, non-cancellable costs incurred by Company in performance of Company’s obligations under the applicable Project Schedule or this Section 14.4.4 or (iii) if payments under a terminated Project Schedule are milestone-based, and the Project Schedule is terminated after costs have been incurred by Company toward achieving a milestone, but that milestone has not yet been completed, AZ will pay Company a pro rata portion of the next applicable milestone fee (according to its percentage completion), and shall reimburse Company for any reasonable non-cancellable costs incurred towards that milestone prior to termination.
14.4.5    In the event of termination of a Project Schedule by AZ at any time in accordance with 14.2.5 (Company Material Breach of a Project Schedule), the Parties shall promptly meet to prepare and enter into a mutually-agreeable close-out Project Schedule for which the Parties are then conducting Activities. Company shall cease performing any work not necessary for the orderly close-out of the Project, for the fulfilment of any requirements of applicable Regulatory Authorities, or that is otherwise required by such close-out Project Schedule.
14.4.6    Any licenses granted by Company to AZ hereunder, except for any license granted or designated to survive under Section 14.4.3 shall terminate upon the effective date of such termination.
14.5    Return of Materials and Confidential Information. At the earlier of completion or termination of a Project (or this Agreement as a whole), and except as otherwise permitted by this Agreement in connection with the exercise of rights under Article 9 that expressly survive termination of the applicable Project Schedule or this Agreement, each Party shall comply with Section 11.6 with regard to the return or destruction of each Party’s Confidential Information and with Section 3.5 with respect to the return or destruction of AZ Materials.

Page 63 of 84

14.6    Remedies. Except as otherwise expressly provided herein, termination of this Agreement in its entirety or any Project Schedule in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.
14.7    Accrued Rights; Surviving Obligations. Termination of this Agreement or any Project Schedule for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination. Such termination shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement or such Project Schedule. Without limiting the foregoing, Sections 3.1, 3.4, 4.5, 8, 9.1, 11, 13, 14.4-14.8, and 15 shall survive the termination or expiration of this Agreement for any reason. If a Project Schedule is terminated pursuant to Section 14.2 or this Agreement is terminated pursuant to Section 14.2 with respect to a particular AZ Product and Associated Company Assay, or with respect to a particular Market (but not in any such case in the event of any termination of this Agreement in its entirety), then following such termination the foregoing provisions of this Agreement shall survive with respect to the terminated Project Schedule, terminated AZ Product and Associated Company Assay, or terminated Market, as applicable, and all provisions not surviving in accordance with the foregoing shall terminate with respect to the terminated Project Schedule, terminated AZ Product and Associated Company Assay, or terminated Market, as applicable.
ARTICLE 15
MISCELLANEOUS
15.1    Non-Exclusive Relationship. The Parties agree that this Agreement and any Project Schedule, and the relationship of the Parties hereunder and thereunder, are non-exclusive. Each Party intends to work with and enter into agreements with one or more Third Parties to develop or seek Regulatory Approval for IVDs for use with Therapeutic Products. Subject to its confidentiality and other obligations under this Agreement, each Party may enter into any such agreements with Third Parties to Develop or Commercialize such IVDs, either prior to or after the Effective Date, without the consent of the other Party. Subject to its confidentiality and other obligations under this Agreement, each Party reserves the right, in its sole discretion, to Develop and Commercialize any IVD that detects any Selected Biomarkers anywhere in the world either prior to or after the Effective Date, without the consent of the other Party.
15.2    Subcontracting. Subject to the terms of this Agreement, each Party shall have the right to engage Affiliates or Third Parties (including in connection with the grant of a license to one or more Third Party (sub)licensees) to perform certain of its Development and Commercialization obligations under this Agreement or any Project Schedule during the Term at such Party’s cost and expense (each such Third Party, a “Subcontractor”); provided that if Company desires to engage any Subcontractor, it shall obtain the prior written consent of AZ, not to be unreasonably withheld, conditioned, or delayed (except in the case of Commercialization Activities under the Project Schedule, with respect to which Company shall not be required to obtain the consent of AZ and shall provide AZ reasonable notice that it has engaged a Subcontractor with respect to such Commercialization Activities).

Page 64 of 84

15.3    Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement or any Project Schedule for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within thirty (30) days after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use Commercially Reasonable Efforts to remedy its inability to perform.
15.4    Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law.
15.5    Assignment.
15.5.1    Neither Party may assign its rights or, except as provided in Section 15.2, delegate its obligations under this Agreement in whole or in part without the prior written consent of the other Party (not to be unreasonably withheld), except that either Party shall have the right, without such consent, (a) to assign any or all of its rights and delegate any or all of its obligations hereunder or under any Project Schedule to (i) any of its Affiliates or (ii) to any successor in interest (whether by merger, acquisition or asset purchase) to all or substantially all of the business to which this Agreement or such Project Schedule relates, including, for clarity, in the case of AZ, with respect to any acquiror of any AZ Product with respect to which a Company Assay is intended for use, and in the case of Company, with respect to any acquiror of the Company Technology Platform and the Company Assay with respect to which an AZ Product is intended for use, and (b) without limitation to the foregoing, in the case of AZ, to assign any or all of its rights and delegate any or all of its obligations hereunder or under any Project Schedule to any (sub)licensee with respect to any AZ Product with respect to which a Company Assay is intended for use; provided that the assigning Party shall provide written notice to the non-assigning Party within thirty (30) days after such assignment or delegation. Any permitted successor of a Party or any permitted assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be 

Page 65 of 84

deemed to be a party to this Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to 

Page 66 of 84

be a party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party. Any attempted assignment or delegation in violation of this Section 15.5.1 shall be void and of no effect.
15.5.2    The rights to Know-How or other information, materials and intellectual property: (a) controlled by a Third Party permitted assignee of a Party that were controlled by such assignee (and not such Party) immediately prior to such assignment (other than as a result of a license or other grant of rights, covenant or assignment by such Party or its Affiliates to, or for the benefit of, such Third Party); or (b) controlled by an Affiliate of a Party that becomes an Affiliate through any Change of Control of such Party, that were controlled by such Affiliate (and not such Party) immediately prior to such Change of Control (other than as a result of a license or other grant of rights, covenant or assignment by such Party or its other Affiliates to, or for the benefit of, such Affiliate), in each case ((a) and (b)), shall be automatically excluded from the rights licensed or granted to the other Party under this Agreement, provided that such Know-How or other information, materials and intellectual property shall be deemed automatically included to the extent they are utilized by such Party or its successor or surviving entity in conducting Activities under a Project Schedule following such Change of Control.
15.5.3    In the event that a Change of Control of Company occurs, as a result of which any of Company’s Affiliates has rights to Develop or Commercialize a product that competes with any AZ Product as of the effective date of the Change of Control (a “Competing Product”), Company shall ensure that, with respect to the research, development and commercialization activities related to such Competing Product, firewalls or other appropriate restrictions are in place to ensure that Confidential Information of AZ is not shared with such Company Affiliate. For clarity, subject to the foregoing clause, such Company Affiliate shall have the benefit of all rights granted to Company under this Agreement.
15.6    Severability. If any provision of this Agreement or any Project Schedule is held to be illegal, invalid or unenforceable under any present or future law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, then (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement or the applicable Project Schedule shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or unenforceable in any respect.
15.7    Dispute Resolution.
15.7.1    Referral to Senior Officers. Except as otherwise provided in this Agreement, if a dispute arises between the Parties in connection with or relating to this Agreement, 

Page 67 of 84

a Project Schedule or any document or instrument delivered in connection herewith or therewith (each, a “Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations during a period of thirty (30) days following referral to the Senior Officers (the “Officer Resolution Period”).
15.7.2    Resolution. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. If such Senior Officers are unable to resolve any such Dispute within such Officer Resolution Period, either Party shall be free to exercise any right of such Party to institute litigation in accordance with Section 15.8.
15.7.3    Interim Relief and Tolling. Notwithstanding anything herein to the contrary, nothing contained in this Section 15.7 shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or other interim equitable relief concerning a Dispute, if necessary to protect the interests of such Party. This Section 15.7.3 shall be specifically enforceable.
15.8    Governing Law, Jurisdiction and Service.
15.8.1    Governing Law. This Agreement and the rights and obligations of the Parties hereunder shall be governed by and construed in accordance with the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods.
15.8.2    Arbitration. Subject to Section 15.12 (Equitable Relief), and provided all applicable dispute resolution requirements expressly required under this Agreement are exhausted, all disputes arising out of or relating to the existence, negotiation, validity, formation, interpretation, breach, performance or application of the Definitive Agreement shall be settled by binding arbitration in accordance with JAMS (formerly Judicial Arbitration and Mediation Services), or its successor, pursuant to the United States Arbitration Act, 9 U.S.C. Sec. 1 et seq. Either Party may commence the arbitration process called for in this Section 15.8.2 by filing a written demand for arbitration with JAMS, with a copy to the other Party. The arbitration will be conducted in accordance with the provisions of JAMS’ Comprehensive Arbitration Rules and Procedures in effect at the time of filing of the demand for arbitration. The number of arbitrators shall be one (1) unless the amount in dispute exceeds the equivalent of U.S. $1,000,000, in which event it shall be three (3). When three (3) arbitrators are involved, each Party shall appoint one (1) arbitrator, and those two (2) shall appoint the third (3rd) within thirty (30) days, who shall be the Chairman. The seat, or legal place, of arbitration shall be New York, New York, and the arbitration shall be conducted in English. The Parties agree that they will participate in the arbitration in good faith, and that they will share equally in its costs. In reaching a decision, the arbitrator(s) shall give full force and effect to the intent of the Parties as expressed in this Agreement, and if a solution is not found in this Agreement, shall apply the governing law of this Agreement. The decision of the arbitrator(s) shall be final and binding upon both Parties, and neither Party shall seek recourse to a law court or other authority to appeal for revisions of the decision. The provisions of this Section may be enforced by any Court of competent jurisdiction, 

Page 68 of 84

and the Party seeking enforcement shall be entitled to an award of all costs, fees and expenses, including attorneys’ fees, to be paid by the Party against whom enforcement is ordered.
15.8.3    Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.9.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court.
15.9    Notices.
15.9.1    Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement (and any applicable Project Schedule) and shall be deemed given only if delivered by hand or sent by electronic transmission (with transmission confirmed) via email or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 15.9.2 or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 15.9.1. Such notice shall be deemed to have been given as of the date delivered by hand or electronically transmitted (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by electronic transmission shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 15.9.1 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement or any Project Schedule.
15.9.2    Address for Notice.
If to AZ, to:
AstraZeneca UK Limited
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
England
Attention:[**]
Email: [**]
with a copy (which shall not constitute notice) to:
[**]
If to Company, to:
ArcherDX, Inc.
2477 55th Street, Suite 202
Boulder, CO 80301
USA

Page 69 of 84

Attention:    General Counsel
15.10    Entire Agreement; Amendments. This Agreement, together with any and all Project Schedules executed hereunder and incorporated herein, set forth and constitute the entire agreement and understanding between the Parties with respect to the subject matter hereof, and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto, including the Prior CDA and any other prior confidentiality agreements covering the exchange of confidential information between the Parties prior to the Effective Date are superseded hereby with respect to such subject matter. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement or any Project Schedule. No amendment, modification, release or discharge with respect to this Agreement or any Project Schedule shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. Subject to Section 2.6, in the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control.
15.11    English Language. This Agreement shall be written and executed in and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof and in the event of any conflict in interpretation between the English version and such translation, the English version shall control.
15.12    Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in Articles 9, 10 and 11, are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of such Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of such Articles, the non-breaching Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or equity. Both Parties agree to waive any requirement that the other (a) post a bond or other security as a condition for obtaining any such relief and (b) show irreparable harm, balancing of harms, and consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in this Section 15.12 is intended or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of this Agreement.
15.13    Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do 

Page 70 of 84

not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.
15.14    No Benefit to Third Parties. The covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns and they shall not be construed as conferring any rights on any other Persons.
15.15    Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement.
15.16    AZ Affiliates. Company acknowledges that AZ is an Affiliate of all business entities whose ultimate parent is AstraZeneca PLC (AstraZeneca and its Affiliates being referred to as the “AZ Group”). Company further acknowledges that the research, development and commercial organizations within the AZ Group operate through multiple business entities. In recognition of the foregoing and without prejudice to the provisions of any clause in this Agreement that explicitly includes AZ or any of its officers, directors, employees and agents, the Parties agree that any Affiliate in the AZ Group and any officers, directors, employees and agents of AZ or any of its Affiliates shall always have the right to perform any or all of AZ’s obligations and exercise any or all of AZ’s rights under this Agreement; provided that AZ shall be responsible for the acts and omissions of its Affiliates performing such obligations or exercising any of such rights.
15.17    Relationship of the Parties. It is expressly agreed that Company, on the one hand, and AZ, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Company, on the one hand, nor AZ, on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any action that will be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party.
15.18    References. Unless otherwise specified, (a) references in this Agreement to any Article, Section, Appendix or Schedule shall mean references to such Article, Section, Appendix or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section and (c) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto.
15.19    Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this 

Page 71 of 84

Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall mean including, without limiting the generality of any description preceding such term. Any capitalized term used in any Project Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto.
15.20    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email or other electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures.
[SIGNATURE PAGE FOLLOWS.]

Page 72 of 84

THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.
	
		
	ASTRAZENECA UK LIMITED
	ARCHER DX, INC

	 
	 

	By: /s/ Ruth March
	By: /s/ Christian LaPointe

	 
	 

	Name: Ruth March
	Name: Christian LaPointe

	 
	 

	Title: SVP Precision Medicine
	Title: Deputy General Counsel

IN VITRO DIAGNOSTICS MASTER COLLABORATION AGREEMENT
SIGNATURE PAGE

Attachment A
FORM OF RFP
		
	1.
	GENERAL INFORMATION

		
	2.
	BIOMARKER INFORMATION

		
	3.
	PRE-EXISTING BIOMARKER ASSAY INFORMATION

		
	4.
	CLINICAL STRATEGY

4.1.
		
	5.
	CLINICAL TRIAL DESIGN

5.1
		
	6.
	CLINICAL TRIAL LOGISTICS

6.1
		
	7.
	REGULATORY INFORMATION

7.1
		
	8.
	MARKETS

8.1

Attachment B
Form of Project Schedule
PROJECT SCHEDULE NO. [ ]
MASTER COLLABORATION AGREEMENT
This Project Schedule No. [ ] (“PROJECT SCHEDULE”) is effective as of the date of the last signature herein (the “PROJECT SCHEDULE Effective Date”) and describes Activities to be performed by ArcherDX, Inc. (“Company”) and AstraZeneca UK Ltd (“AZ”) and is entered pursuant to the Master Collaboration Agreement, dated [         ] between the Parties (the “Master Collaboration Agreement”). This PROJECT SCHEDULE and any appendices hereto shall be incorporated into the Master Collaboration Agreement, and the Activities to be performed hereunder are subject to the terms and conditions of the Master Collaboration Agreement, except as expressly set forth with specificity in this PROJECT SCHEDULE. Each capitalized term in this PROJECT SCHEDULE shall refer to the corresponding definition in the Master Collaboration Agreement, unless otherwise defined within this PROJECT SCHEDULE.
This PROJECT SCHEDULE is divided into the following sections:
	
		
	A. Overview
	Identifies core aspects that are defined in the Master Collaboration Agreement

	B. Milestones, Activities, Inputs & Deliverables
	Describes Activities to be performed and associated Deliverables

	C. Timeline
	Specifies projected start date and projected end date for each Activity, and checkpoint dates (if any), and the associated Deliverables.

	D. Key Assumptions
	Any key assumptions at the outset of the Project that, if they were not to occur during the course of the Project, may require an alteration to this PROJECT SCHEDULE.

	E. Fee Schedules
	Fixed milestone fees or payment amounts.

	F.
	Delays, Project

	Suspensions
	Company FTE rate, if applicable, specific to the Project Schedule.

	G. Service Levels
	Key Performance Indicators (Service Levels), if applicable, specific for the Project Schedule

	H. Special Terms
	Terms applicable to this PROJECT SCHEDULE that the Parties agree are either not specified by provisions of the Master Collaboration Agreement or are that the Parties specifically agree

Insert page numbers when negotiating new Project Schedules

	
		
	 
	to supersede conflicting provisions of the Master Collaboration Agreement.

		
	A.
	OVERVIEW

PROJECT: {cover brief project description from the clinical perspective}
AZ PRODUCT: {which therapeutic is this for}
COMPANY ASSAY: {example: MRD Assay}
SELECTED BIOMARKERS: {example: }
INDICATION(S): {example: solid tumor indication}
MARKETS: {specify the applicable Markets), and specify the commitments to be made by the Company to Develop, obtain Regulatory Approval, and Commercialize the applicable Company Assay in each such Market within this Project Schedule versus Additional Project Schedules to be negotiated in good faith at a later date}
KEY CONTACTS: See Appendix [A] attached hereto.
		
	B.
	MILESTONES, ACTIVITIES, INPUTS and DELIVERABLES

Company and AstraZeneca will each perform the Activities and Deliverables assigned to such party in accordance with the milestones set forth below.
Sets of Activities will be achieved incrementally as indicated by the corresponding planned start and end dates in pursuit of the specified milestones.
Summary of Work
[Description of work to be included]
Milestone #
{Summary of milestone activities per milestone}
	
				
	Inputs/Activities
	Company role
	AZ role
	DATE

	{define activity (e.g. development activities) or input (e.g. review/AZ Materials to be provided by AZ}
	{define roles }
	{define roles and individuals}
	{define date by when it is needed}

Insert page numbers when negotiating new Project Schedules

Deliverables:
With consideration of all the inputs and assumptions described, fulfillment of the Activities and therefore the achievement of each milestone will be evidenced by the following Deliverables:
	
				
	Milestone
	Est. Start Date
	Est. Finish Date
	Deliverables

	0
	 
	 
	 

	1
	 
	 
	 

	2
	 
	 
	 

	3
	 
	 
	 

AZ Materials:
{insert any specifications, instructions and use restrictions relevant to the AZ Materials to be provided by AZ }
{insert costs to be paid by AZ to Company for the return of AZ materials after expiration of Retention Period (as defined under Section [ ] of the Master Collaboration Agreement}
For details regarding transfer of Clinical Data see Exhibit A attached hereto.
Labs which will process Samples:
Any additional audit rights relevant to specific Activities:
		
	C.
	TIMELINE

The Activities are estimated to commence upon the PROJECT SCHEDULE Effective Date and estimated to continue until [DATE].
		
	D.
	FEE SCHEDULES

Invoices and payments shall be processed in accordance with Article [ ] (Payments and Records) of the Master Collaboration Agreement.
Notification. In accordance with the following Fee Schedule (as defined in Section [ ] of the Master Collaboration Agreement), prior to invoicing AstraZeneca, Company shall be required to submit to AstraZeneca written documentation evidencing achievement of the applicable milestone event listed below (each, a “Milestone Event”). Following such notification and barring any good faith dispute about achievement of the Milestone Event, Company shall promptly send an invoice to AstraZeneca for the Milestone Event.
Fee Schedule.

Insert page numbers when negotiating new Project Schedules

Unless otherwise specified in this Project Schedule, AstraZeneca shall pay Company each of the following non-refundable, non-creditable, milestone payments upon achieving the applicable Deliverable.
	
			
	Milestone
	Fee
	Fee Structure

	0
	 
	 

	1
	 
	 

	2
	 
	 

	3
	 
	 

	4
	 
	 

	5
	 
	 

	Total Fee
	 
	 

Measure of Diligence. Company makes no warranty that the inclusion of the Milestone Events in this Section E implies that such Milestone Events can or will be achieved. Any failure by Company to achieve such Milestone Events, or to achieve them within particular time periods, shall not in itself constitute a failure of diligence or breach of this PROJECT SCHEDULE or the Master Collaboration Agreement by Company.
		
	E.
	DELAYS, PROJECT SUSPENSIONS

[FTE rate, if applicable, specific to this Project Schedule.]
		
	F.
	SERVICE LEVELS

Key Performance Indicators (Service Levels) if applicable, specific for this Project Schedule
To be inputted and amended as required from the agreed KPIs.
		
	G.
	SPECIAL TERMS

[TERMS FOR LICENSE GRANT TO COMPANY OF AZ DATA NOT RELATED SPECIFICALLY TO AN AZ PRODUCT]
[ADD SPECIAL TERMS THAT CONFLICT WITH THE MASTER COLLABORATION AGREEMENT AS NEEDED]
IN WITNESS THEREOF, this PROJECT SCHEDULE has been executed by the Parties hereto through their duly authorized representatives as of the PROJECT SCHEDULE Effective Date.
	
							
	ARCHERDX, INC.
	 
	ASTRAZENECA UK LIMITED

	 
	 
	 
	 
	 
	 
	 

Insert page numbers when negotiating new Project Schedules

	
							
	By:
	 
	 
	By:
	 

	 
	 
	 
	 
	 
	 
	 

	Name:
	 
	 
	Name:
	 

Insert page numbers when negotiating new Project Schedules

Appendix [ A ] to Project Schedule [ ]
Project Team Leaders and Business Development Contacts
	
		
	AZ Project Team Leader:
	 

	AZ budget holder
	 

	AZ Business Development Contact:
	 

	AZ Alliance Management Contact:
	 

	AZ Primary Contact Person
	 

	Company Alliance Manager Contact:
	 

	Company Business Development Contact:
	 

	Company Primary Contact Person
	 

Insert page numbers when negotiating new Project Schedules

Exhibit A to Project Schedule [ ]
TRANSFERS OF AZ CLINICAL DATA INVOLVING PERSONAL DATA:
[If AZ Clinical Data is to be transferred set out the exact method of transfer via secure portal etc.]
{(A) de-identified patient-level data; and/or (B) de-identified results of analysed patient data from the Clinical Studies to be provided by AZ to Company pursuant to Section [ ] of the Master Collaboration Agreement}

Insert page numbers when negotiating new Project Schedules

Schedule 8.2
Invoices to AstraZeneca
AZ uses an electronic system for invoice processing. All invoices are examined, and certain fields on each invoice are checked, interpreted, and verified. We therefore kindly ask you to always provide the following information on your invoices:
		
	•
	Invoice date (date of issue)

		
	•
	Invoice number

		
	•
	Purchase Order number (to be provided)

		
	•
	Company’s Tax ID number

		
	•
	Complete reference for the Agreement and, if applicable, the Project Schedule

		
	•
	Company’s full address

		
	•
	Project milestone achieved, or Project Deliverables provided, as described in the Project Schedule delivery date, if different from invoice date

		
	•
	Invoice amount and currency in Dollars

		
	•
	Bank details, preferably IBAN code. Otherwise account number and bank code SWIFT address.

If an invoice lacks the above necessary information it will be returned, and AZ will provide a written explanation of the deficiency with the invoice, which writing may be in the form of email or other electronic communication to Company’s Primary Contact Person or Company’s Alliance Manager or other Company member of the JPT. AZ shall take no further action on such invoice until it is resubmitted, addressing the deficiency. Questions in this regard, should be addressed to AZ’s appointed project manager representative to the applicable JPT.

Insert page numbers when negotiating new Project Schedules

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]